

DKMS FOUNDATION

England & Wales · Charity number 1150056

Details

Other names	DKMS BONE MARROW DONOR CENTRE, "DELETE BLOOD CANCER" (THIS IS THE NAME BY WHICH THE CHARITY WILL BE MOST COMMONLY KNOWN) AND "DKMS", DELETE BLOOD CANCER UK
Status	Registered
Legal form	Charitable company
Company number	08151279
Registered	2012-12-05
Register	View on the Charity Commission register

Contact

Address DKMS Foundation
Ashburnham House
Castle Row
Horticultural Place
London
W4 4JQ

Phone 02087475620

Email finance@dkms.org.uk

Website www.dkms.org.uk

Activities

Objects: THE PRESERVATION AND PROTECTION OF GOOD HEALTH AND THE RELIEF OF SICKNESS OF INDIVIDUALS WHO ARE SUFFERING FROM ANY KIND OF BLOOD CANCER

Activities: The objectives of the UK charity are to raise awareness of stem cell and bone marrow donation and to increase the number of registered potential stem cell donors in the UK and; thus provide a second chance at life for those with a blood cancer whose survival depends upon being matched with an unrelated donor.

Classification

- **How:** Provides Services, Other Charitable Activities
- **What:** The Advancement Of Health Or Saving Of Lives
- **Who:** Other Defined Groups, The General Public/mankind

Geography

- Ireland
- Scotland
- Throughout England And Wales

Finances

Period end	Income	Expenditure	Assets	Employees
2024-12-31	£12,239,270	£12,268,029	£2,659,153	58
2023-12-31	£11,921,693	£11,461,902	£2,687,912	50
2022-12-31	£10,574,284	£9,527,583	£2,228,121	51
2021-12-31	£8,989,925	£8,766,189	£1,181,420	50
2020-12-31	£8,921,145	£9,267,212	£957,684	45

Trustees

Name	Role	Appointed
Benedict Jacob Abel		2012-10-31
Bernd Ernst Weinel		2024-01-08
Dr ALEXANDER SCHMIDT		2013-12-13
Dr Elke Neujahr		2018-11-23
STEPHAN SCHUMACHER		2012-10-31

DKMS FOUNDATION

England & Wales - Charity number 1150056

Accounts

DKMSX
WE DELETE BLOOD CANCER

DKMSX
WE DELETE BLOOD CANCER

UK Impact Report



Year ending 31 December 2024

Tasneem, DKMS volunteer (East Midlands) and valued DKMS supporter

DKMSX
WE DELETE BLOOD CANCER

Be a student
for!



**AUTUMN
RECRUITMENT**

Tuesday 24 September 2024
Opportunities and
Part-Time work Fair
Percy Gee, Student Union

Wednesday 9 October 2024
& Thursday 10 October 2024
Graduate and Placement Fair
Sports Hall, Charles
Wilson Building

Thursday 17 October 2024
STEM and Life Science Fair
Sports Hall, Charles
Wilson Building



Citizen
Ambassador

WE DELETE BLOOD CANCER



Our Vision

To delete blood cancer.



Our Mission

To give as many blood cancer patients as possible a second chance at life.



Our Purpose

To raise awareness of blood cancer and blood disorders, register and retain potential stem cell donors to provide a second chance at life, raise funds to match donor registration costs, provide access to transplantation for more blood cancer patients, and improve blood cancer therapies by our own research.

Contents

Managing Directors' introduction	02
Surpassing donor registration	03
Representation matters	05
From frontline to lifeline	07
From grief to giving	09
Giving back through fundraising	11
DKMS UK support to India & Access to Transplantation	13
Trustee report	15
Statement of financial activities	27
Ways you can support us	51

Managing Directors' *introduction*

We warmly welcome and thank you for your engagement with and support for DKMS UK. We look back on an eventful year 2024 and to review all that was achieved is truly humbling.

We supported many wonderful initiatives for and with our patients and supporters, registering **more than 50,000 potential lifesavers**. Our new e-registration application simplifies the process of registering as a stem cell donor while enhancing the data quality.

Our fundraising efforts focused on forging long-term, mutually beneficial partnerships and we tried something totally new: we launched the DKMS Lottery, which exceeded all our expectations. The Marketing and Communications team prioritised brand awareness, as we recognised that to be truly successful, the foundation from which we must grow is ensuring the people of the UK know who we are, what we stand for and what our life-saving mission is.

2024 was also a significant year for our medical departments: we expanded our staff to provide an even **better and faster service to patients' transplant centre teams** and our donors in 2025. DKMS UK also achieved World Marrow Donor Association (WMDA) accreditation, demonstrating our commitment to upholding the highest standards.

Fair and equitable access to stem cell transplantation is a focus for DKMS globally. In the UK, minority ethnic representation stands at 16%. This is simply not good enough and we are focused on significantly increasing activities within underrepresented communities to sign up more donors in 2025 and beyond. In 2024, DKMS UK extended its influence beyond national borders, supporting our organisation's work in India. Additionally, DKMS' global Access to Transplantation Programme offers patients in low-income countries access to treatment for blood cancer, thalassaemia, and sickle cell disease, which you can read about in this report.

We achieved so much in 2024, and yet there is so much more to do in 2025 and beyond. We are confident that the foundations we have laid this past year will, with your help, enable us to support even more blood cancer patients through our collective essential work.



Peter McCleave



Hasnein Alidina



Surpassing donor registration



Representation matters



From frontline to lifeline



From grief to giving



Giving back through fundraising



DKMS UK support

01

Surpassing donor registration

When Tracy, a 34-year-old mother of two, was diagnosed with acute myeloid leukaemia (AML), she had four rounds of chemotherapy. After her fourth round, she relapsed and was told that she needed more chemotherapy and a stem cell transplant, her only chance for complete remission.

Tracy's community in Omagh, Northern Ireland rallied around her. Her family reached out to DKMS for help organising a stem cell donor registration drive.

“Tracy didn’t have a 100% donor match,” explains her sister Louise. “So, we decided to make a public appeal locally, partnering with DKMS to encourage people to join the stem cell donor register.”

Volunteers spread the word on social media, distributed materials to local businesses, PTAs, churches, and clubs, and shared the event via word of mouth in their tight-knit community. The registration event saw 600 registrations in the first four hours. So many came that a second drive was held. People queued around the block to join the stem cell register as potential donors, and DKMS flew in more swabs from England to make sure everyone could sign up.

This was DKMS UK's biggest registration event in recent years, thanks to the engagement of Tracy's community networks and the people of Omagh. Almost **1,500 people turned up** to support Tracy and patients like her, **1,336 people** made online kit requests and **£7,000 was raised**. Tracy's family were so moved to see the huge turnout and overwhelmed by the strength of their community.



“We were absolutely overwhelmed by the support!”

01

Surpassing donor registration



02

Representation matters



03

From frontline to lifeline



04

From grief to giving



05

Giving back through fundraising



06

DKMS UK support

02 Representation matters

The South Asian community is underrepresented on the stem cell donor register. This year, however, an unwavering commitment to encourage people to sign up – regardless of background or religion – was embodied by Tasneem, a Leicester-based mother, GP and dedicated advocate for stem cell donation.

Tasneem, a member of the DKMS East Midlands volunteering hub, has very personal reasons for supporting the work of DKMS: her own son Yusuf, now 16, was diagnosed with acute leukaemia five years ago. She recalls:

“During the time my son was going through treatment, I sadly saw children with cancer who passed away after not being able to find a match. This seemed so unfair. Being of South Asian origin myself, I saw this as an opportunity to help.”





As a Muslim woman from a South Asian background, as well as a GP, Tasneem is a trusted voice from her community.

She works to increase sign-ups to the stem cell donor register by helping to break down taboos and misunderstandings about stem cell donation.

Tasneem ran several events last year, including a donor registration drive in Highcross Shopping Centre, signing up **188 potential stem cell donors**. Tasneem was also instrumental in establishing a partnership between DKMS UK and Islamic Relief, a renowned charity working to improve lives across the Muslim community.



Tasneem's achievements remind us all that change begins with a single step — with every new person registered bringing hope to those searching for a compatible stem cell donor match.

01

Surpassing donor registration



02

Representation matters



03

From frontline to lifeline



04

From grief to giving



05

Giving back through fundraising



06

DKMS UK support



03

From frontline to lifeline

Paul Smith, 57, from Bexley, has dedicated his life to service. He's a former firefighter who has donated blood 83 times and aims for 100. "I've always felt that donating is such an easy way to help others," he says. Paul joined the stem cell register over 20 years ago and is an advocate for donor registration, particularly within Black and other UK ethnic minority communities.

In January 2024, Paul found out he was a match. Despite initial concerns about his age, he went ahead with the donation, supported by his daughter.

“DKMS were amazing at every stage, and post-donation when I was invited to join a special Facebook group for DKMS donors – I really valued that support being available,” he adds.



Paul's donation gave a young woman in the UK a second chance at life. "My children are very proud of me, and that often makes me get a bit teary when I think about it".

Paul's dedication goes beyond donating. During Blood Cancer Awareness Month in 2024, he teamed up with DKMS UK to speak at The Prince's Trust Youth Voice Programme's #Time2Inspire International Youth Day event. He connected with young people from the Black community, many of whom had never heard of stem cell donation. His powerful storytelling sparked curiosity and action. "It's really important for people in our community," one participant shared. "More awareness should be raised, and I'd like to learn more about it."

Paul's dedication continues to inspire and is a testament to the power of one person's actions.



01

Surpassing donor registration



02

Representation matters



03

From frontline to lifeline



04

From grief to giving



05

Giving back through fundraising



06

DKMS UK support

04

From grief to *giving*



Cecilia was a journalism student when her mother was diagnosed with diffuse large B-cell lymphoma. For over a year, she was by her mum's side through gruelling chemotherapy and treatments.

When doctors needed monocytes, Cecilia didn't hesitate; she underwent cell collection to help give her mum more time. Despite their best efforts, Cecilia's mum sadly passed away. But instead of letting grief define her, Cecilia transformed her pain into purpose.

For her final-year journalism project, Cecilia created Dear Cells, a documentary exploring cell therapy.

Through interviews with medical experts, charities including DKMS, and survivors, she set out to demystify stem cell donation and share its lifesaving potential.

Cecilia also registered as a stem cell donor and became a DKMS volunteer. From Freshers Fairs to patient-led drives and fundraising days, she brings warmth, empathy, and a powerful personal story.

Now leading her university's Stem Cell Society, a DKMS-affiliated volunteering group, Cecilia is committed to engaging students, staff, and local communities in



conversations about blood cancers, blood disorders, and the importance of joining the stem cell registry.

Cecilia's journey is a testament to the impact one person can make. She's not only keeping her mother's memory alive – she's helping save the lives of others.

“I want to bring happiness to people, to see smiles on their faces, as I understand the hopelessness they and their families feel upon hearing a diagnosis,” she says.



01

Surpassing donor registration



02

Representation matters



03

From frontline to lifeline



04

From grief to giving



05

Giving back through fundraising



06

DKMS UK support

05

Giving back through fundraising



Matty from Newcastle was just 25 when he received the devastating diagnosis of Hodgkin lymphoma, an aggressive blood cancer.

Six years later, thanks to a selfless donor on the DKMS stem cell register, Matty is thriving.

“It was a very tough challenge starting at 4am and finishing at 6pm. I ended up walking 50,000 steps that day! However, it was all worth it, as we raised £4,345 for DKMS, which was incredibly rewarding.”




Motivated by his experience, Matty is determined to give back by fundraising to support DKMS's lifesaving mission.

"When a group of my friends and I decided to organise a charity golf tournament, we all agreed to support DKMS through this event, as the charity had helped find my matching stem cell donor. Everyone wanted to contribute because they knew how DKMS had helped save my life."

It costs DKMS £40 to register a potential donor to the stem cell register, meaning Matty and his friends raised enough to cover the cost of 108 potential lifesavers.

Matty's stem cell donor gave him a second chance at life; valuable time which he is using to help other patients find their perfect match. He's also embracing new challenges and appreciating everyday pleasures.

"Since my transplant, I've competed in the World Transplant Games, winning two silver medals in slalom snowboarding in Banff, Canada, and I'm gearing up to compete again next year in Dresden, Germany. Being outside has been a huge part of my healing. Even the simple things, like taking my dog to the beach every day, I feel so grateful for."



01

Surpassing donor registration



02

Representation matters



03

From frontline to lifeline



04

From grief to giving



05

Giving back through fundraising



06

DKMS UK support

06

DKMS UK support to *India*

In 2024, DKMS UK played a vital role in strengthening India's efforts against blood cancer and other blood disorders through marketing and outreach.

These efforts resulted in over 55,000 online and in-person registrations, with a wider, positive impact on DKMS' goal of increasing the donor pool with more diverse HLA types.

Potential donors registered in India not only offer hope for their compatriots, but also worldwide

for people of similar heritages, including in the UK where ethnic minority communities are very underrepresented on the stem cell donor register.

DKMS' global Access to Transplantation programme, offering patients in low-income countries access to treatment for blood cancers and disorders, also plays an essential role, as we see in Jasper's story below.

Jasper - Access to *Transplantation*

Mirror reporter Jeremy Armstrong met Jackson in Zambia, who told him that he had lost a son to sickle cell disease and now his 11-year-old, Jasper, also had it.

Jeremy connected them with DKMS UK. We facilitated free HLA typing and Jasper's sister Mercy was a perfect stem cell donor match. Because the potentially lifesaving procedure is unavailable in Zambia, Jeremy, The Mirror and DKMS' Access to Transplantation programme worked together to

fly Jasper, Mercy and their mother Carol to Bangalore, India, where Jasper had a stem cell transplant at the DKMS-funded BMJH-Sankalp Centre.

After ten months of care, Jasper was back home in time for Christmas and his twelfth birthday.

Jasper's story is a powerful reminder that access to healthcare should not depend on geography and the ability to access care.

Our work in *pictures*



DKMS Foundation: Trustee Report

Preparation of report

The company qualifies as small under section 383 of the Companies Act 2006, the strategic report required of medium and large companies under The Companies Act 2006 (Strategic Report and Director’s Report) Regulations 2013 is not required.

DKMS Foundation (referred to hereinafter as ‘DKMS UK’) is incorporated as a charitable company limited by guarantee and is a registered charity in England and Wales, and in Scotland. It is governed by its Memorandum and Articles of Association. The activities, management, finances and strategy of the Charity are overseen by a Board of Trustees, who are also the Company Directors.

DKMS UK is connected through common Trustees to DKMS Group gGmbH (‘DKMS’), and its related charities.

The Trustees who held office during the financial year and at the date of the report are set out on page 56.

A minimum of two Trustees at any one time are required by the Articles of Association. There is no maximum limit required by the Articles. At every Annual General Meeting (AGM) one-third of the Trustees retire by rotation and are eligible for re-election. There is no restriction on the term of tenure as a Trustee. Trustees do not receive remuneration for their duties.

Purpose

DKMS UK’s charitable purposes are set out in its Memorandum of Association as follows:

“The preservation and protection of good health and the relief of sickness of individuals who are suffering from any kind of blood cancer.”

The aims of DKMS UK are to:

- Raise awareness of blood stem cell donation;
- Increase the number and diversity of registered potential blood stem cell donors in the UK; and
- Provide more second chances at life for those with blood cancer or blood disorders whose survival depends upon being matched with an unrelated blood stem cell donor.

Public benefit

DKMS UK raises awareness of blood cancers and blood disorders in the UK, including the life-changing impact of a diagnosis, in order that increasing numbers of the general public know about the need for more people to register as a potential blood stem cell donor. Increasing the number and diversity of potential blood stem cell donors is vital in increasing the life chances of blood cancer and disorder patients who need a blood stem cell transplant. At present, only 7% of the UK’s eligible population are registered as donors compared to much higher levels in some other countries.

Registering more potential blood stem cell donors means that we are able to provide more second chances at life by finding and supporting an unrelated blood stem cell donor who can and will donate their stem cells for a patient in need of a life-saving blood stem cell transplant.

Through recruiting, registering and supporting blood stem cell donors to be part of life-saving treatments, we deliver significant public benefit to patients and their families and to the National Health Service, which arranges treatment and care for those patients.

The Trustees review the aims, objectives and activities of DKMS UK each year, ensuring the Charity remains focused on its stated purpose. This report looks at what DKMS UK has achieved and the outcomes of its work in the reporting period.

The Trustees have referred to the guidance contained in the Charity Commission’s general guidance on public benefit when reviewing the Charity’s aims and objectives and in planning its future activities. In particular, the Trustees consider how planned activities will contribute to the aims and objectives that have been set.

Board and management operations

The Board of Trustees meets twice a year to review DKMS UK's work, finances and services, and to agree the strategic goals for the Charity.

Recruitment and appointment of new Trustees

Trustees are appointed on the basis of their relevant skills and experience. The ongoing Trustees are responsible for the induction of any new Trustees, which involves an awareness of a Trustee's responsibilities, the governing document, administrative procedures, the history, approach and current business plan of DKMS UK.

The Trustees also make available a welcome pack to include copies of the previous year's annual report and financial statements, a brief history of the charitable company and a copy of the governing document. The pack also includes a copy of the Charity Commission guidance 'The essential Trustee: What you need to know. What you need to do.'

While DKMS UK is connected through common Trustees to DKMS Group gGmbH ('DKMS'), it continues to aim to recruit additional Trustees that can broaden and support its representation in the UK.

Management and organisation

Day-to-day operations of the Charity and strategy implementation is delegated to the Country Managers supported by the Senior Leadership Team (SLT). In the absence of the Country Managers, Stephan Schumacher, Trustee oversees the work of the SLT.

The Senior Leadership Team comprises:

- Country Managers Hasnein Alidina and Peter McCleave.
- Head of Communications and Engagement Daniel Philipp Hoffmann.
- Head of Finance Margaret Brett.
- Head of Fundraising Caroline Richardson.
- Head of Donor Support Services Josh Winters.
- HR Manager Lisa Karlsson.
- Head of Donor Recruitment Hannah Tarrant.
- Donor Request Management Work Up Team Lead Louise Bailey.
- Donor Request Management Confirmatory Typing Team Lead Lindsey Dean.

Related parties

The only related parties are considered to be the Trustees and those connected with the Trustees, including their close family, business and other charity interests. There have been no transactions with related parties, nil reimbursement to Trustees.

DKMS Foundation: Trustee Report

Remuneration

In order to recruit and retain staff of the calibre it requires, DKMS UK's pay policy is to remunerate staff at levels above the voluntary sector median rate, but below the private sector market rate. The Charity has an organisational salary structure based upon a job evaluation study and external salary benchmarking concluded in June 2023. New roles are assessed against the job evaluation criteria and placed in a corresponding grade in the structure.

The salary structure's pay levels are reviewed at least annually by the Country Managers to ensure that salary scales are aligned with those for similar positions in the external market. A review of salaries normally takes place annually, and is usually implemented in January. If changes are to be made, staff are advised in writing of the amount and the date from which it takes effect. A salary review does not imply an increase and in making any pay award the review will be based on the organisation's financial health and achievements.

With reference to the National Council of Voluntary Organisation's 2014 inquiry into executive pay (NCVO, Report of the Inquiry into Charity Senior Executive Pay and Guidance for Trustees on Setting Remuneration), the Board of Trustees is committed to including the following information within its annual statutory report and financial statements:

- A summary statement of the Charity's remuneration policy and approach to senior executive pay.
- Disclosures on the number of staff in receipt of more than £60,000 per annum (in bands of £10,000), and the collective total benefits (including pension payments and employer's national insurance) paid to 'key management personnel' (which we have defined as the Senior Leadership Team), in line with the accounting Statement of Recommended Practice 2019 for charities. Given the Charity's size, the Board of Trustees does not believe it is appropriate to disclose the actual/personal salary of any individual member of staff including senior executives, to the public.
- Disclosures on pensions and other staff benefits (see subsequent notes to the financial statements).

Our approach to fundraising

We continue to uphold the highest standards in how we communicate with our fundraising donors and supporters and ensure that our fundraising practices meet the requirements of the recommended Codes of Practice.

We treat our donors and supporters with great respect and gratitude that befits a community of people and organisations that make our work possible.

Key aspects of our approach to fundraising include:

Registration with the Fundraising Regulator, which maintains the standards for charitable fundraising and ensures that fundraising is respectful, open, honest and accountable to the public. It also takes complaints about fundraising, investigates cases and adjudicates on fundraising practice.

Ensuring our fundraising approach is aligned with the Charity's governing objectives.

We have a complaints policy, which outlines our commitment to resolving fundraising complaints as promptly and amicably as possible. It also sets out our process for handling any complaints received. As per our policy, complaints will be reported and referred to the Fundraising Regulator if a resolution with the complainant cannot be reached or if the complaint is about a breach of any aspect of the Code of Fundraising Practice.

In 2024 we did not receive any complaints across the organisation. Trustees are updated on a bi-annual basis with regards to the number of complaints we have handled in the year.

We raise funds through individual giving requests (cash appeals, regular donation asks and online giving), community, challenge events, corporate and trust fundraising.

We do not carry out any telephone, face-to-face or door-to-door fundraising.

We do not use third party agencies to make fundraising requests, although we do use them for fulfilment purposes, e.g. acquisition of charity place challenge events, processing direct debits or distribution of fundraising direct mail. In such situations, legal agreements are in place. In no other circumstance do we swap or share data and we never sell data.

All fundraising activity complies with the UK General Data Protection Regulation (GDPR) and associated legislation and guidance.

Promotional goods sent out for fundraising purposes, and use of our logo on external fundraising materials, is subject to approval. Official stationery, such as our letterhead, is never sent out for external use.

Risk assessment and management

DKMS UK operates a risk assessment and management framework that reviews major risk areas on a quarterly basis.

The Country Managers and individual members of the SLT take responsibility for the day-to-day management and oversight of the above risk areas. The Trustees review the assessments and mitigating actions at their Board meetings and consider the following areas to be the major risks related to DKMS UK's operations and activities.

Medical safety of donors during the blood stem cell collection process

Although the medical process and procedure for blood stem cell donation and collection is safe, well-established and regulated, there will always be some safety risks and DKMS UK acknowledges these and takes them seriously.

The risks to the safety of our donors before, during and after the donation process, as well as any risks to transplant patients from the collection of poor-quality stem cell product are managed and mitigated in the following ways:

- Working in line with approved and regularly reviewed Standard Operating Procedures that comply with domestic and international standards and regulations, and that include clear identification and reporting mechanisms for Serious Adverse Events and Reactions and Quality Incidents.
- Working only with experienced, trusted and appropriately regulated medical partners and services. These relationships in turn are governed via established legal contracts and service protocols and regular service reviews.
- Ensuring a thorough quality assurance system is in place within the organisation, including compliance with the World Marrow Donor Association (WMDA) standards (qualification for which was achieved and approved in March 2021).
- Ensuring ongoing training, support and continuing professional development for all staff involved in the blood stem cell registration and donation process.

DKMS Foundation: Trustee Report

Data management and protection

The collection, processing, storage and security of our blood stem cell donors' personal data and genetic information is of paramount importance and so represents a major risk in the event of mismanagement, loss or misuse of that data.

The potential damage to individual donors through a data breach, let alone the damage to DKMS UK's and the DKMS Group's reputation and activities in working with patients, donors, supporters and stakeholders would be catastrophic.

We manage and mitigate these risks through:

- Adherence to and compliance with strong information security and data protection policies and practices throughout the whole DKMS Group.
- Ensuring data processing and third parties and protocols are in place with suppliers and partners.
- Regular training and reviews for staff, volunteers and donor registration partners.
- Blood stem cell donor recruitment.

Effective and high-quality blood stem cell donor recruitment is essential to ensuring we meet the needs of patients and transplant centres looking for a match. If we fail to ensure we recruit sufficient numbers of donors with a diverse range of backgrounds, and also with accurate and regularly updated personal health and genetic information and contact details, then we risk not being able to save the lives of more blood cancer and blood disorder patients.

We manage and mitigate this risk by ensuring we have:

- Clear and compelling communications and explanations about the registration process and the need for blood stem cell donors.
- Effective quality check and review processes.
- Quality programmes to enhance the health and contact information we have on the priority groups among our blood stem cell donors.
- A system for prioritisation for recruiting, retaining and supporting potential and actual blood stem cell donors.

Financial risks

There are a number of areas of financial risk faced by DKMS UK:

- Failure to achieve budgeted income levels.
- Inadequate financial controls or fraud.
- Poor financial management, including credit risk management, pricing risk and foreign exchange and liquidity risks.

These risks are managed and mitigated in the following ways:

- Strong planning, budgeting and monitoring processes in relation to income streams, including fundraising.
- Strong internal financial controls and data security.
- Regular reviews of fraud risks.
- Close interaction, support and cross-checking with the international financial management and controlling teams in Germany.
- Vetting by DKMS Germany of international health services, registries and companies involved in stem cell transplantation, so that stringent assessments on credit risk are carried out and appropriate financial terms agreed for all DKMS companies within the Group.
- Ensuring pricing of products and services is set at reasonable and affordable levels, that recognise the Group's role as a healthcare service provider with a primary objective of saving lives. Pricing levels are based on a production cost structure and also acknowledge differences in international economies, as well as the need to ensure patient treatments are not jeopardised by costs.

- Maintaining good cash flow and financial management systems in order to manage fluctuations in the major trading currencies in which DKMS UK deals.
- Cash flow projections are prepared as part of the Charity's strategic planning, while liquidity levels are monitored internally on a daily basis as well as reported to central management and Trustees at each reporting period.
- Adequate balances are maintained in all currencies to ensure sufficient funding is available to meet commitments.

Logistical and supply line business continuity and resilience

Ensuring we have reliable, efficient and cost-effective methods for transporting our swab packs, blood samples and collected blood stem cells is crucial to the successful achievement of our organisational goals and objectives to save more lives, as is having a well-stocked and maintained supply line, resources and medicines. To manage and mitigate the risks of business-critical supplies and logistical arrangements we have:

- Implemented strong review processes for stock control and order processing.
- Made alternative arrangements and contingency plans for business continuity and disaster recovery scenarios.
- Developed contingency plans to provide for business periods where we are working at higher than normal levels of activity or volume (e.g. when running successful campaigns).

UK's economic challenges and its effects on DKMS UK business activities

The UK economy in common with almost all countries in the world experienced a sharp increase in the cost of living with inflation reaching over 11% for a short period in late 2022. The Bank of England and the UK government implemented various economic policies to prevent the inflation rate imbedding in the economy and spiralling out of control. Fall in energy prices and good economic governance has resulted in reducing UK's inflation rate to about 2.5% by mid-2024. The UK economic outlook now appears more positive and predictable. However significant part of the cost increases cannot be passed on and are therefore absorbed by the charity. The UK inflation rate remains at 3.8%.

Financial review

Going concern

The Board of Trustees of the ultimate parent company approved an arrangement to continue funding DKMS UK's main activities to meet all its liabilities from its principal, DKMS Group gGmbH for a period not less than 12 months from the date these financial statements are approved. Accordingly, the Trustees continue to adopt a going concern basis in preparing the financial statements.

The company's business activities in 2024 show positive results to budget and the trend is expected to continue for rest of the year with the company's funding requirements expected to remain well within the amounts approved by the board for next three years.

The charitable company's net current assets at 31 December 2024 were 2,410,827 (2023: £2,665,040). Further details regarding the adoption of the going concern basis can also be found in the Accounting Policies on page 30.

DKMS Foundation: Trustee Report

Financial results

DKMS UK received donations totalling £4,817,209 (2023: £3,597,777) of which £3,025,173, (2023: £2,559,143) was donated funds, £1,792,036 (2023: £1,038,634) was donated services from DKMS in Germany.

The charity company's net expenditure for the year amounted to £28,759 (2023: net income £459,791) The reduction in net income was influenced by absorption of higher costs for its charitable activities and costs of supporting and growing DKMS brand awareness in India. This is to encourage donor awareness and registration for treatment of blood cancer, Thalassemia and other blood disorders.

Reserves policy

DKMS UK's aim is to gradually grow its unrestricted funds and achieve full financial independence. While the Charity is growing its income base and cash flow, it continues to receive funding for its main activities from its principal, DKMS Group gGmbH. The Trustees have approved for this arrangement to continue for the foreseeable future and until DKMS UK becomes financially independent to meet all its liabilities for at least 12 months. As at 31 December 2024 DKMS UK's unrestricted funds were £2,659,153 (2023: £2,687,912).

Principal funding

In the period under review, DKMS UK's significant funding comes from donations from DKMS Group in Germany. In the meantime, the charitable company continues to grow its fee income from referral of potential blood stem cell donors and management of peripheral blood stem cell or bone marrow collections and establishing a broader base of additional funding sources to grow its voluntary donation income.

The charity has also developed a fundraising strategy to raise additional funding through new voluntary donations initiatives and events.

Future developments

DKMS remains focussed on achieving steady growth in number of stem cell donations.

We are aware that our donation volume may show some reduction over next 2-3 years as we refocus on increasing our donor pool of young and preferred aged donor group.

Recruitment must remain targeted, with a particular focus on young donors and from ethnic minority communities, as those groups will further help increase our overall number of matched donors, and move us closer to levelling up access to transplantation in these communities.

Fundraising work is planned to grow significantly over the next three years to support our expansion, with important areas for future growth being community-based and volunteer-led programmes, along with an expanded corporate support programme. This support is vital to achieve our aim of finding a matching donor for every stem cell transplant patient that needs one and where required covering the costs of the transplant.

Change of trustees and directors

Dr A H Schmidt resigned as Trustee on 22nd January 2025.

Trustees' responsibilities statement

The Trustees (who are also directors of DKMS Foundation for the purposes of company law) are responsible for preparing the Trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial year. Under company law the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period.

In preparing these financial statements, the Trustees are required to:

- Select suitable accounting policies and then apply them consistently;
- Observe the methods and principles in the Charities Statement of Recommended Practice (SORP);
- Make judgments and accounting estimates that are reasonable and prudent;
- Prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in operation.

Disclosure of information to auditors

Each of the persons who are Trustees at the time when this Trustees' report is approved has confirmed that:

- So far as that Trustee is aware, there is no relevant audit information of which the charitable company's auditors are unaware, and
- That Trustee has taken all the steps that ought to have been taken as a Trustee in order to be aware of any relevant audit information and to establish that the charitable company's auditors are aware of that information.

This report was approved by the Trustees and signed on their behalf by:



Bernd Weinel
Trustee

Date: 7th November 2025

DKMS Foundation: Independent auditors' report to the members and trustees

Opinion

We have audited the financial statements of DKMS Foundation (the 'charity') for the year ended 31 December 2024 which comprise the Statement of Financial Activities, Balance Sheet, Statement of Cash Flows and notes to the financial statements, including a summary of significant accounting policies.

The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

- Give a true and fair view of the state of the charity's affairs as at 31 December 2024 and of income and expenditure for the year then ended;
- Have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- Have been prepared in accordance with the requirements of the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and regulation 8 of the Charities Accounts (Scotland) Regulations 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the "Auditor's responsibilities for the audit of the financial statements" section of our report. We are independent of the charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charity's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the trustees' report, other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- The information given in the trustees' report which includes the directors' report prepared for the purposes of company law for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- The directors' report included within the trustees' report has been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In light of the knowledge and understanding of the charity and its environment obtained in the course of the audit, we have not identified material misstatements in the directors' report included within the trustees' report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 and Charities Accounts (Scotland) Regulations 2006 requires us to report to you if, in our opinion:

- Adequate and proper accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- The financial statements are not in agreement with the accounting records and returns; or
- Certain disclosures of trustees' remuneration specified by law are not made; or
- We have not received all the information and explanations we require for our audit.
- The trustees were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies' exemption in preparing the trustees' report and from the requirement to prepare a strategic report.

DKMS Foundation: Independent auditors' report to the members and trustees

Responsibilities of Trustees

As explained more fully in the trustees' responsibilities statement set out on page 22, the trustees (who are also directors of the charity for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charity or to cease operations, or have no realistic alternative but to do so.

Auditors' responsibilities for the audit of the financial statements

We have been appointed as auditor under Section 44(1)(C) of the Charities and Trustee Investment (Scotland) Act 2005 and under the Companies Act 2006 and report in accordance with the Acts and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the financial statements.

The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud.

Based on our understanding of the charity and its sector, we considered that non-compliance with the following laws and regulations might have a material effect on the financial statements: employment regulation, health and safety regulation, anti-money laundering regulation.

To help us identify instances of non-compliance with these laws and regulations, and in identifying and assessing the risks of material misstatement in respect to non-compliance, our procedures included, but were not limited to:

- Inquiring of management and, where appropriate, those charged with governance, as to whether the charity is in compliance with laws and regulations, and discussing their policies and procedures regarding compliance with laws and regulations;
- Inspecting correspondence, if any, with relevant licensing or regulatory authorities;
- Communicating identified laws and regulations to the engagement team and remaining alert to any indications of non-compliance throughout our audit; and
- Considering the risk of acts by the charity which were contrary to applicable laws and regulations, including fraud.

We also considered those laws and regulations that have a direct effect on the preparation of the financial statements, such as tax legislation, pension legislation, the Charities Act 2011 and the Companies Act 2006.

In addition, we evaluated the trustees' and management's incentives and opportunities for fraudulent manipulation of the financial statements, including the risk of management override of controls, and determined that the principal risks related to posting manual journal entries to manipulate financial performance, management bias through judgements and assumptions in significant accounting estimates, in particular in relation to accruals, income recognition (which we pinpointed to the cut-off assertion) and significant one-off or unusual transactions.

Our audit procedures in relation to fraud included but were not limited to:

- Making enquiries of the trustees and management on whether they had knowledge of any actual, suspected or alleged fraud;
- Gaining an understanding of the internal controls established to mitigate risks related to fraud;
- Discussing amongst the engagement team the risks of fraud; and
- Addressing the risks of fraud through management override of controls by performing journal entry testing.

Use of the audit report

This report is made solely to the charity's members as a body in accordance with Chapter 3 of Part 16 of the Companies Act 2006, and to the charity's trustees, as a body, in accordance with Regulation 10 of the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the charity's members and trustees those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity, the charity's members as a body and the charity's trustees as a body for our audit work, for this report, or for the opinions we have formed.


[Nicola Wakefield \(Nov 12, 2025 08:09:05 GMT\)](#)

Nicola Wakefield (Senior Statutory Auditor) for and on behalf of Forvis Mazars LLP.

Chartered Accountants and Statutory Auditor,
6 Sutton Plaza, Sutton Court Road, Sutton
Surrey, SM1 4FS.

Date: 12th November 2025

DKMS Foundation: Statement of financial activities

(Incorporating income and expenditure account)
for the year ended 31 December 2024

	Note	Unrestricted funds 2024 £	Total funds 2024 £	Total funds 2023 £
Income from				
Donations and legacies	2	4,817,209	4,817,209	3,597,777
Charitable activities	3	8,079,045	8,079,045	8,323,916
Total Income		12,896,254	12,896,254	11,921,693
Expenditure on				
Raising funds	4	1,317,842	1,317,842	1,275,335
Charitable activities	5, 6 and 9	12,571,825	12,571,825	10,186,570
	7, 19	13,889,667	13,889,667	11,461,905
Net income / (expenditure) before prior year VAT adjustments other recognised gains and losses		-993,413	-993,413	459,791
Net income relating to prior year VAT treatment change	12	964,654	964,654	-
Net income / (expenditure) before other recognised gains and losses		-28,759	-28,759	459,791
Reconciliation of funds				
Total funds brought forward		2,687,912	2,687,912	2,228,121
Total funds carried forward		2,659,153	2,659,153	2,687,912

All activities relate to continuing operations. The unrestricted funds above includes £227,554 of income (2023:£175,000) and £227,554 of expenditure (2023:£175,000) that is restricted to fund blood cancer treatment costs for children in Africa and India and funding for nurses education and training in the UK.

The notes on pages 30 to 49 form part of these financial statements.

DKMS Foundation: Balance Sheet

As at 31 December 2024

		2024		2023	
	Note	£	£	£	£
Fixed assets					
Tangible assets	13		248,324		22,871
Investments	14		1		1
			248,326		22,872
Current assets					
Inventory	15	60,688		258,696	
Debtors	16	2,924,811		2,058,021	
Cash at bank and in hand	22	887,731		1,932,055	
		3,873,230		4,248,772	
Creditors: amounts falling due within one year	17	(1,462,403)		(1,583,732)	
Net current assets			2,410,827		2,665,040
Net assets			2,659,153		2,687,912
Charity Funds					
Unrestricted funds	19		2,659,153		2,687,912
Total funds	20		2,659,153		2,687,912

The company's financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The trustees consider that the company is entitled to exemption from the requirement to have an audit under the provisions of section 477 of the Companies Act 2006 ("the Act") and members have not required the company to obtain an audit for the year in question in accordance with section 476 of the Act. However, an audit is required in accordance with section 144 of the Charities Act 2011.

The trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.

The financial statements were approved and authorised for issue by the trustees.

Bernd Weinel

Bernd Weinel

Trustee

Date: 7th November 2025

The notes on pages 30 to 49 form part of these financial statements.

DKMS Foundation: Statement of cash flows

For the year ended 31 December 2024

		2024	2023
	Note	£	£
Cash flows from operating activities			
Net cash provided by operating activities	21	(765,684)	191,963
Cash flows from investing activities			
Purchase of tangible fixed assets		(278,640)	(9,848)
Net cash used in investing activities		(278,640)	(9,848)
Change in cash and cash equivalents in the year		(1,044,324)	182,115
Cash and cash equivalents brought forward		1,932,055	1,749,940
Cash and cash equivalents carried forward	22	887,731	1,932,055

The notes on pages 30 to 49 form part of these financial statements.

DKMS Foundation: **Notes to the financial statements for the year ended 31 December 2024**

01. Accounting Policies

1.1 Basis of preparation of financial statements

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

DKMS Foundation meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

The financial statements are presented in pound sterling (£).

1.2 Going concern

The trustees of the ultimate parent company review the company's activities and 3 year business plan each year and establish and approve funding level required to enable the company to achieve its goals and meet its business commitments and liabilities

The Trustees have approved arrangement to continue funding the charitable company's main activities from its principal, DKMS Gemeinnutzige GmbH until the company becomes financially independent to meet all its liabilities for a period not less than twelve months from the date these financial statements are approved. Accordingly, they continue to adopt going concern basis in preparing the financial statements.

1.3 Company status

The charitable company is limited by guarantee. The members of the company are the trustees named on the back page. In the event of the company being wound up, the liability in respect of the guarantee is limited to £10 per member of the company.

1.4 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the trustees in furtherance of the general objectives of the company and which have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the company for particular purposes. The costs of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2024

1.5 Income

All income is recognised once the charitable company has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably. Money donation income is recognised when the income is credited into the company's account and revenue for clinical services is recognised after services are delivered.

Donated services or facilities are recognised when the charitable company has control over the item, any conditions associated with the donated item have been met, the receipt of economic benefit from the use by the charitable company of the item is probable and that economic benefit can be measured reliably. In accordance with the Charities SORP (FRS 102). General volunteer time is not recognised. Further information about volunteer contribution is included in the trustees' report.

On receipt, donated professional services and donated facilities are recognised on the basis of the value of the gift to the charitable company which is the amount the charitable company would have been willing to pay to obtain services or facilities of equivalent economic benefit on the open market; a corresponding amount is then recognised in expenditure in the period of receipt.

Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

1.6 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to make payment to a third party, it is probable that settlement will be required and the amount of the obligation can be measured reliably.

All expenditure is accounted for on an accruals basis. All expenses including support costs and governance costs are allocated to the applicable expenditure headings:

- Costs of generating funds comprise the costs associated with attracting voluntary income.

- Charitable expenditure comprises those costs incurred by the charitable company in the delivery of its activities and services for its beneficiaries. It includes both costs that can be allocated directly to such activities and those costs of an indirect nature necessary to support them.
- Governance costs include those costs associated with meeting the constitutional and statutory requirements of the charitable company and include the audit fees and costs linked to the strategic management of the charitable company.
- All costs are allocated between the expenditure categories of the statement of financial activities on a basis designed to reflect the use of the resource. Costs relating to a particular activity are allocated directly; others are apportioned on an appropriate basis. Staff costs are allocated based on staff numbers, premises costs are allocated based on space occupied.

1.7 Tangible fixed assets and depreciation

Tangible fixed assets are carried at cost, net of accumulated depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost of fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

- Leasehold improvements - over period of lease straight line.
- Office equipment - 33.33% per annum straight line.
- Computer equipment - 33.33% per annum straight line.

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2024

1.8 Investments

Investments are a form of basic financial instrument and are initially recognised at their transaction value. Investments in subsidiary companies are stated at cost less diminution in value.

1.9 Interest receivable

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the company; this is normally upon notification of the interest paid or payable by the Bank.

1.10 Debtors

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

1.11 Cash at bank and in hand

Cash at bank and in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

1.12 Creditors and provisions

Creditors and provisions are recognised where the charitable company has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due.

1.13 Pensions

The charitable company operates a defined contribution pension scheme and the pension charge represents the amount payable by the charitable company in respect of the year.

1.14 Financial instruments

The charitable company has applied Sections 11 and 12 of (FRS 102) in respect of financial instruments.

Financial assets and financial liabilities are recognised when the charitable company becomes party to the contractual provisions of the instrument. Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the charitable company after deducting all of its liabilities.

The charitable company's policies for its major classes of financial assets and financial liabilities are set out below.

Financial assets

Basic financial assets, including trade and other debtors, cash and bank balances, related charity working capital balances, and related charity financing are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest for a similar debt instrument. Financing transactions are those in which payment is deferred beyond normal business terms or is financed at a rate of interest that is not a market rate.

Such assets are subsequently carried at amortised cost using the effective interest method, less any impairment.

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2024

Financial liabilities

Basic financial liabilities, including trade and other creditors, bank loans and loans from related charities, are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Financing transactions are those in which payment is deferred beyond normal business terms or is financed at a rate of interest that is not a market rate.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Impairment of financial assets

Financial assets measured at cost and amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss is recognised in the profit and loss account.

For financial assets measured at cost less impairment, the impairment loss is measured as the difference between the asset's carrying amount and the best estimate of the amount the charitable company would receive for the asset if it were to be sold at the reporting date.

For financial assets measured at amortised cost, the impairment loss is measured as the difference between the asset's carrying amount and the present value of estimated cash flows discounted at the asset's original effective interest rate. If the financial asset has a variable interest rate, the discount rate for measuring any impairment loss is the current effective interest rate determined under the contract.

If there is a decrease in the impairment loss arising from an event occurring after the impairment was recognised, the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been had the impairment not previously been recognised. The impairment reversal is recognised in profit or loss.

Derecognition of financial assets and financial liabilities

Financial assets are derecognised when (a) the contractual rights to the cash flows from the asset expire or are settled, or (b) substantially all the risks and rewards of the ownership of the asset are transferred to another party or (c) despite having retained some significant risks and rewards of ownership, control of the asset has been transferred to another party who has the practical ability to unilaterally sell the asset to an unrelated third party without imposing additional restrictions.

Financial liabilities are derecognised when the liability is extinguished, that is when the contractual obligation is discharged, cancelled or expires.

Critical accounting estimates and areas of judgment

Management does not consider there to be any key judgements or estimates made in the preparation of the financial statements.

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2024

02. Donations and legacies

	Unrestricted funds 2024	Total funds 2024	Total funds 2023
	£	£	£
Donation income	1,963,061	1,963,061	1,906,353
International donation income	1,062,112	1,062,112	652,790
Funding for donor recruitment activities from DKMS Gemeinnutzige GmbH	1,792,036	1,792,036	1,038,634
Other income	-	-	-
Total donations and legacies	<u>4,817,209</u>	<u>4,817,209</u>	<u>3,597,777</u>
Total 2023	<u>3,597,777</u>	<u>3,597,777</u>	

Donation income includes £227,554(2023 £175,000) collected to fund blood cancer treatment costs for children in Africa and India and funding for nurses education and training in the UK.

03. Charitable activities

	Unrestricted funds 2024	Total funds 2024	Total funds 2023
	£	£	£
Income from service provision	<u>8,079,045</u>	<u>8,079,045</u>	<u>8,323,916</u>
Total 2023	<u>8,323,916</u>	<u>8,323,916</u>	

In the year ended 31 December 2024 and 2023 all income related to unrestricted funds.

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2024

04. Raising funds

	Unrestricted funds 2024	Total funds 2024	Total funds 2023
	£	£	£
Salaries, national insurance and pensions	433,322	433,322	398,184
Other staff costs and training	22,689	22,689	29,990
Premises costs	65,546	65,546	43,195
Publicity & Awareness costs	586,347	586,347	600,138
Postage, support and stationery	3,396	3,396	1,794
Other admin costs	174,340	174,340	170,539
Travel costs	5,995	5,995	6,367
Loss on foreign exchange	18,495	18,495	17,218
Depreciation	7,712	7,712	7,910
	<u>1,317,842</u>	<u>1,317,842</u>	<u>1,275,335</u>
Total 2023	<u>1,275,335</u>	<u>1,275,335</u>	

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2024

05. Direct costs

	Recruitment of Donors	Raising Awareness	Donor Request Management	Total 2024	Total 2023
	£	£	£	£	£
Other direct costs	168,740	35,719	3,643,346	3,847,805	3,313,754
International donor projects - India - Africa	1,008,727	1,775,824	-	2,784,551	2,053,219
Other staff costs and training	628	394	(5,576)	(4,554)	11,506
Premises cost	70,954	116,416	125,186	312,557	194,271
Publicity cost	77,108	269,832	12,204	359,144	358,734
Loss on foreign exchange	17,432	17,432	41,401	76,266	58,255
Postage, support and stationery	199,843	121,919	143,204	464,966	331,409
Travel costs	32,317	5,822	19,841	57,981	28,322
Donor typing costs	1,062,112	-	-	1,062,112	1,038,634
Salaries, national insurance and pensions	375,377	363,960	874,526	1,613,862	1,341,748
Depreciation	7,269	7,269	17,263	31,801	26,762
	3,020,508	2,714,587	4,871,396	10,606,491	8,756,614
Total 2023	<u>2,121,295</u>	<u>2,364,863</u>	<u>4,270,456</u>	<u>8,756,614</u>	

Direct costs includes £227,554(2023 £175,000) collected to fund blood cancer treatment costs for children in Africa and India and funding for nurses education and training in the UK.

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2024

06. Support costs

	Recruitment of Donors	Raising Awareness	Donor Request Management	Total 2024	Total 2023
	£	£	£	£	£
Legal and professional fees	23,507	40,268	39,855	103,631	160,697
Loss on foreign exchange	7,228	7,228	17,166	31,621	24,965
Other staff costs and training	29,039	29,039	68,968	127,047	144,394
Premises costs	24,100	41,283	40,859	106,241	69,379
Travel costs	2,657	2,657	6,311	11,626	24,834
Other support costs	110,121	110,121	308,300	528,541	142,938
Postage, support and stationery	560	560	1,331	2,450	1,122
Admin costs	(1,576)	(1,576)	(3,742)	(6,893)	1,243
Salaries, national insurance and pensions	228,288	228,288	542,184	998,760	783,979
Depreciation	3,014	3,014	7,158	13,186	11,470
Total 2024	426,938	460,882	1,028,391	1,916,210	1,365,021
Total 2023	287,006	324,217	753,798	1,365,021	

In the year ended 31 December 2024 and 2023 all expenditure related to unrestricted funds.

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2024

07. Analysis of expenditure by expenditure type

	Staff Costs 2024	Depreciation 2024	Other Costs 2024	Total 2024	Total 2023
	£	£	£	£	£
Expenditure on raising voluntary income	433,322	7,712	876,808	1,317,842	1,275,335
Costs of raising funds	433,322	7,712	876,808	1,317,842	1,275,335
Recruitment of donors	603,665	10,283	2,833,499	3,447,446	2,408,299
Raising awareness	592,248	10,283	2,572,940	3,175,470	2,689,081
Donor request management	1,416,710	24,422	4,458,654	5,899,786	5,024,255
Charitable activities	2,612,622	44,987	9,865,093	12,522,702	10,121,635
Expenditure on governance	0	0	49,124	49,124	64,932
Total 2024	3,045,944	52,699	10,791,024	13,889,668	11,461,902
Total 2023	<u>2,523,912</u>	<u>46,142</u>	<u>8,891,848</u>	<u>11,461,902</u>	

Direct costs includes £227,554(2023 £175,000) collected to fund blood cancer treatment costs for children in Africa and India and funding for nurses education and training in the UK.

Expenditure on raising voluntary income has not been allocated to specific activities as all costs relate to general charitable activities.

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2024

08. Analysis of expenditure by activities

	Activities undertaken directly 2024	Support costs 2024	Total 2024	Total 2023
	£	£	£	£
Recruitment of donors	3,020,508	426,938	3,447,446	2,408,301
Raising awareness	2,714,587	460,882	3,175,469	2,689,080
Donor request management	4,871,396	1,028,391	5,899,786	5,024,254
Total 2024	10,606,491	1,916,211	12,522,702	10,121,635
Total 2023	8,756,614	1,365,021	10,121,635	

Direct costs includes £227,554(2023 £175,000) collected to fund blood cancer treatment costs for children in Africa and India and funding for nurses education and training in the UK.

09. Governance costs

	Unrestricted funds 2024	Total funds 2024	Total funds 2023
	£	£	£
Auditors' remuneration	25,750	25,750	29,400
Legal and professional fees	23,374	23,374	35,532
Total	49,124	49,124	64,932

In the year ended 31 December 2024 and 2023 all costs of direct charitable activities related to unrestricted funds.

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2024

10. Net resources expended

This is stated after charging:

	2024	2023
	£	£
Depreciation of tangible fixed assets		
- Owned by the charity	52,699	46,142
Auditors' remuneration - audit	25,750	29,400
- Non-audit services Taxation advice	<u>31,100</u>	<u>26,710</u>

During the year, no trustees received any remuneration (2023- £Nil).

During the year, no trustees received any benefits in kind (2023 - £Nil).

During the year, no trustees received any reimbursement of expenses (2023 - £Nil).

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2024

11. Staff Costs

Staff costs were as follows:

	2024	2023
	£	£
Salaries	2,645,831	2,197,776
Social security costs	263,127	218,697
Pension costs	103,519	80,823
Total	<u>3,012,477</u>	<u>2,497,296</u>

The average monthly number of employees was: 58 (2023: 50) and the average monthly number of employees during the year expressed as follows

Full time equivalents was as follows (including part-time and fixed period temporary staff):

	2024	2023
	No.	No.
Donor recruitment	8	6
Fundraising	6	6
Communications	8	6
Medical	19	17
Administration	8	8
Donor Service	6	6
Charity activity development	3	1
Total	<u>58</u>	<u>50</u>

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2024

The number of higher paid employees was:

	2024	2023
	No.	No.
In the band £60,001 - £70,000	4	4
In the band £70,001 - £80,000	3	1
In the band £80,001 - £90,000	0	0
In the band £90,001 - £100,000	0	0
In the band £100,001 - £110,000	1	0
In the band £110,001 - £120,000	0	1
In the band £120,001 - £130,000	0	0
In the band £130,001 - £140,000	0	0
In the band £140,001 - £150,000	1	0
In the band £150,001 - £160,000	0	0
Total	9	6

The charitable company trustees were not paid or received any other benefits from employment with the charitable company in the year (2023: £Nil) neither were they reimbursed expenses during the year (2023: £Nil). No charitable company trustee received payment for professional or other services supplied to the charitable company (2023: £Nil)

The key management personnel of the charitable company are the trustees, the Chief Executive Officer, the heads of departments and team leads. There are 11 heads of department and team leads (2023: 6), nine of whom received remuneration in excess of £60,000 during the year (2023: 6). The total employee benefits of the key management personnel of the charitable company were £927,942 (2023: £626,365).

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2024

12. Net income relating to prior year VAT treatment change

The adjustment relates to net VAT charge following change in the charity's VAT status from a change in Stem cell collection process in 2020. Input VAT of £656,984 is now payable and output VAT of £1,621,638 is now claimable for periods from July 2020 - December 2023

13. Tangible assets

	Office Equipment	Computer Equipment	Leasehold Improvements	Total
Cost	£	£	£	£
At 1 January 2024	69,800	176,721	228,855	475,376
Additions	123,952	29,414	125,274	278,640
Disposals	(80,973)	(22,176)	(104,369)	(207,518)
At 31 December 2024	<u>112,779</u>	<u>183,959</u>	<u>249,760</u>	<u>546,498</u>
Accumulated Depreciation				
At 1 January 2024	65,887	157,763	228,855	452,505
Charge for the year	18,623	18,402	15,673	52,698
Release on disposal	(80,973)	(21,688)	(104,369)	(207,030)
At 31 December 2024	<u>3,537</u>	<u>154,477</u>	<u>140,159</u>	<u>298,173</u>
Net book value				
At 31 December 2024	<u>109,242</u>	<u>29,482</u>	<u>109,601</u>	<u>248,325</u>
At 31 December 2023	<u>3,913</u>	<u>18,958</u>	-	<u>22,871</u>

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2024

14. Investments

Shares in Group Undertakings

	£
Costs and net book value	
At 31 December 2024 and 31 December 2023	<u><u>1</u></u>

The company's wholly owned subsidiary, Delete Blood Cancer UK Marketing Limited, registered at Ashburnham House, Castle Row, Horticultural Place, London W4 4JQ is a dormant company. Its net liability position at 31 December 2024. £10,245 (2023: £10,245) is represented by amounts due to parent company and is fully provided for in the accounts of the parent company.

15. Inventory

Inventory costs were as follows:

	2024	2023
	£	£
Materials stock	50,999	153,757
Work in progress costs	9,689	104,939
Total	<u><u>60,688</u></u>	<u><u>258,696</u></u>

Inventories are valued at lower of cost and net realisable value. Work in progress costs are reimbursable costs incurred for active stem cell collections awaiting to be billed.

16. Debtors

	2024	2023
	£	£
Due within one year		
Trade debtors	1,949,139	1,505,825
Amounts owed by group undertakings	10,245	10,245
Amounts owed by related charity	217,495	332,338
Other debtors	495,757	8,092
Prepayments and accrued income	252,175	201,521
Total	<u><u>2,924,811</u></u>	<u><u>2,058,021</u></u>

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2024

17. Creditors: Amounts falling due within one year

	2024	2023
	£	£
Trade creditors	431,061	459,989
Amounts owed to related charity	6,929	10,336
Other creditors	109,038	184,490
Deferred revenue - UK Gala	223,519	270,000
Other taxation and social security	80,899	67,473
Accruals	610,957	591,444
Total	1,462,403	1,583,732

Other creditors include £223,519 (2023: £270,000) deposits received for the fundraising event scheduled to be held in May 2025.

18. Financial instruments

	2024	2023
	£	£
Financial assets		
Financial assets that are debt instruments measured at amortised cost	2,672,636	1,856,500
Financial liabilities		
Financial liabilities measured at amortised cost	(437,990)	(470,325)
Total	2,234,646	1,386,175

Financial assets measured at amortised cost include trade debtors, amounts owed by group companies, other debtors and amounts owed by related charity

Financial liabilities include trade creditors and amounts owed to a related charity.

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2024

19. Summary of funds

	2024	2023
	£	£
At 1 January	2,687,912	2,228,121
Income for year	12,896,254	11,921,693
Resource expended	(13,889,667)	(11,461,902)
Net income relating to prior year VAT treatment change	964,654	-
At 31 December	2,659,153	2,687,912

20. Analysis of net assets between funds

Analysis of net assets between funds - current year:

	Unrestricted funds 2024	Total funds 2024
	£	£
Tangible fixed assets	248,325	248,325
Fixed asset investments	1	1
Current assets	3,873,230	3,873,230
Creditors due within one year	(1,462,403)	(1,462,403)
Total	2,659,153	2,659,153

Analysis of net assets between funds - prior year:

	Unrestricted funds 2023	Total funds 2023
	£	£
Tangible fixed assets	22,871	22,871
Fixed asset investments	1	1
Current assets	4,248,772	4,248,772
Creditors due within one year	(1,583,732)	(1,583,732)
Total	2,687,912	2,687,912

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2024

21. Reconciliation of net movement in funds to net cash flow from operating activities

	2024	2023
	£	£
Net income for the year (as per Statement of Financial activities)	(28,759)	459,791
Adjustment for		
Depreciation charges	52,698	46,142
Loss on disposal	488	-
(Increase) in debtors	(866,790)	(744,872)
Increase / (Decrease) in creditors	(121,329)	404,583
Decrease in inventory	198,008	26,319
Total	(765,684)	191,963

22. Analysis of cash and cash equivalents

	2024	2023
	£	£
Cash at bank and in hand	887,731	1,932,055
Total	887,731	1,932,055

23. Operating lease commitments

At 31 December 2024 the total of the charity's future minimum lease payments under non-cancellable operating leases was:

	2024	2023
	£	£
Within 1 year	266,951	266,951
Between 2 and 5 years	740,150	1,007,101
Over 5 years	-	-
Total	1,007,101	1,274,052

Lease payments recognised as an expense amounted to **£270,705** (2023: £255,910).

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2024

24. Related party transactions

The company has taken advantage of the exemption contained in FRS 102 section 33 "Related Party Disclosures" from disclosing transactions with entities which are a wholly owned part of the group.

Transactions with other related parties are as follows:

Name (relationship)	Transaction	Amount		Amount due from / (to) related party	
		2024	2023	2024	2023
		£	£	£	£
DKMS Donor Centre gGmbH (Common Trustees)	Donated services	6,250	-	(395)	-
DKMS Donor Centre gGmbH (Common Trustees)	Intercompany funding	-	560,484	-	319,810
DKMS Group gGmbH (Common Trustees)	Donated services	1,062,112	1,038,634	-	-
DKMS Group gGmbH (Common Trustees)	ATT	230,000	-	-	-
DKMS Group gGmbH (Common Trustees)	Intercompany recharges	477,048	302,352	-	(12,994)
DKMS Group gGmbH (Common Trustees)	Interco funding	1,792,036	-	186,351	-
DKMS Registry Gemeinnutzige GmbH	Intercompany service provision	102,058	101,610	(5,665)	(3,780)
DKMS USA (Common Trustees)	Intercompany service provision and recharges	29,747	10,341	(839)	(942)
DKMS USA (Common Trustees)	International money donation	50,519	7,857	-	-
DKMS ASIA (India)	Intercompany support services	1,650,873	-	-	-
DKMS BMST (India)	Intercompany support services	1,011,916	2,142,741	-	-
DKMS Foundation NPC (South Africa)	Intercompany service provision	35,879	50,635	14,696	12,703
Fundacja DKMS (Poland)	Intercompany Recharges	1,695	-	1,695	-

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2024

Amounts owed to related parties are unsecured, interest free and due for repayment within one year.

DKMS Group gGmbH is the Controlling company and exercises full control over the charitable company through its common Trustees who are also directors of the company. The controlling company recharges the charitable company actual or appropriately apportioned costs it incurs in providing support to the latter.

The controlling company DKMS Group gGmbH entered into a contract with DKMS Life Science Lab whereby DKMS Foundation receives typing services for no consideration from 01 January 2021.

DKMS Life Science Lab is one of the leading HLA laboratories and provides this service for all DKMS entities.


25. Post balance sheet events

No post balance sheet events.

26. Controlling party

The trustees are the immediate controlling party and DKMS Group gGmbH is the ultimate controlling party. The principal address of the ultimate parent is Kressbach 1, 72072 Tubingen, Germany.

Copies of the group financial statements are available at www.dkms.de.



Ways you can support us

Organise a donor registration event

Organise an event to encourage your friends, family or colleagues to register as potential stem cell donors.

Create a bespoke partnership

DKMS can provide your company with networking and marketing opportunities aligned with our purposes and shared values.

Payroll giving

Donate to DKMS through your company's Payroll Giving Scheme if employees are paid through PAYE.

The 2K Club

Join our club of corporate supporters whose contribution goes towards helping the more than 2,000 people in the UK searching for a matching stem cell donor each year.

Sponsored activities

From local 10k runs and marathons to multi-day cycle trips, challenge yourself and get fit!

Fundraising events

Whether holding a bake sale, organising a music night or giving up a vice, every penny you raise helps in the fight against blood cancer.

Daredevil challenges

If you fancy standing on top of a plane, jumping out of one, or filling your run with obstacles, we have something for everyone.

Giving in memory

Many people choose to remember a loved one by fundraising for DKMS. We'll help you through the process to make sure their memory lives on through our work.





“We would like to say a huge thanks to all Charitable Trust funders and Foundations who gave us their generous and ongoing support”





A huge *thank you*

We would like to say a huge thanks to all Charitable Trust funders and Foundations who gave us their generous and ongoing support especially:

PF Charitable

C.A. Rookes Charitable Trust

B-CH 1971 Charitable Trust

Beaverbrook Charitable Trust

Gallagher Insurance
Neighbourly Fund

Hudson Charitable Trust

Old Epsomian Lodge

The Artemis Charitable Foundation

The Clemens Neumann Nathan
Charitable Trust

The Mistra Trust

Trustees

Dr. E Neujahr
B J Abel
Bernd Weinel
Dr. A H Schmidt (resigned 22nd January 2025)
S Schumacher

110,000

Transplants for people in need

Principal staff

Hasnein Alidina, Country Manager,
Finance and Operations

Peter McCleave, Country Manager,
Communications and Engagement

12m

Potential donors registered

Registered company number

08151279

24

Lifesaving stem cell donations each day*

Charity registered number

1150056 (England & Wales)

SC046917 (Scotland)

*Global DKMS statistics as of 31 December 2024

Registered office

Ashburnham House, Castle Row,
Horticultural Place
London W4 4JQ

Company secretary

B J Abel

Independent auditors

Forvis Mazars LLP
6 Sutton Plaza
Sutton Court Road
Sutton
Surrey
SM1 4FS

Bankers

Barclays Bank plc
74 Shepherd's Bush Green
Shepherd's Bush
London W12 8QD

Commerzbank AG
30 Gresham Street
London EC2V 7PG

DKMS is the trading name of DKMS Foundation, a company limited by guarantee registered in England and Wales (08151279) and a charity registered in England and Wales (1150056) and Scotland (SC046917).

DKMS FOUNDATION

England & Wales - Charity number 1150056

Accounts

DKMS
WE DELETE BLOOD CANCER

Elsie is thriving in her life, nine years after her successful stem cell transplant.



Impact Report and Financial Statements

»» Year ending 31 December 2023



Our Vision

To delete blood cancer.



Our Mission

To give as many blood cancer patients as possible a second chance at life.



Our Purpose

To raise awareness of blood cancer and blood disorders, recruit and retain potential stem cell donors to provide a second chance at life, raise funds to match donor registration costs, provide access to transplantation for more blood cancer patients, and improve blood cancer therapies by our own research.

Contents

Managing Director's introduction	02
Introduction	03
Donor recruitment	09
Fundraising	13
Volunteering	17
Trustees' Report for the year ended 31 December 2023	21
Independent auditors' report to the members and Trustees of DKMS Foundation	27
Statement of financial activities	31
Ways you can support us	54

Managing Director's introduction

2023 was a year of exciting developments across all departments. During Blood Cancer Awareness Month, we orchestrated 14 registration events over a single weekend — collaborating with mothers whose children had received life-saving stem cell donations. Through these events, we added more than 3,500 potential lifesavers to our database.

In the medical domain, we established partnerships with two additional experienced collection centres. In April, we expanded our services through a collaboration with The Christie NHS Foundation in Manchester, and in July, we solidified our partnership with The Scottish National Blood Transfusion Service (SNTBS). As a result, our donors now have the option to undergo collection procedures in both Edinburgh and Manchester in addition to London and Sheffield.

In the realm of fundraising, our partnership with ING deserves a special mention. Through this collaboration, we raised £125,000 — an achievement that translates to the registration of over 3,000 new donors.

Our Customer Service Team was pleased to implement Salesforce for customer service purposes early in 2023. Consequently, we now have significantly enhanced analytical capabilities, allowing us to provide an even better service to our donors.

Another significant milestone was our Address Update Mailing campaign in November/December, during which over 80,000 donors confirmed or updated their details. This will have a positive effect on stem cell donations

we orchestrate, as it is crucial for us to keep our donors informed and addresses up to date when they become lifesaver for a patient worldwide.

And let's not forget our invaluable volunteers. With the establishment of the new East Midlands Volunteering Hub, we now have a total of six hubs spread across the UK. These hubs have been instrumental in bolstering our activities at universities. Notable registration events took place at the University of Stirling, the City of Glasgow College and the Royal Agricultural University, among others.

By the end of 2023, we also paved the way for Pete McCleave to assume the role of Managing director for Communication & Engagement and to replace Stephan in his role. We wish him every success!



Stephan Schumacher



Hasnein Alidina

Following my diagnosis of myeloma nearly eight years ago, I dedicated significant energy and time to supporting DKMS UK in its crucial mission. After successful campaigns such as 10,000 Donors and Gob4Good, I am now pleased to contribute as the Managing director for Community & Engagement. I eagerly anticipate collaborating with our teams, as we have ambitious goals ahead.

I extend my gratitude to Stephan and Hasnein for establishing a solid foundation over the past few years, and I look forward to working alongside the dedicated DKMS UK teams.

A pivotal project for me in 2024 is the e-registration initiative. Our aim is to simplify and modernise the registration process for stem cell donors. Additionally, digital data capture will enhance overall quality.

Drawing from my volunteer experience with DKMS UK, I understand the critical importance of informing and educating new donors. Particularly within ethnic minority communities — dispelling myths and misinformation remains essential to overcoming barriers to registration.


These very communities play a vital role in improving the global situation for individuals reliant on compatible stem cell donors.

Given my personal history, volunteering holds a special place in my heart. This is why one of my most valued projects focuses on revitalising our volunteer program. I hope to attract even more dedicated volunteers and make volunteering for DKMS UK both engaging and fulfilling.

As we approach the end 2024, I welcome the challenges that lie ahead. Together, we will bring success that our wonderful charity was designed to deliver and by extension, offer hope to the patients, families and friends who need us most in 2025 and beyond.



Peter McCleave



01

Introduction



02

Donor Recruitment



03

Fundraising



04

Volunteering

01 Introduction

In 2023, DKMS UK made a significant impact by continuing to expand and diversify the stem cell register, as well as by offering crucial support to patients with blood cancer and blood disorders. 2023 was particularly special as we celebrated our tenth anniversary of beginning work in the UK.

Our focus throughout the year was to increase awareness around the stem cell registry and to register more potential lifesavers across the UK. Our efforts facilitated critical stem cell transplants, profoundly affecting hundreds of lives, both nationally and globally. Meanwhile, our fundraising campaigns led to significant corporate partnerships, further amplifying our mission.

Looking ahead to 2024, we are committed to intensifying our efforts, with a special focus on registering donors from minority ethnic communities to ensure everyone has an equal opportunity to find a potentially lifesaving stem cell match. The notable, recent growth in our staff numbers has enhanced our capacity to support this mission.

The stories presented in this report illustrate the vital impact DKMS UK has had on the lives of patients with blood cancers or disorders, stem cell donors, and our supporters throughout 2023.

Our Work With Donors

In 2023, our Confirmatory Typing (CT) team saw considerable growth in the number of team members to accommodate the increased volume of CT requests, amplifying DKMS's commitment to eliminate blood cancer. The CT team works quickly and effectively in time-sensitive situations, often making a potentially lifesaving difference for patients in need of a stem cell transplant.



As the first point of contact for potential donors, the CT team plays a crucial role in the donation process, ensuring that donors are well-prepared to provide the best possible results for patients. By prioritising donor safety, we aim to achieve the best outcomes for patients. The stories of stem cell donors like Joe and Poonam, as told below, highlight the incredible lifesaving potential that stem cell transplants can have.

In 2023, the CT team handled an impressive 3,941 CT requests, which is a significant increase from previous years: 296 more than in 2022 and 856 more than in 2021. This represents more than double the number of requests since 2018, when we managed 1,961 requests. This growth proves our dedication and efficiency in meeting the rising demand for stem cell donors. A key achievement in 2023 was the successful conversion of 3,941 CT requests into 359 collections, achieving a remarkable conversion rate.

Looking ahead to 2024, we are committed to intensifying our efforts, with a special focus on registering donors from minority ethnic communities to ensure everyone has an equal opportunity to find a potentially lifesaving stem cell match.

The notable, recent growth in our staff numbers has enhanced our capacity to support this mission.

01

Introduction



02

Donor Recruitment



03

Fundraising



04

Volunteering

Here, two of our incredible donors tell their stories.

Empowering people to become stem cell donors: Joe's story

"It's an opportunity to possibly save a life. It made me feel joyful – you will feel so much joy if you get that chance too."

Joe loves outdoor activities – getting out cycling, camping, running and keeping fit. He's also passionate about encouraging more people from his community to register as potentially life-saving stem cell donors, even more so after recently becoming a donor himself.

"I registered with DKMS as a potential donor back in 2017, after a friend and colleague of mine in the Royal Navy needed a stem cell transplant.

He is from St Vincent, and he needed a specific genetic match with someone from a Caribbean background. I'm from Trinidad and Tobago, and I wanted to help.

We don't have enough people from our community registered, but it is giving someone a chance of living, of getting better. So, I organised a series of events at Royal Navy bases across the UK to encourage more colleagues to join the DKMS stem cell register. I was really happy that over 1,000 people signed up – if I can play a part, then I want to help all I can. Thankfully, my friend found a match, and he is much better today.



During the summer of 2023, I was working at the Edinburgh Military Tattoo – I do supply logistics for the Navy, and I was busy supporting musicians from Trinidad and Tobago. I got a call from DKMS to say that I was potentially a match for someone needing a transplant.

For me, it's something you have to act upon, if you get called and asked if you will be a donor. I thought, 'Let's get it done!'

At the start of the donation process, Joe first went for medical checks at Scotland's new stem cell collection centre, launched in August 2023 by DKMS and the Scottish National Blood Transfusion Service.

"DKMS's medical team had explained everything. Once everything was OK to go ahead, and I went in to donate; the nursing staff were amazing."

DKMS UK is committed to working with heroes like Joe, to empower more people from ethnic minority communities to make an informed choice about joining the stem cell register.

Joe shares: "In our community, there can be a lot of stigmas around going into hospital for anything; if you come from a Caribbean background, people can fear

that you will go into hospital and not come out, and historically there can be fears that procedures will be done and not properly followed up. We need to break down these sorts of barriers, and I think it's really good for people from my community to see someone like me complete the process of registering as a donor and stem cell donation.

I was able to give someone a possible second chance. I know now that the patient who had my stem cells transplanted was a little boy. This made me feel humbled and honoured to have the opportunity to do my little part in this ever-changing society. Hopefully my experience will encourage others to step up and get registered."



"I was able to give someone a possible second chance. I know now that the patient who had my stem cells transplanted was a little boy. This made me feel humbled and honoured to have the opportunity to do my little part in this ever-changing society. Hopefully my experience will encourage others to step up and get registered."

01

Introduction

Meeting my stem cell recipient – a spur to action: Poonam and Viren’s story

“We ring regularly, and I’ll send him updates about my children. I felt awkward calling him Viren because, culturally, you wouldn’t call someone who’s much older by their first name. You’d say, ‘Viren uncle’. And he’s like, ‘No!’ He’ll joke and say, ‘I’m only three years old’, because he feels his transplant means he has a new life.”

Poonam donated her stem cells at the London Clinic in 2020, during the first UK-wide lockdown at the start of the Covid-19 pandemic. She remembers:

“All I knew about my recipient was that it was a man. They explained we couldn’t directly contact each other for two years, and only if both sides agreed. But we could write anonymously via DKMS, if we’d like to.

So, I wrote a letter quite soon afterwards – DKMS checked it and sent it on to him. He didn’t get it until a few months later, because of Covid, but I sent some sunflower seeds and wrote ‘By the time these have bloomed, hopefully you’re OK’.

I got a letter back from him, and then we used to write quite regularly. I wrote about how I’d had another child, and he’d write about things that he was doing. I thought ‘Wow, this person sounds so articulate and well-educated’, and I suppose I had a bit of a presumption that he was someone older, and that he might be from a similar heritage or culture. But it was like writing to a friend you’ve always known, it was really nice.”

02

Donor Recruitment

03

Fundraising

04

Volunteering





“A bond was naturally in place. I don’t think either one of us was surprised at how easily we related to each other. We are a part of life together. Few are as fortunate as I am.”

In 2023, a year after they’d both agreed to direct contact, Poonam and her family flew to New York, to meet her stem cell recipient Viren and his family. Viren was born in India in 1950 but came to America where he gained a pharmacology doctorate and an MBA. In 2019, he developed myelofibrosis: a stem cell transplant was the only treatment.

“As we planned our meeting, I was honest and open,” Poonam continues. “Viren and his wife asked, ‘Should we record it?’ and I said, ‘I really don’t want any big fanfare’. Because I didn’t do it for any kind of gain. I did it because I’d want someone to do the same for my family, if we were in that position. Viren’s a great listener, so, when we met they just kind of like ‘Oh, how are you?’ They were so nice and normal.

To be honest, one thing I’d been dreading was, ‘what if we meet, and I don’t like him?’ But Viren’s such a lovely, nice, kind man. He’s done really well in life, but he’s still very humble, and very grateful.

We were staying with them, but they made a point of saying, ‘This is your time away from work and everything. Please just treat it like a holiday.’ So, we did a lot of stuff with the kids, like walking round Times Square. Then some evenings we did things with Viren and his family.

One evening, everyone had gone to bed and it was just me, and him and his daughter, and we were talking about lots of things. He said to me, ‘You do realise now you’re like family to me, you’re like a daughter to me’. I think of him as an older, caring friend.”

Viren says: “A bond was naturally in place. I don’t think either one of us was surprised at how easily we related to each other. We are a part of life together. Few are as fortunate as I am.

I appreciate DKMS’s amazing work. Poonam’s stem cells have built a happy home in my bone marrow, my blood group has changed to hers, and my old, dry skin is greatly improved. Now if only I can figure out how to get her sparkling, vivacious energy and her deeply rooted ethics! But her stem cells have done much more: I continue to enjoy in my full and fulfilled life.”

Both Viren and Poonam, on opposite sides of the Atlantic, encourage more people to join the global stem cell register. Viren advocates at universities for students to sign up as potential stem cell donors when they start their studies.

Poonam concludes, “I know that there are so many people impacted, so the more I do with DKMS – like helping them encourage more people from our community to mark Diwali by joining the register – will help make sure that other people find their stem cell match.”

01

Introduction



02

Donor
Recruitment



03

Fundraising



04

Volunteering



02 Donor recruitment

In 2023, our Donor Recruitment team celebrated having one million active registered stem cell donors in the UK – a milestone we reached in October.

In April, we had nearly 10,000 kit requests thanks to patient appeals in Northern Ireland. This helped DKMS UK to build relationships with local businesses and create future partnerships for 2024.

During Blood Cancer Awareness Month, we worked with a group of mothers with children who have received a life-threatening diagnosis of leukaemia or bone marrow failure. With them, we ran a campaign to raise awareness for childhood cancer: 'Swab to Save a Child'. On Sunday 17 September, they hosted 14 events simultaneously across England, to register new potential stem cell donors.

Along with other events held across the weekend of 16-17 September, this resulted in over 3,500 potential new donors signing up with DKMS.

Families were a main theme in 2023 – from helping families find a stem cell match for their loved ones in need, to mothers donating their stem cells. Here are just two stories from people we've worked with to encourage people to join the UK stem cell register.

Inspiring others to register: Jo's story

"There are so many things that we can't change in the world, but this we can. By signing people up to the stem cell register, we can have a chain of people ready and waiting to help other people and completely change their lives."

Jo's son Oti received a stem cell transplant after being diagnosed with acute myeloid leukaemia in 2022. Today, at three years old, he is healthy and thriving.

"I am forever grateful to Oti's donor. Oti now tells people that he has 'magic blood'. Watching him loving life inspired me to encourage more people to join the stem cell register.


In September 2023, to help mark Blood Cancer Awareness Month, I decided to organise a swabbing event at a restaurant near where we live in Essex. I worked with DKMS to spread the word locally about what we were doing – and about how a stem cell transplant had completely given Oti a second chance at life – to help people make an informed choice.

So many gave up their precious Sunday morning: it was the busiest and best day and felt like such a celebration. Over 200 people signed up there and then, with even more people going online afterwards to request a swab kit from DKMS.

Even better, already one of the people who came along on the day has proved to be a compatible match for a patient needing a stem cell transplant, and has been called to donate. That could mean the world to someone!"

After Jo's success in registering new potential donors, she's continued to support DKMS by sharing her story with journalists, and playing a key role in developing our partnership with Battle Cancer. Her message for anyone thinking of hosting a stem cell registration event themselves?

"One: go for it. Two: you will be completely supported. Three: you can't fail. If you manage to get one person on the register, that person could be a match for someone with a blood cancer or disorder. It's made me feel so incredible about humanity and what we can do for each other."



"I am forever grateful to Oti's donor. Oti now tells people that he has 'magic blood'. Watching him loving life inspired me to encourage more people to join the stem cell register."

01

Introduction



02

Donor
Recruitment



03

Fundraising



04

Volunteering

Curiosity, conversations and stem cell registration: Fran's story

"Donating is one of the single most amazing things I've ever done, and I am so proud. I will talk about it to everyone."

Fran joined the stem cell register in 2018 after coming across a Facebook post sharing a link to DKMS.

"It blew my mind that this was a thing, and I signed up straight away. It was a quick turnaround of three weeks to a month from the time I signed up to the time I got the call saying I was a compatible match for someone needing a stem cell transplant.

When I first heard about stem cell transplants, I assumed that if you needed one, it would just happen instantly, whether it was through someone related to you or straight through the NHS.

The amount of people walking around completely unaware that they can save lives, when the process is a walk in the park. I went to donate my stem cells on my own, without my children, and it was a nice break! There was no negative impact for me; it was so straightforward, and it was made very easy. I got in touch after my donation with DKMS about volunteering, and joined their Scotland Hub."

The DKMS Scotland Hub and Student vs Blood Cancer volunteers planned a Superswab event at the University of Stirling in February 2023, signing up over 100 people to the stem cell register. The hub also has an ongoing partnership with Scotblood and attend their blood drives across Scotland to sign up people who are interested to the stem cell register. The Scotland Hub was also at the Scotblood Conference in Stirling to raise awareness for DKMS and the stem cell register. Overall, in 2023, the Scotland Hub organised 15 drive events and registered nearly 500 potential donors. Fran was a frequent participant, and her story is a driving force in inspiring others to sign up for the register.





“For the most part, at donor drive events, people are curious and have questions around the process. Everyone will know at least one person affected by cancer – most people will want to help but have questions and misconceptions around the process. When running drives, we start with a small group of volunteers. They receive training, and go through the swabbing process themselves, so they see how simple it is. The atmosphere at these events is positive because these volunteers feedback their energy to the people coming in.”

Fran donated her stem cells in 2018, and says that she wouldn't hesitate to donate again if asked.

“One of the best days of my life was getting a ‘thank you’ letter from my patient, who was a woman my age, and had a daughter the same age as my son. She spoke about being able to watch her daughter grow up. You can't put a price on that. It really helps to put yourselves in their shoes. If it was someone that you knew that needed help, you wouldn't even think first.

We equip people with every bit of information we can so that they can make their choice.”

As well as inspiring others to sign up, Fran is a passionate fundraiser for DKMS. In 2023, she ran the London Landmarks marathon with her husband, and alongside the Scotland Hub has taken part in a variety of events to raise money and spread awareness of the need for more people to join the stem cell register.

“Donating is one of the single most amazing things I've ever done, and I am so proud. I will talk about it to everyone – it is vital to keep talking, and raising awareness and registering donors, especially within ethnic minority groups.”

01

Introduction



02

Donor
Recruitment



03

Fundraising



04

Volunteering

03 Fundraising

In 2023, the DKMS UK Fundraising team continued to put the fun into fundraising with an array of activities, including community events, regular giving and corporate partnerships. The team supported a wide range of people – from marathon runners to bakers, skydivers to yoga enthusiasts – giving our amazing supporters the chance to make a difference to the lives of people with blood cancer or a life-limiting blood disorder. This year saw some exciting fundraising initiatives, such as:

Campaigns & mailings:

DKMS raised over £17,500 during 2023 working on campaigns including the Coronation appeal, launched in recognition of the coronation of our new king, Charles III. This generated over £5,000 over a two-week period.

Corporate partnerships:

DKMS raised over £125,000 working with various corporates on some fun and inspiring Charity of the Year partnerships and events, including CAMRA's Great British Beer Festival, PwC and ING Bank.

Community fundraising:

DKMS raised over £150,000 in community fundraising, made possible by our dedicated and passionate supporters taking on incredible challenges such as climbing Mount Kilimanjaro, and festive celebrations such as 'A Series of Carol Singing', raising over £3,200 throughout December.

We would like to thank Lord Leverhulme's Charitable Trust and the C A Rookes Charitable Trust, along with all the other trust funders who gave us their generous and ongoing support.

"We are constantly inspired by our incredible fundraisers, who not only undertake amazing challenges and activities but also understand that raising money is part of the journey to eliminating blood cancer. Here are just some of their inspirational stories."

Caroline Richardson,
Head of Fundraising, DKMS UK.

From transplant recipient to fundraiser: Ethan's story

“Each step of my journey from transplant to marathon shouts out resilience and inspires others to join the fight against blood cancer.”

Amazingly, just a few months after receiving a lifesaving stem cell transplant, Ethan ran the Edinburgh Marathon in May 2023 with his brother Jordan in support of DKMS.

“My active and busy life changed overnight when I was told that I would need several rounds of chemotherapy and ultimately a stem cell transplant.

“It was turned upside down while I waited for an unrelated stranger to be found as my potential lifesaver. Luckily, at the end of 2022, a match was found and I received a successful transplant.


Ethan was diagnosed with blood cancer – non-Hodgkin lymphoma – in July 2022, at just 28 years old.

“Until my diagnosis, I'd been a generally fit and healthy professional rugby player at the top of my game – I'd represented Wales at various international rugby championships. Then, early in 2022, I started experiencing signs of thrombocytopenia – which is a deficiency of platelets in the blood – and was treated for what doctors initially thought was a viral infection. It was only when I went to A&E that I was diagnosed and told I would need a stem cell transplant.”

The incredible rugby community rallied behind him, organising stem cell donor drives, taking on fundraising challenges and sharing his story far and wide. Only 160 days after receiving his stem cell transplant, Ethan ran the 2023 Edinburgh Marathon with Jordan. Together they raised over £3,200 – enough to cover the registration costs of 80 potential stem cell matches for other blood cancer patients in need. The brothers didn't stop there, and have already signed up to run the Chester Marathon together in 2024!

“Fundraising at DKMS is about giving people like me a shot at turning our struggles into success stories. Going from a fit rugby player to battling cancer shows how life can throw curveballs. But DKMS and my community had my back, showing why fundraising is a key part of the journey of finding more potential lifesavers. Each step of my journey from transplant to marathon shouts out resilience and inspiring others to join the fight against blood cancer.

When Jordan and I tackled the Edinburgh Marathon just a few months after my transplant, it was more than just a run. It was a celebration of life, of hope, and of coming back stronger. We knew that each person who registered as part of my campaign to find my lifesaver had cost the charity £40. By chipping in with fundraising, I'm not just covering the tab for registering donors; I'm fuelling the drive to save lives. Let's keep pushing forward together, we've got this.”



01

Introduction

DKMS and ING: Olive's story

"When the opportunity to vote for DKMS to be our charity of the year came around, it was an opportunity to continue the work and continue to build a partnership around fundraising and raising awareness."

Olive, a director at ING in the UK and charity champion, knows only too well how important it can be to find a matching stem cell donor. Her young daughter received a cord stem cell transplant in 2020, and is now healthy and enjoying a carefree childhood.

"We did a range of events to register staff and raise money for DKMS, including generous donations, colleagues undertaking fundraising challenges, and exciting events throughout the year, including sporting challenges, office-based bake sales and live music events. DKMS UK has supported us with various fundraising initiatives, including stewarding

marathon runners, providing materials for our office events, and training volunteers to host swabbing events to help get more people on the stem cell register. In the first year alone, the ING partnership has generated nearly £40,000 in fundraising, the equivalent of covering costs for registering 1,000 potential new donors.

DKMS were there for my family at a time when we were unsure what the future held. When your child is sick, you feel so helpless and hopeless. We held public registration events in our London office to increase the pool of potential stem cell donors and helped to raise aware of stem cell donation. It gave us something positive to focus our energy on. My wish for the future would be that over 50% of those from an ethnic minority and mixed-heritage groups are registered on the DKMS donor list."

02

Donor
Recruitment


03

Fundraising

04

Volunteering





Giving back to DKMS: Arun and Helen's story

"DKMS helped us through the most difficult time in our lives. We can't thank them enough for all their help and support."

Elsie's story featured as part of DKMS UK's end-of-year fundraising campaign in 2023, which raised over £18,000 – the equivalent of funding the registrations of 450 new, potential stem cell donors. During the campaign, we were delighted to update our supporters on Elsie's great progress, eight years on from when we first met her and her parents, Helen and Arun. Not only did Elsie celebrate her eleventh birthday this year, but also her ninth transplant 'birthday'.

"Elsie has had a chance at life because of her donated stem cells," says Arun. "Without them, it is unlikely she would still be with us. She has been through so much but still remains a happy, loving child. The team at DKMS is brilliant, we are so lucky to have had their support, so we are always happy to help DKMS whenever we can."

Elsie was also the star of our ING Christmas carol concert at St Margaret's Church, Lothbury in London, in which she sang a carol with another patient, helping to raise further vital funds for DKMS.

"I'm just so happy that everybody can have a little bit of Elsie!" says Helen. "I'm in total awe of my wonderful little girl and how far she's come. Seeing her shine so bright with such joy and warmth makes me the proudest and luckiest mummy, and it's even better if our story can raise money to help DKMS help other children and adults with blood cancer."

01

Introduction



02

Donor
Recruitment



03

Fundraising



04

Volunteering

04 Volunteering

In 2023, volunteering continued to have a key impact on DKMS's mission. DKMS UK has well over 116 active volunteers, who this year have:

- organised or supported donor registration drives across the UK
- helped raise vital funds through fundraising events
- raised awareness about blood cancers and disorders, and the need for more people to join the stem cell register, within their local communities.

We now have six volunteering hubs across the UK, with our new East Midlands Hub launching this year. Our other volunteering hubs in the West Midlands, Scotland, Bedford, South West England and West London have also had some exciting milestones this year, including:

- Students vs. Blood Cancer:** we increased the number of universities and colleges running donor registration drives organised by student volunteers and supported by our volunteering hubs during the academic year (for example, University of Stirling, City of Glasgow College, Royal Agricultural University and Hartpury College and University RFC). We also supported them to help us build long-term partnerships with a number of other colleges and universities.
- Annual volunteer fundraising day:** 2023 was the first year we organised a collective fundraising day for our volunteers, bringing a group of them to abseil down the ArcelorMittal Orbit in London, raising over £5,000 for DKMS.
- Fundraising events organised by volunteers:** the array of fundraising activities organised by our volunteers this year included a charity dinner and dance event (West Midlands Hub), which raised over £34,000. Vital funds for DKMS also came from events organised by our Scotland Hub, which included a dinner party at Aberdeen FC and a Bandioke singing event.

Here, two of our amazing volunteers tell their stories.

"Volunteering with DKMS gives me a sense of purpose and fulfilment, as it allows me to actively contribute to a cause that is deeply important to me. Ultimately, I hope that through our collective efforts, we can prevent other families from experiencing the same challenges that my own family has faced."

A deep, personal connection to DKMS: Gilly's story

"Volunteering with DKMS gives me a sense of purpose and fulfilment, as it allows me to actively contribute to a cause that is deeply important to me. Ultimately, I hope that through our collective efforts, we can prevent other families from experiencing the same challenges that my own family has faced."

Sandeep, known as Gilly, has been a dedicated volunteer with the DKMS Bedford Hub since 2019, when he also joined the DKMS stem cell register.

"Given my long-standing desire to contribute to charitable causes, I reached out to inquire about joining the hub. My brother and I served as coaches for a local football team called Meltis Rangers. At the time, the under-12 squad was seeking a shirt sponsor, and we suggested that they partner with DKMS. Rather than asking for funds, our goal was to publicise and raise awareness for the organisation – the team continue to 'spread the word' by organising a stem cell donor drive every summer at their club's presentation evening, supported by volunteers from DKMS' Bedford hub."

Tragically, since becoming a volunteer, Gilly's family has been touched by blood cancer.

"In March 2021, my brother Amardeep began experiencing fatigue and exhaustion following a light jog with his daughter. These symptoms persisted for several

days, and after various tests and a bone biopsy, he was diagnosed with an aggressive form of acute lymphoblastic leukaemia.

Amardeep responded positively to his chemotherapy sessions, and his cancer levels had dropped to an extent that even some of his neighbours were unaware of his condition. A stem cell donor match was identified – a 23-year-old woman from Germany with a 90% compatibility rate. However, in 2021 his cancer returned, necessitating an increase in his chemotherapy sessions. Unfortunately, he developed sepsis while receiving the final chemo blast, and was forced to battle both this and the aggressive cancer and sepsis with a severely weakened immune system. Despite a valiant effort to hold on, Amardeep passed away on 3 December 2021.

In 2023, I had the opportunity to volunteer when the Jaskomal Foundation, which helps raise awareness of blood cancer and increase the number of Asian donors on the stem cell register, partnered with DKMS to register potential donors at the Vaisakhi Festival at Trafalgar Square. It was great to raise awareness of blood cancer within the south Asian community.

Additionally, in June 2023, I decided to take part in the first-ever DKMS annual Volunteer Fundraising Day, by abseiling down the ArcelorMittal Orbit. My goal was to reach £500 in donations: I raised £1,465 and the combined efforts of the hub raised an amazing £3,440!

I like anything sporty – fitness or any type of adrenaline activities. As this wasn't a fitness activity, I didn't do any preparation or training, and I wasn't nervous at all. In fact, I was over the moon that I had raised so much for DKMS charity and wanted to experience this day to the fullest. I have a big family across the globe and whilst it was a shame they couldn't be there on the day, they were so happy that I was doing this abseil in memory of my brother. I'm now looking forward to completing my next adrenaline activity to fundraise for DKMS."

Gilly continues to regularly support local DKMS donor registration and fundraising events through the DKMS Bedford Hub. He concludes:

"Volunteering for DKMS has offered me the chance to acquire new skills and knowledge while enabling me to connect with new people, forming lasting relationships and friendships. My volunteering experience has also enhanced my understanding and empathy towards others, as it exposed me to a range of different perspectives and experiences."



01

Introduction

Leading community action: Manj's story

"We can't wait until it hits close to home to take action."

Manj, a dedicated DKMS volunteer, has been organising stem cell donor registration drives and fundraising events through the West Midlands Hub since 2018, when she also joined the register.

"It all began when I signed up with DKMS to be on the stem cell register, because my cousin's son needed a match. I was uneducated on stem cells and transplants at the time, so I started to read up on the DKMS website, and contacted them to ask if I could help in any way. I was put in touch with a local volunteer and went for training on how to swab and sign up people. Then I set up my first stem cell drive at my local Gurdwara, and I've helped with many DKMS events since.

I've also witnessed the devastating impact of cancer on my own family, losing two special people in my life – my husband Raj and my mother. I've seen first-hand the urgent need for a diverse donor pool, and it has made me determined to help others have a chance of survival. I couldn't save my special people, but I can try to help other people's special people. Nobody chooses to have cancer, but the reality is that we will all be affected by it in some shape or form. However, we can all choose to sign up to the stem cell registry and potentially help save a life.

We need more people from Asian and other ethnic minority communities to become potential stem cell donors. So, with DKMS I increase awareness about stem cell transplants, and educate people on how easy it is to donate.

02

Donor Recruitment

03

Fundraising

04

Volunteering



In October 2023, I was delighted to join with other West Midlands Hub volunteers in organising a charity event at Birmingham's Manor Grove banqueting hall, where we welcomed 400 guests for a sold-out, black-tie awareness and fundraising evening. They joined us in celebrating having registered more than 500 people – predominately from the Asian community – as potential stem cell donors over the past year, whilst highlighting the need for even more people to do so.

It took a lot of planning – the event was hosted by Harjap Bhangal, and guests enjoyed a cocktail reception, followed by a three-course dinner. They danced to performances from PBN, Sardara Gill, Ultimate Bangra, Dr Tabla, Beat Asylum, and USR; and there was a raffle, along with live and silent auctions of sporting memorabilia ranging from a signed Manchester United shirt and a prize belt donated by Tyson Fury, to a cricket bat signed by India vs England players. I was so thrilled that the evening raised a magnificent £34,000 to support DKMS's mission to delete blood cancer.

I would like to say a big 'thank you' to the DKMS West Midlands volunteers for welcoming me and making me part of their family. They've unknowingly been a tremendous support – volunteering with them is always fun and rewarding, and I've met new friends who have become family.

But most of all, hearing that a patient has found a stem cell match and knowing that we have been part of the process in potentially saving someone's life – that is priceless."



"I would like to say a big 'thank you' to the DKMS West Midlands volunteers for welcoming me and making me part of their family. They've unknowingly been a tremendous support – volunteering with them is always fun and rewarding, and I've met new friends who have become family."

DKMS Foundation: Trustees' Report for the year ended 31 December 2023

Preparation of report

The company qualifies as small under section 383 of the Companies Act 2006, the strategic report required of medium and large companies under The Companies Act 2006 (Strategic Report and Director's Report) Regulations 2013 is not required.

DKMS Foundation (referred to hereinafter as 'DKMS UK') is incorporated as a charitable company limited by guarantee and is a registered charity in England and Wales, and in Scotland. It is governed by its Memorandum and Articles of Association. The activities, management, finances and strategy of the Charity are overseen by a Board of Trustees, who are also the Company Directors.

DKMS UK is connected through common Trustees to DKMS gemeinnützige GmbH ('DKMS'), and its related charities.

The Trustees who held office during the financial year and at the date of the report are set out on page 55.

A minimum of two Trustees at any one time are required by the Articles of Association. There is no maximum limit required by the Articles. At every Annual General Meeting (AGM) one-third of the Trustees retire by rotation and are eligible for re-election. There is no restriction on the term of tenure as a Trustee. Trustees do not receive remuneration for their duties.

Purpose

DKMS UK's charitable purposes are set out in its Memorandum of Association as follows:

"The preservation and protection of good health and the relief of sickness of individuals who are suffering from any kind of blood cancer."

The aims of DKMS UK are to:

- Raise awareness of stem cell donation;
- Increase the number and diversity of registered potential stem cell donors in the UK; and
- Provide more second chances at life for those with blood cancer or blood disorders whose survival depends upon being matched with an unrelated stem cell donor.

Public benefit

DKMS UK raises awareness of blood cancers and blood disorders in the UK, including the life-changing impact of a diagnosis, in order that increasing numbers of the general public know about the need for more people to register as a potential stem cell donor. Increasing the number and diversity of potential stem cell donors is vital in increasing the life chances of blood cancer and disorder patients who need a stem cell transplant. At present, only 3.5% of the UK population are registered as donors compared to much higher levels in some other countries.

Registering more potential stem cell donors means that we are able to provide more second chances at life by finding and supporting an unrelated stem cell donor who can and will donate their stem cells for a patient in need of a life-saving blood stem cell transplant.

Through recruiting, registering and supporting stem cell donors to be part of life-saving treatments, we deliver significant public benefit to patients and their families and to the National Health Service, which arranges treatment and care for those patients.

The Trustees review the aims, objectives and activities of DKMS UK each year, ensuring the Charity remains focused on its stated purpose. This report looks at what DKMS UK has achieved and the outcomes of its work in the reporting period.

The Trustees have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing the Charity's aims and objectives and in planning its future activities. In particular, the Trustees consider how planned activities will contribute to the aims and objectives that have been set.

Board and management operations and structure of Board of Trustees

The Board of Trustees meets twice a year to review DKMS UK's work, finances and services, and to agree the strategic goals for the Charity.

DKMS Foundation: Trustees' Report for the year ended 31 December 2023

Recruitment and appointment of new Trustees

Trustees are appointed on the basis of their relevant skills and experience. The ongoing Trustees are responsible for the induction of any new Trustees, which involves an awareness of a Trustee's responsibilities, the governing document, administrative procedures, the history, approach and current business plan of DKMS UK.

The Trustees also make available a welcome pack to include copies of the previous year's annual report and financial statements, a brief history of the charitable company and a copy of the governing document. The pack also includes a copy of the Charity Commission guidance 'The essential Trustee: What you need to know. What you need to do.'

While DKMS UK is connected through common Trustees to DKMS gemeinnützige GmbH ('DKMS'), it continues to aim to recruit additional Trustees that can broaden and support its representation in the UK.

Management and organisation

Day-to-day operations of the Charity and strategy implementation is delegated to the Country Managers supported by the Senior Leadership Team (SLT). In the absence of the Country Managers, Stephan Schumacher, Trustee oversees the work of the SLT.

The Senior Leadership Team comprises:

- Country Managers Hasnein Alidina and Peter McCleave
- Head of Communications and Engagement Daniel Philipp Hoffmann
- Head of Finance Margaret Brett
- Head of Fundraising Caroline Richardson
- Head of Donor Support Services Josh Winters
- HR Manager Regina Salih
- Donor Recruitment Team Lead Hannah Tarrant
- Donor Request Management Work Up Team Lead Louise Bailey
- Donor Request Management Confirmatory Typing Team Lead Lindsey Dean

Related parties

The only related parties are considered to be the Trustees and those connected with the Trustees, including their close family, business and other charity interests. There have been no transactions with related parties, other than the reimbursement of reasonable travel expenses for the purposes of attendance at Board meetings and other relevant organisational activities. Additionally, there are related parties with other DKMS entities around the world. Details of the nature and amount of any related party transactions with these DKMS entities has been disclosed within Note 23.

Remuneration

In order to recruit and retain staff of the calibre it requires, DKMS UK's pay policy is to remunerate staff at levels above the voluntary sector median rate, but below the private sector market rate. The Charity has an organisational salary structure based upon a job evaluation study and external salary benchmarking concluded in June 2023. New roles are assessed against the job evaluation criteria and placed in a corresponding grade in the structure.

The salary structure's pay levels are reviewed at least annually by the Country Managers to ensure that salary scales are aligned with those for similar positions in the external market. A review of salaries normally takes place annually, and is usually implemented in January. If changes are to be made, staff are advised in writing of the amount and the date from which it takes effect. A salary review does not imply an increase and in making any pay award the review will be based on the organisation's financial health and achievements.

With reference to the National Council of Voluntary Organisation's 2014 inquiry into executive pay (NCVO, Report of the Inquiry into Charity Senior Executive Pay and Guidance for Trustees on Setting Remuneration), the Board of Trustees is committed to including the following information within its annual statutory report and financial statements:

- A summary statement of the Charity's remuneration policy and approach to senior executive pay.
- Disclosures on the number of staff in receipt of more than £60,000 per annum (in bands of £10,000), and the collective total benefits (including pension payments and employer's national insurance) paid to 'key management personnel' (which we have defined as the Senior Leadership Team), in line with the accounting Statement of Recommended Practice 2019 for charities. Given the Charity's size, the Board of Trustees does not believe it is appropriate to disclose the actual/personal salary of any individual member of staff including senior executives, to the public.
- Disclosures on pensions and other staff benefits (see subsequent notes to the financial statements).

Our approach to fundraising

We continue to uphold the highest standards in how we communicate with our fundraising donors and supporters and ensure that our fundraising practices meet the requirements of the recommended Codes of Practice.

We treat our donors and supporters with great respect and gratitude that befits a community of people and organisations that make our work possible.

DKMS Foundation: Trustees' Report for the year ended 31 December 2023

Key aspects of our approach to fundraising include:

- Registration with the Fundraising Regulator, which maintains the standards for charitable fundraising and ensures that fundraising is respectful, open, honest and accountable to the public. It also takes complaints about fundraising, investigates cases and adjudicates on fundraising practice.
- Ensuring our fundraising approach is aligned with the Charity's governing objectives.
- We have a complaints policy, which outlines our commitment to resolving fundraising complaints as promptly and amicably as possible. It also sets out our process for handling any complaints received. As per our policy, complaints will be reported and referred to the Fundraising Regulator if a resolution with the complainant cannot be reached or if the complaint is about a breach of any aspect of the Code of Fundraising Practice.
- In 2023 we did not receive any complaints across the organisation. Trustees are updated on a bi-annual basis with regards to the number of complaints we have handled in the year.
- We raise funds through individual giving requests (cash appeals, regular donation asks and online giving), community, challenge events, corporate and trust fundraising.
- We do not carry out any telephone, face-to-face or door-to-door fundraising.
- We do not use third party agencies to make fundraising requests, although we do use them for fulfilment purposes, e.g. acquisition of charity place challenge events, processing direct debits or distribution of fundraising direct mail. In such situations, legal agreements are in place. In no other circumstance do we swap or share data and we never sell data.
- All fundraising activity complies with the UK General Data Protection Regulation (GDPR) and associated legislation and guidance.
- Promotional goods sent out for fundraising purposes, and use of our logo on external fundraising materials, is subject to approval. Official stationery, such as our letterhead, is never sent out for external use.

Risk assessment and management

DKMS UK operates a risk assessment and management framework that reviews major risk areas on a quarterly basis.

The Country Managers and individual members of the SLT take responsibility for the day-to-day management and oversight of the above risk areas. The Trustees review the assessments and mitigating actions at their Board meetings and consider the following areas to be the major risks related to DKMS UK's operations and activities.

Medical safety of donors during the stem cell collection process

Although the medical process and procedure for stem cell donation and collection is safe, well-established and regulated, there will always be some safety risks and DKMS UK acknowledges these and takes them seriously.

The risks to the safety of our donors before, during and after the donation process, as well as any risks to transplant patients from the collection of poor-quality stem cell product are managed and mitigated in the following ways:

- Working in line with approved and regularly reviewed Standard Operating Procedures that comply with domestic and international standards and regulations, and that include clear identification and reporting mechanisms for Serious Adverse Events and Reactions and Quality Incidents.
- Working only with experienced, trusted and appropriately regulated medical partners and services. These relationships in turn are governed via established legal contracts and service protocols and regular service reviews.
- Ensuring a thorough quality assurance system is in place within the organisation, including compliance with the World Marrow Donor Association (WMDA) standards (qualification for which was achieved and approved in March 2021).
- Ensuring ongoing training, support and continuing professional development for all staff involved in the stem cell registration and donation process.

DKMS Foundation: Trustees' Report for the year ended 31 December 2023

Data management and protection

The collection, processing, storage and security of our stem cell donors' personal data and genetic information is of paramount importance and so represents a major risk in the event of mismanagement, loss or misuse of that data.

The potential damage to individual donors through a data breach, let alone the damage to DKMS UK's and the DKMS Group's reputation and activities in working with patients, donors, supporters and stakeholders would be catastrophic.

We manage and mitigate these risks through:

- Adherence to and compliance with strong information security and data protection policies and practices throughout the whole DKMS Group.
- Ensuring data processing and third parties and protocols are in place with suppliers and partners.
- Regular training and reviews for staff, volunteers and donor registration partners.
- Stem cell donor recruitment.

Effective and high-quality stem cell donor recruitment is essential to ensuring we meet the needs of patients and transplant centres looking for a match. If we fail to ensure we recruit sufficient numbers of donors with a diverse range of backgrounds, and also with accurate and regularly updated personal health and genetic information and contact details, then we risk not being able to save the lives of more blood cancer and blood disorder patients. We manage and mitigate this risk by ensuring we have:

- Clear and compelling communications and explanations about the registration process and the need for stem cell donors.
- Effective quality check and review processes.
- Quality programmes to enhance the health and contact information we have on the priority groups among our stem cell donors.
- A system for prioritisation for recruiting, retaining and supporting potential and actual blood stem cell donors.

Financial risks

There are a number of areas of financial risk faced by DKMS UK:

- Failure to achieve budgeted income levels.
- Inadequate financial controls or fraud.
- Poor financial management, including credit risk management, pricing risk and foreign exchange and liquidity risks.

These risks are managed and mitigated in the following ways:

- Strong planning, budgeting and monitoring processes in relation to income streams, including fundraising.
- Strong internal financial controls and data security.
- Regular reviews of fraud risks.
- Close interaction, support and cross-checking with the international financial management and controlling teams in Germany.
- Vetting by DKMS Germany of international health services, registries and companies involved in stem cell transplantation, so that stringent assessments on credit risk are carried out and appropriate financial terms agreed for all DKMS companies within the Group.
- Ensuring pricing of products and services is set at reasonable and affordable levels, that recognise the Group's role as a healthcare service provider with a primary objective of saving lives. Pricing levels are based on a production cost structure and also acknowledge differences in international economies, as well as the need to ensure patient treatments are not jeopardised by costs.
- Maintaining good cash flow and financial management systems in order to manage fluctuations in the major trading currencies in which DKMS UK deals.
- Cash flow projections are prepared as part of the Charity's strategic planning, while liquidity levels are monitored internally on a daily basis as well as reported to central management and Trustees at each reporting period.
- Adequate balances are maintained in all currencies to ensure sufficient funding is available to meet commitments.

DKMS Foundation: Trustees' Report for the year ended 31 December 2023

Logistical and supply line business continuity and resilience

Ensuring we have reliable, efficient and cost-effective methods for transporting our swab packs, blood samples and collected stem cells is crucial to the successful achievement of our organisational goals and objectives to save more lives, as is having a well-stocked and maintained supply line, resources and medicines. To manage and mitigate the risks of business-critical supplies and logistical arrangements we have:

- Implemented strong review processes for stock control and order processing.
- Made alternative arrangements and contingency plans for business continuity and disaster recovery scenarios.
- Developed contingency plans to provide for business periods where we are working at higher than normal levels of activity or volume (e.g. when running successful campaigns).

UK's economic challenges and its effects on DKMS UK business activities

The UK economy in common with almost all countries in the world experienced a sharp increase in the cost of living with inflation reaching over 11% for a short period in late 2022. The Bank of England and the UK government implemented various economic policies to prevent the inflation rate imbedding in the economy and spiralling out of control. Fall in energy prices and good economic governance has resulted in reducing UK's inflation rate to about 2.5% by mid-2024. The UK economic outlook now appears more positive and predictable. However significant part of the cost increases cannot be passed on and are therefore absorbed by the charity.

Financial review

Going concern

The Board of Trustees of the ultimate parent company approved an arrangement to continue funding DKMS UK's main activities to meet all its liabilities from its principal, DKMS gemeinnützige GmbH for a period not less than 12 months from the date these financial statements are approved. Accordingly, the Trustees continue to adopt a going concern basis in preparing the financial statements.

The company's business activities in 2023 show positive results to budget and the trend is expected to continue for rest of the year with the company's funding requirements expected to remain well within the amounts approved by the board for next three years.

The charitable company's net current assets at 31 December 2023 were £2,665,040 (2022: £2,168,955). Further details regarding the adoption of the going concern basis can also be found in the Accounting Policies on page 34.

Financial results

DKMS UK received donations totalling £3,597,777 (2022: £3,603,214) of which £2,559,143, (2022: £1,951,981) was donated funds, £1,038,634 (2022: £1,651,233) was donated services from DKMS in Germany.

The charity company's net income for the year amounted to £459,791 (2022: £1,046,701). The reduction in net income was influenced by absorption of higher costs for its charitable activities and costs of creating DKMS brand awareness in India. This is to encourage donor awareness and registration for treatment of blood cancer, Thalassaemia and other blood disorders.

Reserves policy

DKMS UK's aim is to gradually grow its unrestricted funds and achieve full financial independence. While the Charity is growing its income base and cash flow, it continues to receive funding for its main activities from its principal, DKMS gemeinnützige GmbH. The Trustees have approved for this arrangement to continue for the foreseeable future and until DKMS UK becomes financially independent to meet all its liabilities for at least 12 months. As at 31 December 2023 DKMS UK's unrestricted funds were £2,687,912 (2022: £2,228,121).

DKMS Foundation: Trustees' Report for the year ended 31 December 2023

Principal funding

In the period under review, DKMS UK's significant funding comes from donations from DKMS in Germany. In the meantime, the charitable company continues to grow its fee income from referral of potential stem cell donors and management of peripheral stem cell or bone marrow collections and establishing a broader base of additional funding sources to grow its voluntary donation income.

The charity has also developed a fundraising strategy to raise additional funding through new voluntary donations initiatives and events.

Future developments

DKMS remains on track to increase the number of blood stem cell donations to exceed 500 within the next two years and continues adding new stem cell donors to the UK register to support this aim.

Recruitment must remain targeted, with a particular focus on those from ethnic minority communities, as those groups will further help increase our overall number of matched donors, and move us closer to levelling up access to transplantation in these communities.

Fundraising work is planned to grow significantly over the next three years to support our expansion, with important areas for future growth being community-based and volunteer-led programmes, along with an expanded corporate support programme. This support is vital to achieve our aim of finding a matching donor for every stem cell transplant patient that needs one and where required covering the costs of the transplant.

Change of Trustees and directors

Jerome - Oliver Quella, CFO and Director resigned on 9 November 2023 and was replaced by Bernd Weinel appointed on 8 January 2024.

Trustees' responsibilities statement

The Trustees (who are also directors of DKMS Foundation for the purposes of company law) are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial year. Under company law the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period.

In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities Statement of Recommended Practice (SORP);
- make judgments and accounting estimates that are reasonable and prudent;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in operation.

Disclosure of information to auditors

Each of the persons who are Trustees at the time when this Trustees' Report is approved has confirmed that:

- so far as that Trustee is aware, there is no relevant audit information of which the charitable company's auditors are unaware, and
- that Trustee has taken all the steps that ought to have been taken as a Trustee in order to be aware of any relevant audit information and to establish that the charitable company's auditors are aware of that information.

This report was approved by the Trustees
on _____ and signed on their
behalf on _____ by: 25/1/2024



Bernd Weinel

Trustee

Independent Auditors report for the year ended 31 December 2023

Opinion

We have audited the financial statements of DKMS Foundation (the 'charity') for the year ended 31 December 2023 which comprise the Statement of Financial Activities, the Balance Sheet, Statement of Cash Flows, and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

- Give a true and fair view of the state of the charity's affairs as at 31 December 2023 and of its income and expenditure for the year then ended;
- Have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- Have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the Trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charity's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the Trustees with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report, other than the financial statements and our auditor's report thereon. The Trustees are responsible for the other information. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements, or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Independent Auditors report for the year ended 31 December 2023

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- The information given in the Trustees' Report which includes the Directors' Report prepared for the purposes of company law, for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- The Directors' Report included within the Trustees' Report has been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In light of the knowledge and understanding of the charity and its environment obtained in the course of the audit, we have not identified material misstatements in the Directors' Report included within the Trustees' Report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

- Adequate and proper accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- The financial statements are not in agreement with the accounting records and returns; or
- Certain disclosures of Trustees' remuneration specified by law are not made; or
- We have not received all the information and explanations we require for our audit.
- The Trustees were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies' exemption in preparing the Trustees' Report.

Responsibilities of the Trustees

As explained more fully in the Trustees' responsibilities statement set out on page 26, the Trustees (who are also the Directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Trustees' are responsible for assessing the charity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the charity or to cease operations, or have no realistic alternative but to do so.

Independent Auditors report for the year ended 31 December 2023

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the financial statements.

The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud.

Based on our understanding of the charity and its industry, we considered that non-compliance with the following laws and regulations might have a material effect on the financial statements: employment regulation, health and safety regulation and anti-money laundering regulation.

To help us identify instances of non-compliance with these laws and regulations, and in identifying and assessing the risks of material misstatement in respect to non-compliance, our procedures included, but were not limited to:

- Inquiring of management and, where appropriate, those charged with governance, as to whether the charity is in compliance with laws and regulations, and discussing their policies and procedures regarding compliance with laws and regulations;
- Inspecting correspondence, if any, with relevant licensing or regulatory authorities;
- Communicating identified laws and regulations to the engagement team and remaining alert to any indications of non-compliance throughout our audit; and
- Considering the risk of acts by the charity which were contrary to applicable laws and regulations, including fraud.

We also considered those laws and regulations that have a direct effect on the preparation of the financial statements, such as tax legislation, pension legislation, the Companies Act 2006 and the Charities Statement of Recommended Practice.

In addition, we evaluated the Trustees' and management's incentives and opportunities for fraudulent manipulation of the financial statements, including the risk of management override of controls, and determined that the principal risks related to posting manual journal entries to manipulate financial performance, management bias through judgements and assumptions in significant accounting estimates, income recognition (which we pinpointed to the cut-off assertion), and significant one-off or unusual transactions.

Our audit procedures in relation to fraud included but were not limited to:

- Making enquiries of the Trustees and management on whether they had knowledge of any actual, suspected, or alleged fraud;
- Gaining an understanding of the internal controls established to mitigate risks related to fraud;
- Discussing amongst the engagement team the risks of fraud; and
- Addressing the risks of fraud through management override of controls by performing journal entry testing.

There are inherent limitations in the audit procedures described above and the primary responsibility for the prevention and detection of irregularities including fraud rests with management. As with any audit, there remained a risk of non-detection of irregularities, as these may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal controls.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

Independent Auditors report for the year ended 31 December 2023

Use of the audit report

This report is made solely to the charity's members as a body in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charity's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charity's members as a body for our audit work, for this report, or for the opinions we have formed.

Nicola Wakefield (Senior Statutory Auditor)
for and on behalf of Forvis Mazars LLP

Chartered Accountants and Statutory Auditor
6 Sutton Plaza, Sutton Court Road, Sutton,
Surrey, SM1 4FS

Date: 30th Sept. 2024


Nicola Wakefield (Sep 30, 2024 11:15 GMT+1)

**(Incorporating income and expenditure account)
for the year 31 December 2023**

	Note	Unrestricted funds 2023 £	Total funds 2023 £	Total funds 2022 £
Income from				
Donations and legacies	2	3,597,777	3,597,777	3,603,214
Charitable activities	3	8,323,916	8,323,916	6,971,070
Total Income		11,921,693	11,921,693	10,574,284
Expenditure on				
Raising funds	4	1,275,335	1,275,335	1,188,144
Charitable activities	5, 6 and 9	10,186,567	10,186,567	8,339,439
	7, 18	11,461,902	11,461,902	9,527,583
Net Income before other recognised gains and losses		459,791	459,791	1,046,701
		459,791	459,791	1,046,701
Reconciliation of funds				
Total funds brought forward		2,228,121	2,228,121	1,181,420
Total funds carried forward		2,687,912	2,687,912	2,228,121

All activities relate to continuing operations.

The notes on pages 34 to 53 form part of these financial statements.

DKMS Foundation: Balance Sheet

As at 31 December 2023


	Note	2023		2022	
		£	£	£	£
Fixed assets					
Tangible assets	12		22,871		59,165
Investments	13		1		1
			<u>22,872</u>		<u>59,166</u>
Current assets					
Inventory	14	258,696		285,015	
Debtors	15	2,058,021		1,313,149	
Cash at bank and in hand	21	1,932,055		1,749,940	
		<u>4,248,772</u>		<u>3,348,104</u>	
Creditors: amounts falling due within one year	16	<u>(1,583,732)</u>		<u>(1,179,149)</u>	
Net current assets			<u>2,665,040</u>		<u>2,168,955</u>
Net assets			<u>2,687,912</u>		<u>2,228,121</u>
Charity Funds					
Unrestricted funds	18		<u>2,687,912</u>		<u>2,228,121</u>
Total funds	19		<u>2,687,912</u>		<u>2,228,121</u>

The company's financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The Trustees consider that the company is entitled to exemption from the requirement to have an audit under the provisions of section 477 of the Companies Act 2006 ("the Act") and members have not required the company to obtain an audit for the year in question in accordance with section 476 of the Act. However, an audit is required in accordance with section 144 of the Charities Act 2011.

The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.

The financial statements were approved and authorised for issue by the Trustees on and signed on their behalf, by:


B J Abel 25/10 9/2024
 Trustee

The notes on pages 34 to 53 form part of these financial statements.

For the year ended 31 December 2023

	Note	2023 £	2022 £
Cash flows from operating activities			
Net cash provided by operating activities	20	191,963	749,434
Cash flows from investing activities			
Purchase of tangible fixed assets		(9,848)	(17,217)
Net cash used in investing activities		(9,848)	(17,217)
Change in cash and cash equivalents in the year		182,115	732,217
Cash and cash equivalents brought forward		1,749,940	1,017,723
Cash and cash equivalents carried forward	21	1,932,055	1,749,940

The notes on pages 34 to 53 form part of these financial statements.

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2023

01. Accounting Policies

1.1 Basis of preparation of financial statements

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

DKMS Foundation meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

The financial statements are presented in pound sterling (£).

1.2 Going concern

The Trustees of the ultimate parent company review the company's activities and 3 year business plan each year and establish and approve the funding level required to enable the company to achieve its goals and meet its business commitments and liabilities.

The Trustees have an approved arrangement to continue funding the charitable company's main activities from its principal, DKMS Gemeinnutzige GmbH until the company becomes financially independent to meet all its liabilities for a period not less than twelve months from the date these financial statements are approved. Accordingly, they continue to adopt the going concern basis in preparing the financial statements.

1.3 Company status

The charitable company is limited by guarantee. The members of the company are the Trustees named on page 55. In the event of the company being wound up, the liability in respect of the guarantee is limited to £10 per member of the company.

1.4 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the company and which have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the company for particular purposes. The costs of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

1.5 Income

All income is recognised once the charitable company has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably. Money donation income is recognised when the income is credited into the company's account and revenue for clinical services is recognised after services are delivered.

Donated services or facilities are recognised when the charitable company has control over the item, any conditions associated with the donated item have been met, the receipt of economic benefit from the use by the charitable company of the item is probable and that economic benefit can be measured reliably. In accordance with the Charities SORP (FRS 102). General volunteer time is not recognised. Further information about volunteer contribution is included in the Trustees' Report.

On receipt, donated professional services and donated facilities are recognised on the basis of the value of the gift to the charitable company which is the amount the charitable company would have been willing to pay to obtain services or facilities of equivalent economic benefit on the open market; a corresponding amount is then recognised in expenditure in the period of receipt.

Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

1.6 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to make payment to a third party, it is probable that settlement will be required and the amount of the obligation can be measured reliably.

All expenditure is accounted for on an accruals basis. All expenses including support costs and governance costs are allocated to the applicable expenditure headings:

Costs of generating funds comprise the costs associated with attracting voluntary income.

Charitable expenditure comprises those costs incurred by the charitable company in the delivery of its activities and services for its beneficiaries.

It includes both costs that can be allocated directly to such activities and those costs of an indirect nature necessary to support them.

Governance costs include those costs associated with meeting the constitutional and statutory requirements of the charitable company and include the audit fees and costs linked to the strategic management of the charitable company.

All costs are allocated between the expenditure categories of the statement of financial activities on a basis designed to reflect the use of the resource. Costs relating to a particular activity are allocated directly; others are apportioned on an appropriate basis. Staff costs are allocated based on staff numbers, premises costs are allocated based on space occupied.

1.7 Tangible fixed assets and depreciation

Tangible fixed assets are carried at cost, net of accumulated depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost of fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Leasehold improvements - over period of lease (4 years) straight line.

Office equipment - 33.33% per annum straight line.

Computer equipment - 33.33% per annum straight line.

1.14 Financial instruments

The charitable company has applied Sections 11 and 12 of (FRS 102) in respect of financial instruments.

Financial assets and financial liabilities are recognised when the charitable company becomes party to the contractual provisions of the instrument. Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the charitable company after deducting all of its liabilities.

The charitable company's policies for its major classes of financial assets and financial liabilities are set out below.

Financial assets

Basic financial assets, including trade and other debtors, cash and bank balances, related charity working capital balances, and related charity financing are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest for a similar debt instrument. Financing transactions are those in which payment is deferred beyond normal business terms or is financed at a rate of interest that is not a market rate.

Such assets are subsequently carried at amortised cost using the effective interest method, less any impairment.

1.8 Investments

Investments are a form of basic financial instrument and are initially recognised at their transaction value. Investments in subsidiary companies are stated at cost less diminution in value.

1.9 Interest receivable

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the company; this is normally upon notification of the interest paid or payable by the Bank.

1.10 Debtors

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

1.11 Cash at bank and in hand

Cash at bank and in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

1.12 Creditors and provisions

Creditors and provisions are recognised where the charitable company has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due.

1.13 Pensions

The charitable company operates a defined contribution pension scheme and the pension charge represents the amount payable by the charitable company in respect of the year.

Financial liabilities

Basic financial liabilities, including trade and other creditors, bank loans and loans from related charities, are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Financing transactions are those in which payment is deferred beyond normal business terms or is financed at a rate of interest that is not a market rate.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Impairment of financial assets

Financial assets measured at cost and amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss is recognised in the Statement 9 financial activities.

For financial assets measured at cost less impairment, the impairment loss is measured as the difference between the asset's carrying amount and the best estimate of the amount the charitable company would receive for the asset if it were to be sold at the reporting date.

For financial assets measured at amortised cost, the impairment loss is measured as the difference between the asset's carrying amount and the present value of estimated cash flows discounted at the asset's original effective interest rate. If the financial asset has a variable interest rate, the discount rate for measuring any impairment loss is the current effective interest rate determined under the contract.

If there is a decrease in the impairment loss arising from an event occurring after the impairment was recognised, the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been had the impairment not previously been recognised. The impairment reversal is recognised in profit or loss.

Derecognition of financial assets and financial liabilities

Financial assets are derecognised when (a) the contractual rights to the cash flows from the asset expire or are settled, or (b) substantially all the risks and rewards of the ownership of the asset are transferred to another party or (c) despite having retained some significant risks and rewards of ownership, control of the asset has been transferred to another party who has the practical ability to unilaterally sell the asset to an unrelated third party without imposing additional restrictions.

Financial liabilities are derecognised when the liability is extinguished, that is when the contractual obligation is discharged, cancelled or expires.

Critical accounting estimates and areas of judgment

Management does not consider there to be any key judgements or estimates made in the preparation of the financial statements.

DKMS Charitable activities in the financial statements for the year ended 31 December 2023

02. Donations and legacies

	Unrestricted funds 2023	Total funds 2023	Total funds 2022
	£	£	£
Donation income	1,906,353	1,906,353	1,932,099
International donation income	652,790	652,790	19,882
Funding for donor recruitment activities from DKMS Gemeinnutzige GmbH	1,038,634	1,038,634	1,651,233
Other income	-	-	-
Total donations and legacies	3,597,777	3,597,777	3,603,214
Total 2022	3,603,214	3,603,214	

Donation income includes £175,000 (2022 £nil) collected and has been ring-fenced to fund blood cancer treatment costs for children in Africa and India and funding for nurses education and training in the UK.

03. Charitable activities

	Unrestricted funds 2023	Total funds 2023	Total funds 2022
	£	£	£
Income from service provision	8,323,916	8,323,916	6,971,070
Total 2022	6,971,070	6,971,070	

In the year ended 31 December 2023 and 2022 all income related to unrestricted funds.

04. Raising funds

	Unrestricted funds 2023	Total funds 2023	Total funds 2022
	£	£	£
Salaries, national insurance and pensions	398,184	398,184	336,699
Other staff costs and training	29,990	29,990	27,301
Premises costs	43,195	43,195	60,032
Publicity & Awareness costs	600,138	600,138	626,982
Postage, support and stationery	1,794	1,794	1,593
Other admin costs	170,539	170,539	130,313
Travel costs	6,367	6,367	4,795
Loss/(Gain) on foreign exchange	17,218	17,218	(8,786)
Depreciation	7,910	7,910	9,215
	<u>1,275,335</u>	<u>1,275,335</u>	<u>1,188,144</u>
Total 2022	<u>1,188,144</u>	<u>1,188,144</u>	

CPMRA Charitable Trusts and the Joint Fund for the year ended 31 December 2023

05. Direct costs

	Recruitment of Donors	Raising Awareness	Donor Request Management	Total 2023	Total 2022
	£	£	£	£	£
Other direct costs	133,736	84,584	3,095,434	3,313,754	2,751,342
International donor projects - India - Africa	338,885	1,543,808	170,526	2,053,219	-
Other staff costs and training	137	11,362	7	11,506	47,440
Premises cost	43,198	67,565	83,508	194,271	292,083
Publicity cost	73,284	303,139	(17,689)	358,734	267,781
Loss/(Gain) on foreign exchange	12,053	12,053	34,149	58,255	(44,071)
Postage, support and stationery	151,870	50,609	128,930	331,409	603,171
Travel costs	15,289	3,261	9,772	28,322	51,459
Donor typing costs	1,038,634	-	-	1,038,634	1,651,232
Salaries, national insurance and pensions	308,672	282,945	750,131	1,341,748	1,247,237
Depreciation	5,537	5,537	15,688	26,762	46,225
	<u>2,121,295</u>	<u>2,364,863</u>	<u>4,270,456</u>	<u>8,756,614</u>	<u>6,913,899</u>
Total 2022	<u>2,474,906</u>	<u>1,203,974</u>	<u>3,235,019</u>	<u>6,913,899</u>	

In the year ended 31 December 2023 and 2022 all costs of direct charitable activities related to unrestricted funds.

06. Support costs

	Recruitment of Donors	Raising Awareness	Donor Request Management	Total 2023	Total 2022
	£	£	£	£	£
Legal and professional fees	36,452	62,442	61,803	160,697	51,443
Loss/(Gain) on foreign exchange	5,165	5,165	14,635	24,965	(13,917)
Other staff costs and training	29,875	29,875	84,644	144,394	176,313
Premises costs	15,738	26,959	26,682	69,379	95,782
Travel costs	5,138	5,138	14,558	24,834	22,657
Other support costs	29,573	29,573	83,792	142,938	185,706
Postage, support and stationery	232	232	658	1,122	1,578
Admin costs	257	257	729	1,243	3,387
Salaries, national insurance and pensions	162,203	162,203	459,573	783,979	835,700
Depreciation	2,373	2,373	6,724	11,470	14,597
Total 2023	287,006	324,217	753,798	1,365,021	1,373,246
Total 2022	293,461	503,033	576,752	1,373,246	

In the year ended 31 December 2023 and 2022 all costs related to unrestricted funds.

Notes Formulating part of the financial statements
for the year ended 31 December 2023

07. Analysis of expenditure by expenditure type

	Staff Costs 2023	Depreciation 2023	Other Costs 2023	Total 2023	Total 2022
	£	£	£	£	£
Expenditure on raising voluntary income	398,184	7,910	869,241	1,275,335	1,188,144
Costs of raising funds	<u>398,184</u>	<u>7,910</u>	<u>869,241</u>	<u>1,275,335</u>	<u>1,188,144</u>
Recruitment of donors	470,873	7,910	1,929,516	2,408,299	2,768,368
Raising awareness	445,149	7,910	2,236,022	2,689,081	1,707,007
Donor request management	1,209,706	22,412	3,792,137	5,024,255	3,811,770
Charitable activities	<u>2,125,728</u>	<u>38,232</u>	<u>7,957,675</u>	<u>10,121,635</u>	<u>8,287,145</u>
Expenditure on governance	-	-	64,932	64,932	52,294
Total 2023	<u>2,523,912</u>	<u>46,142</u>	<u>8,891,848</u>	<u>11,461,902</u>	<u>9,527,583</u>
Total 2022	<u>2,419,635</u>	<u>70,038</u>	<u>7,037,910</u>	<u>9,527,583</u>	

In the year ended 31 December 2023 and 2022 all costs of direct charitable activities related to unrestricted funds.

Expenditure on raising voluntary income has not been allocated to specific activities as all costs relate to general charitable activities.

08. Analysis of expenditure by activities

	Activities undertaken directly 2023	Support costs 2023	Total 2023	Total 2022
	£	£	£	£
Recruitment of donors	2,121,295	287,006	2,408,301	2,768,367
Raising awareness	2,364,863	324,217	2,689,080	1,707,007
Donor request management	4,270,456	753,798	5,024,254	3,811,771
Total 2023	8,756,614	1,365,021	10,121,635	8,287,145
Total 2022	6,913,899	1,373,246	8,287,145	

In the year ended 31 December 2023 and 2022 all costs of direct charitable activities related to unrestricted funds.

09. Governance costs

	Unrestricted funds 2023	Total funds 2023	Total funds 2022
	£	£	£
Auditors' remuneration	29,400	29,400	27,600
Legal and professional fees	35,532	35,532	24,694
Total	64,932	64,932	52,294

In the year ended 31 December 2023 and 2022 all costs of direct charitable activities related to unrestricted funds.

Trustees' Remuneration Report for the financial year ended 31 December 2023

10. Net income

This is stated after charging:

	2023	2022
	£	£
Depreciation of tangible fixed assets		
- Owned by the charity	46,142	70,038
Auditors' remuneration - audit	29,400	27,600
- Non-audit services Taxation advice	26,710	21,221
	<u>102,252</u>	<u>118,859</u>

During the year, no Trustees received any remuneration (2022- £Nil).

During the year, no Trustees received any benefits in kind (2022 - £Nil).

During the year, no Trustees received any reimbursement of expenses (2022 - £Nil).

11. Staff Costs

Staff costs were as follows:

	2023	2022
	£	£
Salaries	2,197,776	2,198,589
Social security costs	218,697	235,156
Pension costs	80,823	80,122
Total	<u>2,497,296</u>	<u>2,513,867</u>

The average monthly number of employees was: 50 (2022: 51).

Full time equivalents was as follows (including part-time and fixed period temporary staff):

	2023	2022
	No.	No.
Donor recruitment	6	7
Fundraising	6	5
Communications	6	8
Medical	17	16
Administration	15	15
Total	<u>50</u>	<u>51</u>

Notes to the Financial Statements
for the year ended 31 December 2023

The number of higher paid employees was:

	2023	2022
	No.	No.
In the band £60,001 - £70,000	4	3
In the band £70,001 - £80,000	1	1
In the band £80,001 - £90,000	0	1
In the band £90,001 - £100,000	0	0
In the band £100,001 - £110,000	0	0
In the band £110,001 - £120,000	1	0
In the band £120,001 - £130,000	0	0
In the band £130,001 - £140,000	0	0
In the band £140,001 - £150,000	0	0
In the band £150,001 - £160,000	0	1
Total	<u>6</u>	<u>6</u>

The charitable company Trustees were not paid or received any other benefits from employment with the charitable company in the year (2022: £Nil) neither were they reimbursed expenses during the year (2022: £Nil). No charitable company Trustee received payment for professional or other services supplied to the charitable company (2022: £Nil)

The key management personnel of the charitable company are the Trustees, the Chief Executive Officer, the heads of departments and team leads. There are 6 heads of department and team leads (2022: 6), six of whom received remuneration in excess of £60,000 during the year (2022: 6). The total employee benefits of the key management personnel of the charitable company were £626,365 (2022: £590,985).

12. Tangible assets

	Office Equipment	Computer Equipment	Leasehold Improvements	Total
Cost	£	£	£	£
At 1 January 2023	69,800	166,873	228,855	465,528
Additions	-	9,848	-	9,848
Disposals	-	-	-	-
At 31 December 2023	<u>69,800</u>	<u>176,721</u>	<u>228,855</u>	<u>475,376</u>
Accumulated Depreciation				
At 1 January 2023	61,475	138,163	206,725	406,363
Charge for the year	4,412	19,600	22,130	46,142
Release on disposal	-	-	-	-
At 31 December 2023	<u>65,887</u>	<u>157,763</u>	<u>228,855</u>	<u>452,505</u>
Net book value				
At 31 December 2023	<u>3,913</u>	<u>18,958</u>	-	<u>22,871</u>
At 31 December 2022	<u>8,325</u>	<u>28,710</u>	22,130	<u>59,165</u>

UKMO Shareholding in Shares by the Investment Company plc
for the year ended 31 December 2023

13. Investments

Shares in Group Undertakings

£

Costs and net book value

At 31 December 2023 and 31 December 2022

1

The company's wholly owned subsidiary, Delete Blood Cancer UK Marketing Limited, registered at Ashburnham House, Castle Row, Horticultural Place, London W4 4JQ is a dormant company. Its net liability position at 31 December 2023 £10,245 (2022: £10,245) is represented by amounts due to parent company and is fully provided for in the accounts of the parent company.

14. Inventory

Inventory costs were as follows:

	2023	2022
	£	£
Materials stock	153,757	241,509
Work in progress costs	104,939	43,506
Total	258,696	285,015

Inventories are valued at lower of cost and net realisable value. Work in progress costs are reimbursable costs incurred for active stem cell collections awaiting to be billed.

15. Debtors

	2023	2022
	£	£
Due within one year		
Trade debtors	1,505,825	1,062,565
Amounts owed by group undertakings	10,245	10,245
Amounts owed by related charity	332,338	36,735
Other debtors	8,092	5,621
Prepayments and accrued income	201,521	197,983
Total	2,058,021	1,313,149

16. Creditors: Amounts falling due within one year

	2023	2022
	£	£
Trade creditors	459,989	385,315
Amounts owed to related charity	10,336	59,050
Other creditors	454,490	63,401
Other taxation and social security	67,473	67,672
Accruals	591,444	603,711
Total	1,583,732	1,179,149

Other creditors include £270,000 (2022: £nil) deposits received for the fundraising event scheduled to be held in May 2024.

17. Financial instruments

	2023	2022
	£	£
Financial assets		
Financial assets that are debt instruments measured at amortised cost	1,856,500	1,115,166
Financial liabilities		
Financial liabilities measured at amortised cost	(470,325)	(444,365)
Total	1,386,175	670,801

Financial assets measured at amortised cost include trade debtors, amounts owed by group companies, other debtors and amounts owed by related charity.

Financial liabilities include trade creditors and amounts owed to a related charity.

City of San Francisco Financial Statements to the Department of Public Works
for the year ended 31 December 2023

18. Summary of funds

	2023	2022
	£	£
At 1 January	2,228,121	1,181,420
Income for year	11,921,693	10,574,284
Resource expended	(11,461,902)	(9,527,583)
At 31 December	2,687,912	2,228,121

19. Analysis of net assets between funds

Analysis of net assets between funds - current year:

	Unrestricted funds 2023	Total funds 2023
	£	£
Tangible fixed assets	22,871	22,871
Fixed asset investments	1	1
Current assets	4,248,772	4,248,772
Creditors due within one year	(1,583,732)	(1,583,732)
Total	2,687,912	2,687,912

Analysis of net assets between funds - prior year:

	Unrestricted funds 2022	Total funds 2022
	£	£
Tangible fixed assets	59,165	59,165
Fixed asset investments	1	1
Current assets	3,348,104	3,348,104
Creditors due within one year	(1,179,149)	(1,179,149)
Total	2,228,121	2,228,121

20. Reconciliation of net movement in funds to net cash flow from operating activities

	2023	2022
	£	£
Net income for the year (as per Statement of Financial activities)	459,791	1,046,701
Adjustment for		
Depreciation charges	46,142	70,038
(Increase) in debtors	(744,872)	(142,065)
Increase/(Decrease) in creditors	404,583	(120,311)
Decrease/(Increase) in inventory	26,319	(104,929)
Total	<u>191,963</u>	<u>749,434</u>

21. Analysis of cash and cash equivalents

	2023	2022
	£	£
Cash at bank and in hand	1,932,055	1,749,940
Total	<u>1,932,055</u>	<u>1,749,940</u>

22. Operating lease commitments

At 31 December 2023 the total of the charity's future minimum lease payments under non-cancellable operating leases was:

	2023	2022
	£	£
Within 1 year	266,951	214,541
Between 2 and 5 years	1,007,101	3,097
Over 5 years	-	-
Total	<u>1,274,052</u>	<u>217,638</u>

Lease payments recognised as an expense amounted to **£255,910** (2022: £282,183).

The company entered into a new 10 year lease ending 30 September 2033 (with a break clause at end of year 5) for its current office premises at annual rent of £266,220 and a 3 year lease ending October 2024 for purchase of operating equipment at annual rent of £3,097.

DKMS Foundation Notes to the Financial Statements for the year ended 31 December 2023

23. Related party transactions

The company has taken advantage of the exemption contained in FRS 102 section 33 "Related Party Disclosures" from disclosing transactions with entities which are a wholly owned part of the group.

Transactions with other related parties are as follows:

Name (relationship)	Transaction	Amount		Amount due from/ (to) related party	
		2023	2022	2023	2022
		£	£	£	£
DKMS Gemeinnutzige GmbH (Common Trustees)	Donated services	1,599,118	1,651,233	319,810	-
DKMS Gemeinnutzige GmbH (Common Trustees)	Intercompany recharges	302,352	349,474	(12,994)	(52,617)
DKMS Life Science Lab (Common Trustees)	Intercompany service provision	-	-	-	-
DKMS Registry Gemeinnutzige GmbH (Common Trustees)	Intercompany service provision	101,610	77,119	(3,780)	(5,676)
DKMS USA (Common Trustees)	Intercompany service provision	10,341	68,120	(942)	(744)
DKMS USA (Common Trustees)	International money donation	7,857	19,882	-	-
DKMS BMST (Common Trustees)	Intercompany support services	2,142,741	-	-	11,785
DKMS Foundation NPC (Common Trustees)	Intercompany service provision	50,635	38,310	12,703	24,950

Amounts owed to related parties are unsecured, interest free and due for repayment within one year.

DKMS Gemeinnutzige GmbH is the Controlling company and exercises full control over the charitable company through its common Trustees who are also directors of the company. The controlling company recharges the charitable company actual or appropriately apportioned costs it incurs in providing support to the latter.

The controlling company DKMS Gemeinnutzige GmbH entered into a contract with DKMS Life Science Lab whereby DKMS Foundation receives typing services for no consideration from 01 January 2021.

DKMS Life Science Lab is one of the leading HLA laboratories and provides this service for all DKMS entities.

24. Post balance sheet events

The UK Board approved a strategic project to increase registrations from diverse ethnic minority communities in India in 2023 and to extend it to the Republic of South Africa thereafter. This will help increase the number of registered donors from these communities and help find more matching donors for the Indian and African diaspora globally.

25. Controlling party

The Trustees are the immediate controlling party and DKMS Gemeinnutzige GmbH is the ultimate parent. The principal address of the ultimate parent is Kressbach 1, 72072 Tubingen, Germany.

Copies of the group financial statements are available at www.dkms.de.

Ways you can support us

Organise a donor registration event

Organise an event to encourage your friends, family or colleagues to register as potential stem cell donors.

Create a bespoke partnership

DKMS can provide your company with networking and marketing opportunities aligned with our purposes and shared values.

Payroll giving

Donate to DKMS through your company's Payroll Giving Scheme if employees are paid through PAYE.

The 2K Club

Join our club of corporate supporters whose contribution goes towards helping the more than 2,000 people in the UK searching for a matching stem cell donor each year.

Sponsored activities

From local 10k runs and marathons to multi-day cycle trips, challenge yourself and get fit!

Fundraising events

Whether holding a bake sale, organising a music night or giving up a vice, every penny you raise helps in the fight against blood cancer.

Daredevil challenges

If you fancy standing on top of a plane, jumping out of one, or filling your run with obstacles, we have something for everyone.

Giving in memory

Many people choose to remember a loved one by fundraising for DKMS. We'll help you through the process to make sure their memory lives on through our work.



Trustees

Dr. E Neujahr
B J Abel
Bernd Weimel
Dr. A H Schmidt
S Schumacher

Principal staff

Stephan Schumacher, Country Manager, UK

Registered company number

08151279

Charity registered number

1150056 (England & Wales)

SC046917 (Scotland)

Registered office

Ashburnham House, Castle Row,
Horticultural Place
London W4 4JQ

Company secretary

B J Abel

Independent auditors

Forvis Mazars LLP
8 Sutton Plaza
Sutton Court Road
Sutton
Surrey
SM1 4FS

Bankers

Barclays Bank plc
74 Shepherds Bush Green
Shepherds Bush
London W12 8QD

Commerzbank AG
30 Gresham Street
London EC2V 7PG

110,000

Transplants for people in need

12m

Potential donors registered

24

Lifesaving stem cell donations each day*

*Global DKMS statistics as of 31 December 2023

DKMS is the trading name of DKMS Foundation, a company limited by guarantee registered in England and Wales (08151279) and a charity registered in England and Wales (1150056) and Scotland (SC046917).

DKMS FOUNDATION

England & Wales - Charity number 1150056

Accounts

Impact Report and Financial Statements



Year ending 31 December 2022



Our Vision

To delete blood cancer.



Our Mission

To give as many blood cancer patients as possible a second chance at life.



Our Purpose

To raise awareness of blood cancer and blood disorders, recruit and retain potential blood stem cell donors to provide a second chance at life, raise funds to match donor registration costs, provide access to transplantation for more blood cancer patients, and improve blood cancer therapies by our own research.

Contents

Country Manager's introduction	03
Daniel's blood cancer diagnosis	04
The search for a match	06
Covering costs	08
Donor evaluation	10
Stem cell donation	12
Daniel today	16
Thank you	18
Trustees' Report for the year ended 31 December 2022	20
Trustees' responsibilities statement for the year ended 31 December 2022	25
Independent auditors' report	26
Statement of financial activities	30
Ways you can support us	54



Country Manager's introduction

In a year where the world continued to face a number of global challenges, it has been especially poignant to see the true meaning of community and the spirit of generosity triumph. As a global organisation we are able to see the health and social inequalities highlighted more recently by the cost of living crisis and how this causes uncertainty and anguish across countries, cities, villages and communities the world over. Seeing people stand up to support others in crisis reinforced the ethos behind which DKMS was founded: to always strive to provide second chances.

As cancer continues to be a leading cause of death worldwide, in 2022 DKMS UK achieved 325 stem cell donations and remains the largest contributor to the aligned UK stem cell register. As we strive towards reaching the one million donors mark, one of our main focuses continues to be our commitment to diversify the register, for which we have already achieved over a 13% increase in the number of donors from minority ethnic backgrounds from 2021 to 2022.

Seeing communities come together to achieve a collective goal was never more apparent than in the story of Daniel whose journey from blood cancer diagnosis to blood stem cell transplant can be followed throughout this report. Diagnosed with acute myeloid leukaemia in 2022, sharing his search to find a matching donor contributed to us hosting over 300 in-person donor recruitment events across the UK last year and also saw us form new corporate partnerships to help spread awareness of the register far and wide. Having achieved

over 1,500 registrations online and offline, Daniel thankfully found a matching donor from Germany.

The aim of this report is to highlight the achievements the organisation has experienced over the past year, with the example of Daniel being just one of the many patients we have worked with who have been successful in finding their match. We are aware now more than ever that the fight against blood cancer is not yet won, and that more work is needed to ensure we are able to support the hundreds of patients like Daniel in the UK looking for their second chance at life. Therefore, we will continue our work with zeal and with the support of our remarkable volunteers, supporters and staff we will continue to bring hope to those with blood cancer and their loved ones. Above all, we continue to remain in awe of all the seemingly ordinary people who make the very special choice to register to become a blood stem cell donor for DKMS, and who go on to provide a patient in need with the most extraordinary gift ever.

“We will continue our work with zeal and with the support of our remarkable volunteers, supporters and staff.”



Patient diagnosis



Search for a match



Covering costs




Donor evaluation



Stem cell donation



Daniel today



01 Daniel's blood cancer diagnosis

Every year, more than 2,400 people in the UK are in need of a blood stem cell donation from an unrelated donor. However, finding a matching donor is like finding a needle in a haystack, which means that for some patients there won't be a match readily available on the stem cell donor register.

Last year, as part of our ongoing donor recruitment efforts, DKMS UK worked with 28 new patients with blood cancer and blood disorders to help them find a matching donor. One of these was Daniel, based in Northern Ireland.

Daniel was diagnosed with acute myeloid leukaemia (AML) in May 2022 at just 14 years old. At the time of his diagnosis there was no match available for him on the global stem cell register.

Daniel spent his last weekend before being diagnosed with blood cancer performing at a local jazz festival. On the Monday he passed a singing exam, and had his rugby training and orchestra practice front of mind. But, instead of joining his peers to perform at a once-in-a-lifetime concert at Carnegie Hall in New

York on St. Patrick's Day, he was hospitalised and diagnosed with AML two days later. Suddenly, there was no more rugby training and trumpet practice, Daniel was fighting for his life.

The diagnosis took the family completely by surprise. Anne Delargy, Daniel's mother, explains: "There is absolutely no blood cancer history in our family! Cancer is an awfully random thing which is why it is so important to encourage as many people as possible to register with DKMS as the need for stem cell donors is huge. It can happen to anybody."

"I suppose it takes everybody by surprise, but if your kid has an exceptionally good diet, loves fruit and vegetables, is good at sports, you wouldn't think that he is in a risk group for getting cancer. I never foresaw this coming to my door."



AML had to be treated fairly quickly with a high dosage of chemotherapy. Daniel's first session lasted for 10 days and included about 25 different drugs just at that initial stage. He was very unwell and desperate to get out of hospital, but the only way to totally beat the cancer for Daniel, as for many more like him, was to receive a matching stem cell transplant. He desperately needed this transplant to help his bone marrow to produce new healthy blood cells on its own.

While Daniel was battling cancer in the hospital, his loved ones launched the #DoItForDaniel appeal, working with DKMS UK to encourage people to sign up to the blood stem cell register.

Blood cancer is the fifth most common cancer in the UK

Daniel's family was utterly grateful to see so many people from their local community come forward and try to save Daniel. With all the help, the Greer family registered over 1,500 new donors to the blood stem cell register, providing many more chances for someone to find a match, receive a donation and recover from cancer.

Blood cancer is the fifth most common cancer in the UK and accounts for nearly half of all cancer diagnoses in children. Daniel's story is proof that we need more blood stem cell donors. It's evidence of the impact that can be achieved when communities and businesses work together towards DKMS' shared goal of finding a match for every person with blood cancer or a blood disorder.

“No one would ever suspect that this active boy was sick with leukaemia. It was completely unexpected and new to us. I have never personally known someone who was fighting with cancer. In my mind leukaemia was something to affect mainly babies or younger children, not a healthy teenage boy.”

Anne, Daniel's mother

01

Patient diagnosis



02

Search for a match



03

Covering costs



04

Donor evaluation



05

Stem cell donation



06

Daniel today

02 The search for a match

When someone reaches out to DKMS for support in finding a donor, our dedicated patient campaign team will develop an appeal to encourage potential donors to sign up to the stem cell register. This appeal will be shared far and wide in the hope of finding a matching donor.

Daniel's appeal #DoltForDaniel illustrated what is possible when we are able to work closely with a family to find new potential donors.

The family felt comfortable to reach out to their local community with Daniel's story, which led to several local events arranged by community members and businesses. DKMS UK also partnered with McKeever's Chemists, a chain of pharmacies which was able to offer in-person donor registration at some of its Northern Ireland locations. McKeever's also arranged a registration event at a Belfast Giants ice hockey game at the SSE Arena in Belfast where 88 new potential donors were registered. In 2023, McKeever's was awarded the 'Working in Partnership' award at the Pharmacy in Focus Awards, a significant accolade and a wonderful testament to the company's work with DKMS.

Over 300 in-person donation events in 2022

Daniel's campaign also reached beyond Northern Ireland through a family connection, inspiring footballer Jimmy Dunne to rally his club, Queens Park Rangers in London, to hold a registration event at its ground on match day. The club also released a video featuring Jimmy appealing to the wider football community to register as donors, in the hope of someone being Daniel's match. This appeal was widely shared through news sites such as The Independent and The Irish Times, and also featured on talkSPORT radio. The drive was supported by two members of staff and three volunteers. On match day, DKMS signed up 90 potential blood stem cell donors.

With the football community behind Daniel's appeal, we were also able to register more than 1,500 new potential blood stem cell donors who were inspired by his story. This included 1,096 online registrations driven by social media.

Beyond Daniel's appeal, DKMS' donor recruitment team worked tirelessly through the year to register as many potential donors as possible, so that every patient searching for a match could have the best possible chance of finding one. There were over 300 in-person donor recruitment events across the UK in 2022, including 59 corporate events at workplaces – the Department for Education ran a series of 'swab-along' events at their different sites, while Siemens and TalkTalk held registration events at their offices.

One of the most heart-warming corporate events of 2022 was organised by Heena, an employee at management consultant Deloitte. She felt compelled to do something when she realised that she knew a DKMS patient, and also one of her Deloitte colleagues, Richard, had survived blood cancer thanks to a stem cell donation. Heena approached DKMS UK and together we came up with the idea of swabbing as many people as possible at a regional conference Deloitte was holding in London.

“It was like conducting the most vital orchestra. It was an emotional event as delegates clearly realised the impact such a simple act could have.”

Louise, DKMS Donor Recruitment Manager

Richard took to the stage to share his story and explained how without a stem cell donation, he wouldn't be alive today. DKMS Donor Recruitment Manager Louise, who also attended, bravely shared her own story of the loss of her husband from blood cancer and the devastating effect it had on her and her children. With virtually the whole audience in tears, Lou called on them to take action there and then. Eligible delegates were asked to take out the swab sticks from the swab packs they had been given and complete their registrations together.

£40 to register each new donor

Deloitte went above and beyond to encourage its employees to join the donor register. Not only did more than 100 employees register on the day of the company's conference, but Deloitte also donated £4,000 towards the cost of those registrations. It costs DKMS £40 to register each new donor, so all those inspired to sign up at the event were covered by Deloitte's generous contribution. This type of corporate event helps to build community in an organisation, benefits a company brand, and thanks to Deloitte's input was also a huge help towards DKMS' goal of registering more donors at little cost to the charity. For these reasons, corporate events are some of the most powerful ways that DKMS builds its donor register.

76,294

How many people we registered last year

1,531

How many people registered for Daniel's appeal (online and offline)



01

Patient diagnosis



02

Search for a match



03

Covering costs



04

Donor evaluation



05

Stem cell donation



06

Daniel today

03 Covering costs

This year we were thrilled to see the DKMS community stepping up to the challenge of raising money to help cover the cost of donor registrations. From corporate partnerships to everyday giving, triathletes to daredevils, there was a lot of fundraising to celebrate.

Alongside their registration events, Daniel's supporters also organised sponsored concerts and chose DKMS UK as their charity of the year (see below). It costs DKMS UK £40 to register each new potential donor which is why we are always looking for fundraisers and corporate partners to support our work.

"DKMS UK has been blown away by the support we have received from companies, fundraisers and supporters" says Caroline Richardson, Head of Fundraising. "In addition to the many corporate events that took place up and down the country, over 400 people gave a regular gift and 87 people ran their hearts out for us. Twenty one people put on their hiking boots and walked in support and 15 adrenaline junkies undertook a crazy event. Eleven people did something significant in memory of someone special who lost their fight against a blood cancer or a blood disorder. In total we had 171 fundraising events across the year and 110 people celebrated their birthdays with us. To each and every one of you we thank you for kindness and dedication to furthering the work of DKMS, helping us to fund second chances at life. We really couldn't do it without you!"



Charity of the Year: Education Authority Music Service, Northern Ireland

Never is the power of music more resonant than when it comes from the heart. The Education Authority Music Service (EAMS) in Northern Ireland demonstrated this when it chose DKMS as its charity of the year in support of the #DoItForDaniel campaign.

Daniel, part of EAMS orchestra's horn section, had to give up playing when he was diagnosed with blood cancer and underwent treatment. His fellow young musicians were eager to come to his aid and supported Daniel's search for a donor match by putting on a series of concerts. In 2022 they raised a total of £2,636, with more fundraising concerts planned for 2023.

What DKMS can achieve with your financial support



Raise awareness of and register more donors to the blood stem cell register



Cover the cost of donor registrations




Support more patients to find their potentially lifesaving match



Engage with more corporate partners and their employees to deliver workshops, fundraising activities and registration events

How our registration costs are split up



Campaigns



Queen's Jubilee: The first in our ongoing series of 'When I grow up' fundraising campaigns, we asked our community to help more little princesses, like Esha and Livia, who were both diagnosed with acute myeloid leukaemia (AML), grow up to be queens by helping to cover the cost of new donor registrations.



What do you want to be when you grow up?: In the second part of our campaign series, we focused on Josie and Shahera, who both dream of being doctors. Their dreams are currently on hold while they search for a donor, but with the help of the money this campaign raised, we can continue to support their search.



Swabtember: A new campaign which was launched in September 2022 to coincide with Blood Cancer Awareness Month. Swabtember is a virtual activity that challenged participants to collectively, as a team, or individually travel 635 miles, the journey each of our swab kits takes from the UK to our laboratories in Germany.

“We do not receive any government funding so depend on generous donations from our amazing supports, individuals, fundraisers and companies, to recruit more people to the register. It costs £40 to register each potential lifesaver so your money is vital to help us save more lives.”

Caroline Richardson,
Head of Fundraising

Corporates - vital collaborations

In 2022, DKMS:



Was the chosen charity of the year for three organisations; Toton Banks Road School, Yarm Methodist Church and Broome Manor Golf Club Wiltshire Ladies Team

8+

companies to the £2k Club, a club of corporate supporters whose contribution of £2,000 will give membership of the club for one year

59

corporate registration events organised

01

Patient diagnosis



02

Search for a match



03

Covering costs



04

Donor evaluation



05

Stem cell donation



06

Daniel today

04 Donor evaluation

“It took us several months to find Daniel a donor. We were initially told of two potential matches that fell through, but luckily, the third time was a success and we got confirmation that our son was paired with a young lady from Germany.”

Anne, Daniel’s mother

Daniel was fortunate to find his matching donor, but for many patients, the search continues.

When a person joins the donor database, their cheek swabs are sent to our cutting-edge laboratory where the donor’s human leukocyte antigen (HLA) tissue type is added to the global DKMS stem cell register.

Our state-of-the-art laboratory

For more than 20 years, the DKMS Life Science Lab in Dresden, Germany, has repeatedly set new standards in genotyping. An accredited clinical laboratory and a clinical research centre are attached to the lab, with a team of experts in the fields of genetics, biotechnology and bioinformatics working to ensure the best possible high-resolution typing. This team is making continuous scientific progress in improving donor profiling. The better and more detailed the profiles, the more patients will be able to find their match - and this process happens much faster than in previous years, which can make a huge difference to the patients’ treatment.


Through this state-of-the-art-laboratory, DKMS is able to provide the best quality typing for the lowest possible cost.

A real strength of DKMS’ international database is the growing diversification of donors on the register. By being based in Europe, Africa, North and South America and Asia, DKMS is able to increase the number of second chances at life for patients from a diverse range of ethnic backgrounds. A patient is much more likely to be

matched with a donor from the same ethnic background but, unfortunately, people with minority ethnic backgrounds still only have a 37% chance of finding a matching blood stem cell donor, compared to a 72% chance for those from a white Caucasian background. While DKMS UK is currently the most diverse and largest contributor to the UK aligned stem cell register, we are continuing outreach work among the UK’s diverse range of minority ethnic communities to increase the possibility of finding a match for every person in need. In 2022, 476 people in the UK received stem cell transplants from DKMS donors from around the world.



Contributors to the aligned UK stem cell registry 2022



*NHSBT: NHS Blood and Transplant

**WBMDR: Welsh Bone Marrow Donor Registry

Donors on the DKMS UK register by ethnicity

	2022	2021	% increase
African-Caribbean	14,165	13,076	8.3%
Asian	84,671	71,987	17.6%
Middle Eastern/Mediterranean	17,098	15,108	13.2%
Mixed background	20,150	17,750	13.5%
British, Irish and European	785,356	685,851	14.5%
Other	47,128	43,625	8.0%
TOTAL	968,568	847,397	



01

Patient diagnosis



02

Search for a match



03

Covering costs



04

Donor evaluation



05

Stem cell donation



06

Daniel today

05 Stem cell donation

Finding a matching stem cell donor is about as rare as finding a needle in a haystack. That's why we call our donors lifesavers-in-waiting, and why we need so many people on the register. In 2022, DKMS donors provided over 7,700 donations globally to patients on all continents.

In order to provide more lifesaving matches, DKMS not only recruits donors to the register but also supports them at every step of their lifesaving journey. From explaining the medical process during the initial contact to arranging accommodation and transport at no cost to the donor, DKMS provides support throughout the process.

At the end of 2022, our post-donation survey showed that 99% of donors, regardless of whether they had donated via peripheral blood stem cell (PBSC) or bone marrow donation, would be willing to donate again. DKMS UK also invites donors to join a Donor Club,

so that they can share their experience with others who understand what it's like donating to a stranger.

Joe, who is from the same city in Northern Ireland as Daniel, donated his stem cells via PBSC donation in June 2022 – around the same time that Daniel received his diagnosis.

"I'm not 100% sure where I heard about DKMS, but I think it was on Children in Need. I remember seeing that and thinking it's only a swab in the mouth to get my name on the register. So, I signed up. I then didn't hear anything until seven years later!"





"I received a phone call from a number I didn't recognise. I normally wouldn't answer the phone when it's a strange number, but this day I picked up and it was a nice man telling me I was a potential match.

"I was excited. It's good to be able to help somebody, even if you don't know them, to give somebody an extra chance of living.

Right now, I'm becoming a fire fighter as well. I joined the fire service to be able to help save lives. This was a great opportunity.

"The donation took place in London. First of all, I travelled there to have my medical examination. There was a period of back and forth because at my first examination my blood pressure was high. I had got lost on the way and I also hate needles and having blood samples taken, so I needed a letter from my GP to clear things up. I went back for a second medical examination which was all clear and was then given the G-CSF (a naturally occurring growth hormone that stimulates the production of stem cells in the blood) injections to

take home and use prior to going back for the actual donation day."

"My only real side effect from the injections was I got a very sore head. Emotionally, I suppose when you're taking them and you know you're producing more stem cells and you're going to be giving them to somebody else, it's quite a big feeling that you're doing something to help somebody, even if it's a stranger. You're potentially saving their life. The pros outweigh the cons.

"I travelled over on the donation day back to The London Clinic and the staff are all very nice. I was starting to get a bit sweaty when they were putting my needles in, but they were brilliant and just what I needed. I felt fine and it only took a few hours.

"After the donation, I felt great. I was back at work a couple of days later. There were no side effects whatsoever. If that's all it is at the end of the day to save someone's life it's well worth it.

"The DKMS team were brilliant. They're very friendly and communicative. I wasn't waiting on phone calls and knew what was going on. It was very informal and they would ring me with any updates which was great.

"Around 10% of donations are carried out by bone marrow harvest. The patient team will choose which donation method would be most beneficial for the patient based on a variety of factors, including the patient's medical diagnosis, their current condition and the stage of the disease. A bone marrow harvest is a procedure carried out under general anaesthetic, in which a doctor makes two small incisions in the donor's lower back and removes bone marrow from their pelvic bone using a needle."

Louise Bailey, Team Lead, Work Up, DKMS UK

01

Patient diagnosis



02

Search for a match



03

Covering costs



04

Donor evaluation



05

Stem cell donation



06

Daniel today

“Looking back on it, I would definitely do it again. I’d do it every month if I could save somebody.

“It was a bit of a coincidence that I got called up when Daniel’s appeal had just started. Other local people were targeted by it, just like I was, but I had donated already. I was on the register for seven years and didn’t hear anything from DKMS but as a coincidence a local family needed help and DKMS were there for them. It was great to be able to help out at the same time. I was excited and I was hoping that maybe I was the match for Daniel, but it turned out I wasn’t. But it’s great to be able to connect myself with Daniel regardless. Somebody though needed it then and it made me more aware and emotional that I was able to help.

“At the time, I talked to family members and people at work who were talking about Daniel, and I was able to say, ‘I’m doing that! I don’t I don’t think it’s for Daniel, I’m doing a stem cell donation for somebody’. I got arm bands sent over and started handing them out to colleagues to help promote the register.


“I left some with a friend who works at a local sports shop and he helped hand some out.

“If someone said they were thinking about becoming a donor, I would tell them 100% don’t hesitate or think that you shouldn’t be doing it because it’s well, well worth it. It’s probably the most amazing thing you’ll ever do in your life.

“If I had the chance to speak to Daniel’s family, I’d tell them they did a great job with promoting DKMS and they had great fundraising ideas. The passion that they had for fighting for donors, it was unbelievable. I mean of course they would do it. Anyone would do it. They were fighting for life.

“Most importantly, it paid off. That’s the bottom line. Daniel found his donor and he’s recovering. Plus, a lot of people signed up to the register because of him, so even if they’re not Daniel’s match there’s thousands more people that are on the register that could potentially save someone else’s life.”

Global breakdown: where DKMS UK sent stem cells in 2022



476 UK patients received a stem cell transplant from DKMS in 2022



YOU COULD
BE A
LIFESAVER

Sign up today to become a
potential blood stem cell donor
dkms.org.uk

01

Patient diagnosis



02

Search for a match



03

Covering costs



04

Donor evaluation



05

Stem cell donation



06

Daniel today

06 Daniel today

Daniel is just one of the 28 newly diagnosed patients from the UK supported by DKMS UK in 2022. We also shared various international appeals, like that for 13-year-old Amelia from Poland who was diagnosed with leukaemia and seven-month-old Javi from the US who was diagnosed with acute lymphoblastic leukaemia (ALL).

Finding a matching stem cell donor can be difficult, regardless of the patient's genetic background. DKMS' work is far from finished, but with the support of our fundraisers, partners and donors, we can continue to give hope to those with blood cancer and their loved ones.

Thankfully, Daniel's perfect match was found in October 2022, and he successfully received his stem cell donation a month later. Daniel was well enough to fly home from Bristol Royal Hospital for children just before Christmas. All the family know about the donor is that she's a young lady from Germany. Daniel sent a Christmas card to her wishing her a healthy New Year and got a reply in which she called him her 'genetic twin'. Daniel is hoping to meet his donor one day to thank her in person for giving him a chance for the future.

Although the transplant was successful, the road to recovery has been long and full of bumps along the way. Daniel had a very rough February and early March, so it was decided to transfer him back to Bristol Royal Hospital's Children Haematology Department, where he received his transplant. He stayed there until he overcame Graft versus Host Disease (GvHD), a systemic disorder that occurs when the graft's immune cells recognise the host as foreign and attack the recipient's body cells.

Nevertheless, Daniel and his family stay hopeful: the blood tests show that the donor transplant was a success. What is next for Daniel is to overcome any further post-transplant complications. He is not living his old life just yet, but he and his family hope he'll be back at home, picking up the trumpet and scoring tries in the near future. They are eternally grateful to his donor and want to ensure other families whose lives have been shaken by a blood cancer diagnosis, are able to find their own generous stranger to save their loved ones.





Daniel's diagnosis had an enormous effect not just on his life, but on the lives of everyone in his family, which is why his mother has become an active advocate to raise awareness about the donor registration process and encourage more people to join. Anne says, "If I could say one thing to nudge people to sign up it would be: it could be you. You never know with cancer. If you were happy to accept a donation for yourself or for somebody else in your family, then really you should be on that donor list. It's not a one-way street."

Anne believes one of the main reasons people do not sign up is the lack of understanding of the process of stem cell transplants. Even though she is a doctor, Anne didn't realise how easy the process actually was. In reality, around 90% of all donations are made through a method called peripheral blood stem cell (PBSC) donation, which is similar to the process of giving blood. In return, someone is given a chance to survive cancer.

It is vital to remember that Daniel's story is not a single case. In spring 2023, DKMS has just started working with another young patient named Bobby who is from the same area of Northern Ireland as Daniel's family, and once again the local community is ready to come to his aid. The impact of Daniel's story, and all the donors who DKMS was able to register through his appeal in 2022, doesn't end with Daniel's transplant. It will continue to be seen through the increased awareness of the stem cell donor register and through those who will register as a result.

This is why it is so important to raise awareness about the process of blood stem cell donation to increase the number of informed sign-ups. Every registration could give someone a second chance at life.

In April 2023, the first donor who registered as a result of Daniel's appeal went on to donate their stem cells.

Thank you

With the help of other organisations who support our mission to delete blood cancer, DKMS is able to work more effectively, finance more donor registrations, and support more patients and donors.

Thank you to all the trusts and foundations which supported us in 2022:

- Anthony Alex
- Artemis Charitable Foundations
- Bright Funds Foundation
- Doris Field
- F B Laurence
- Florian Settlement Charitable Trust
- Gunner Lewis Vale Trust
- Hobsons Charity
- Hudson Charitable Trust
- Leonard Curtis
- Mary Robertson
- P F Charitable
- RZK Foundation

Our thanks also go to our many recruitment partners, in particular those listed below, who have continued to support our mission:

- 10,000 donors
- ACLT
- AME-BCT
- Jain and Hindu Organ Donation Steering Group
- Jaskomal Foundation
- Kevin Karawa Leukaemia Trust
- Love Hope Strength
- Race Against Blood Cancer
- Sue Harris Trust
- Team Margot
- Upahaar

Thank you to our transplant centres:

- London Haematology, The London Clinic
- Therapeutic Apheresis Service, Royal Hallamshire Hospital

Finally, special thanks go to our haematology and transfusion medicine consultant, DKMS Medical Advisor Dr Khaled El-Ghariani.



This is Vansh (left) meeting his donor Harshil in 2019. Some donors are lucky to have the opportunity to meet their patient after donation. This depends on international guidelines and exact circumstances will vary from country to country.

DKMS Foundation: trustees' report for the year ended 31 December 2022

Preparation of report

As the company qualifies as small under section 383 of the Companies Act 2006, the strategic report required of medium and large companies under The Companies Act 2006 (Strategic Report and Director's Report) Regulations 2013 is not required.

DKMS Foundation (referred to hereinafter as 'DKMS UK') is incorporated as a charitable company limited by guarantee and is a registered charity in England and Wales, and in Scotland. It is governed by its Memorandum and Articles of Association, and the work, management, finances and strategy of the Charity are overseen by a Board of Trustees, who are also the Company Directors.

DKMS UK is connected through common trustees to DKMS gemeinnützige GmbH ('DKMS'), and its related charities.

The trustees who held office during the financial year and at the date of the report are set out on page 55.

A minimum of two trustees at any one time are required by the Articles of Association. There is no maximum limit required by the Articles. At every Annual General Meeting (AGM) one-third of the trustees retire by rotation, but are eligible for re-election. There is no restriction on the term of tenure as a Trustee. Trustees do not receive remuneration for their duties.

Purpose

DKMS UK's charitable purposes are set out in its Memorandum of Association as follows: "The preservation and protection of good health and the relief of sickness of individuals who are suffering from any kind of blood cancer."

The aims of DKMS UK are to:

- Raise awareness of blood stem cell donation;
- Increase the number and diversity of registered potential blood stem cell donors in the UK; and
- Provide more second chances at life for those with blood cancer or blood disorders whose survival depends upon being matched with an unrelated blood stem cell donor.

Public benefit

DKMS UK raises awareness of blood cancers and blood disorders in the UK, including the life-changing impact of a diagnosis, in order that increasing numbers of the general public know about the need for more people to register as a potential blood stem cell donor. Increasing the number and diversity of potential blood stem cell donors is vital in increasing the life chances of blood cancer and disorder patients who need a blood stem cell transplant. At present, only 3% of the UK population are registered as donors compared to much higher levels in some other countries.

Registering more potential blood stem cell donors means that we are able to provide more second chances at life by finding and supporting an unrelated blood stem cell donor who can and will donate their stem cells for a patient in need of a life-saving blood stem cell transplant.

Through recruiting, registering and supporting blood stem cell donors to be part of life-saving treatments, we deliver significant public benefit to patients and their families and to the National Health Service, which arranges treatment and care for those patients.

The trustees review the aims, objectives and activities of DKMS UK each year, ensuring the Charity remains focused on its stated purpose. This report looks at what DKMS UK has achieved and the outcomes of its work in the reporting period.

The trustees have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing the Charity's aims and objectives and in planning its future activities. In particular, the trustees consider how planned activities will contribute to the aims and objectives that have been set.

Board and management operations and structure of Board of Trustees

The Board of Trustees meets twice a year to review DKMS UK's work, finances and services, and to agree the strategic goals for the Charity.

DKMS Foundation: trustees' report for the year ended 31 December 2022

Recruitment and appointment of new trustees

Trustees are appointed on the basis of their relevant skills and experience. The ongoing trustees are responsible for the induction of any new trustees, which involves an awareness of a Trustee's responsibilities, the governing document, administrative procedures, the history, approach and current business plan of DKMS UK.

The trustees also make available a welcome pack to include copies of the previous year's annual report and financial statements, a brief history of the charitable company and a copy of the governing document. The pack also includes a copy of the Charity Commission guidance 'The essential Trustee: What you need to know. What you need to do.'

While DKMS UK is connected through common trustees to DKMS gemeinnützige GmbH ('DKMS'), it continues to aim to recruit additional trustees that can broaden and support its representation in the UK.

Management and organisation

Day-to-day operations of the Charity and strategy implementation is delegated to the Country Manager supported by the Senior Leadership Team (SLT). In the absence of the Country Manager, Stephan Schumacher, Interim CEO oversees the work of the SLT.

The Senior Leadership Team comprises:

- Head of Communications and Engagement Daniel Philipp Hoffmann
- Head of Finance & Corporate Services Hasnein Alidina
- Head of Fundraising Caroline Richardson
- HR Manager Regina Salih

Related parties

The only related parties are considered to be the trustees and those connected with the trustees, including their close family, business and other charity interests. There have been no transactions with related parties, other than the reimbursement of reasonable travel expenses for the purposes of attendance at Board meetings and other relevant organisational activities.

Remuneration

In order to recruit and retain staff of the calibre it requires, DKMS UK's pay policy is to remunerate staff at levels above the voluntary sector median rate, but below the private sector market rate.

The Charity has an organisational salary structure based upon a job evaluation study and external salary benchmarking concluded in June 2023. New roles are assessed against the job evaluation criteria and placed in a corresponding grade in the structure.

The salary structure's pay levels are reviewed at least annually by the Country Manager to ensure that salary scales are aligned with those for similar positions in the external market. A review of salaries normally takes place annually, and is usually implemented in January. If changes are to be made, staff are advised in writing of the amount and the date from which it takes effect. A salary review does not imply an increase and in making any pay award the review will be based on the organisation's financial health and achievements.

With reference to the National Council of Voluntary Organisation's 2014 inquiry into executive pay (NCVO, Report of the Inquiry into Charity Senior Executive Pay and Guidance for Trustees on Setting Remuneration), the Board of Trustees is committed to including the following information within its annual statutory report and financial statements:

- A summary statement of the Charity's remuneration policy and approach to senior executive pay.
- Disclosures on the number of staff in receipt of more than £60,000 per annum (in bands of £10,000), and the collective total benefits (including pension payments and employer's national insurance) paid to 'key management personnel' (which we have defined as the Senior Leadership Team), in line with the accounting Statement of Recommended Practice 2019 for charities. Given the Charity's size, the Board of Trustees does not believe it is appropriate to disclose the actual/personal salary of any individual member of staff, including senior executives, to the public.
- Disclosures on pensions and other staff benefits (see subsequent notes to the financial statements).

Our approach to fundraising

We continue to uphold the highest standards in how we communicate with our fundraising donors and supporters and ensure that our fundraising practices meet the requirements of the recommended Codes of Practice.

We treat our donors and supporters with great respect and gratitude that befits a community of people and organisations that make our work possible.

DKMS Foundation: trustees' report for the year ended 31 December 2022

Key aspects of our approach to fundraising include:

- Registration with the Fundraising Regulator, which maintains the standards for charitable fundraising and ensures that fundraising is respectful, open, honest and accountable to the public. It also takes complaints about fundraising, investigates cases and adjudicates on fundraising practice.
- Ensuring our fundraising approach is aligned with the Charity's governing objectives.
- We have a complaints policy, which outlines our commitment to resolving fundraising complaints as promptly and amicably as possible. It also sets out our process for handling any complaints received. As per our policy, complaints will be reported and referred to the Fundraising Regulator if a resolution with the complainant cannot be reached or if the complaint is about a breach of any aspect of the Code of Fundraising Practice.
- In 2022 we did not receive any complaints across the organisation. Trustees are updated on a bi-annual basis with regards to the number of complaints we have handled in the year.
- We raise funds through individual giving requests (cash appeals, regular donation asks and online giving), community, challenge events, corporate and trust fundraising.
- We do not carry out any telephone, face-to-face or door-to-door fundraising.
- We do not use third party agencies to make fundraising requests, although we do use them for fulfilment purposes, e.g. acquisition of charity place challenge events, processing direct debits or distribution of fundraising direct mail. In such situations, legal agreements are in place. In no other circumstance do we swap or share data and we never sell data.
- All fundraising activity complies with the UK General Data Protection Regulation (GDPR) and associated legislation and guidance.
- Promotional goods sent out for fundraising purposes, and use of our logo on external fundraising materials, is subject to approval. Official stationery, such as our letterhead, is never sent out for external use.

Risk assessment and management

DKMS UK operates a risk assessment and management framework that reviews major risk areas on a quarterly basis.

The Country Manager and individual members of the SLT take responsibility for the day-to-day management and oversight of the above risk areas. The trustees review the assessments and mitigating actions at their Board meetings and consider the following areas to be the major risks related to DKMS UK's operations and activities.

Medical safety of donors during the blood stem cell collection process

Although the medical process and procedure for blood stem cell donation and collection is safe, well-established and regulated, there will always be some safety risks and DKMS UK acknowledges these and takes them seriously.

The risks to the safety of our donors before, during and after the donation process, as well as any risks to transplant patients from the collection of poor-quality stem cell product are managed and mitigated in the following ways:

- Working in line with approved and regularly reviewed Standard Operating Procedures that comply with domestic and international standards and regulations, and that include clear identification and reporting mechanisms for Serious Adverse Events and Reactions and Quality Incidents.
- Working only with experienced, trusted and appropriately regulated medical partners and services. These relationships in turn are governed via established legal contracts and service protocols and regular service reviews.
- Ensuring a thorough quality assurance system is in place within the organisation, including compliance with the World Marrow Donor Association (WMDA) standards (qualification for which was achieved and approved in March 2021).
- Ensuring ongoing training, support and continuing professional development for all staff involved in the blood stem cell registration and donation process.

DKMS Foundation: trustees' report for the year ended 31 December 2022

Data management and protection

The collection, processing, storage and security of our blood stem cell donors' personal data and genetic information is of paramount importance and so represents a major risk in the event of mismanagement, loss or misuse of that data.

The potential damage to individual donors through a data breach, let alone the damage to DKMS UK's and the DKMS Group's reputation and activities in working with patients, donors, supporters and stakeholders would be catastrophic.

We manage and mitigate these risks through:

- Adherence to and compliance with strong information security and data protection policies and practices throughout the whole DKMS Group.
- Ensuring data processing and third parties and protocols are in place with suppliers and partners.
- Regular training and reviews for staff, volunteers and donor registration partners.
- Blood stem cell donor recruitment.

Effective and high-quality blood stem cell donor recruitment is essential to ensuring we meet the needs of patients and transplant centres looking for a match. If we fail to ensure we recruit sufficient numbers of donors with a diverse range of backgrounds, and also with accurate and regularly updated personal health and genetic information and contact details, then we risk not being able to save the lives of more blood cancer and blood disorder patients. We manage and mitigate this risk by ensuring we have:

- Clear and compelling communications and explanations about the registration process and the need for blood stem cell donors.
- Effective quality check and review processes.
- Quality programmes to enhance the health and contact information we have on the priority groups among our blood stem cell donors.
- A system for prioritisation for recruiting, retaining and supporting potential and actual blood stem cell donors.

Financial risks

There are a number of areas of financial risk faced by DKMS UK:

- Failure to achieve budgeted income levels.
- Inadequate financial controls or fraud.
- Poor financial management, including credit risk management, pricing risk and foreign exchange and liquidity risks.

These risks are managed and mitigated in the following ways:

- Strong planning, budgeting and monitoring processes in relation to income streams, including fundraising.
- Strong internal financial controls and data security.
- Regular reviews of fraud risks.
- Close interaction, support and cross-checking with the international financial management and controlling teams in Germany.
- Vetting by DKMS Germany of international health services, registries and companies involved in stem cell transplantation, so that stringent assessments on credit risk are carried out and appropriate financial terms agreed for all DKMS companies within the Group.
- Ensuring pricing of products and services is set at reasonable and affordable levels, that recognise the Group's role as a healthcare service provider with a primary objective of saving lives. Pricing levels are based on a production cost structure and also acknowledge differences in international economies, as well as the need to ensure patient treatments are not jeopardised by costs.
- Maintaining good cash flow and financial management systems in order to manage fluctuations in the major trading currencies in which DKMS UK deals.
- Cash flow projections are prepared as part of the Charity's strategic planning, while liquidity levels are monitored internally on a daily basis as well as reported to central management and trustees at each reporting period.
- Adequate balances are maintained in all currencies to ensure sufficient funding is available to meet commitments.

DKMS Foundation: trustees' report for the year ended 31 December 2022

Logistical and supply line business continuity and resilience

Ensuring we have reliable, efficient and cost-effective methods for transporting our swab packs, blood samples and collected blood stem cells is crucial to the successful achievement of our organisational goals and objectives to save more lives, as is having a well-stocked and maintained supply line, resources and medicines. To manage and mitigate the risks of business-critical supplies and logistical arrangements we have:

- Implemented strong review processes for stock control and order processing.
- Made alternative arrangements and contingency plans for business continuity and disaster recovery scenarios.
- Developed contingency plans to provide for business periods where we are working at higher than normal levels of activity or volume (e.g. when running successful campaigns).

Effect on DKMS UK business activity and post Brexit and UK's economic challenges

In 2022 the UK economy witnessed a short period of economic turmoil. The UK economic outlook appears to be more positive and predictable since the last budget. However high and persistent level of inflation, after effects of Brexit, strikes and economic inactivity has resulted in very sharp cost increases. A significant part of these cost increases cannot be passed on and are therefore absorbed by the charity.

Post-balance sheet events

The UK Board approved a strategic project to increase registrations from diverse ethnic minority communities in India in 2023 and to extend it to the Republic of South Africa thereafter. This will help increase the number of registered donors from these communities and help find more matching donors for the Indian and African diaspora globally.

Financial review

Going concern

The Board of Trustees of the ultimate parent company approved an arrangement to continue funding DKMS UK's main activities to meet all its liabilities from its principal, DKMS gemeinnützige GmbH for a period not less than 12 months from the date these financial statements are approved. Accordingly, the trustees continue to adopt a going concern basis in preparing the financial statements.

The company's business activities in 2022 show positive results to budget and the trend is expected to continue for rest of the year with the company's funding requirements expected to remain well within the amounts approved by the board for next three years.

The charitable company's net current assets at 31 December 2022 were £2,253,427 (2021: £1,069,433). Further details regarding the adoption of the going concern basis can also be found in the Accounting Policies on page 33.

Financial results

DKMS UK received donations totalling £3,603,214 (2021: £2,608,270) of which £1,951,981, (2021: £775,451) was donated funds, £1,651,233 (2021: £1,825,114) was donated services from DKMS in Germany and other income £nil (2021: £7,705).

The charity company's net income for the year amounted to £1,046,701 (2021: £223,736) mainly from increase in Fundraising income. Activity levels in stem cell transplants in the year remained at similar levels as in prior year and generated income of £6,971,070 (2021: £6,381,655).

Reserves policy

DKMS UK's aim is to gradually grow its unrestricted funds and achieve full financial independence. While the Charity is growing its income base and cash flow, it continues to receive funding for its main activities from its principal, DKMS gemeinnützige GmbH. The trustees have approved for this arrangement to continue for the foreseeable future and until DKMS UK becomes financially independent to meet all its liabilities for at least 12 months. As at 31 December 2022 DKMS UK's unrestricted funds were £2,228,121 (2021: £1,181,420).

DKMS Foundation: trustees' report for the year ended 31 December 2022

Principal funding

In the period under review, DKMS UK's principal funding has come from donations from DKMS in Germany. In the meantime, the charitable company continues to grow its fee income from referral of potential blood stem cell donors and management of peripheral blood stem cell or bone marrow collections and establishing a broader base of additional funding sources to grow its voluntary donation income.

The charity has also developed a fundraising strategy to raise additional funding through new voluntary donations initiatives and events.

Future developments

DKMS remains on track to increase the number of blood stem cell donations to exceed 500 within the next 2 years and continues adding new blood stem cell donors to the UK register to support this aim.

Recruitment must remain targeted, with a particular focus on those from ethnic minority communities, as those groups will further help increase our overall number of matched donors, and move us closer to levelling up access to transplantation.

Fundraising work is planned to grow significantly over the next three years to support our expansion, with important areas for future growth being community-based and volunteer-led programmes, along with an expanded corporate support programme. This support is vital to achieve our aim of finding a matching donor for every stem cell transplant patient that needs one and where required covering the costs of the transplant.

Change of auditors

PricewaterhouseCoopers LLC (PwC) resigned as auditors on 24 October 2022 after their proposal for significantly higher than the rate of inflation fee increase was not accepted by the Board of DKMS UK. PwC confirmed there were no other matters connected with their ceasing to hold office as auditors of the Foundation that they considered need to be brought to the attention of the Foundation's members or creditors.

The Board appointed Mazars LLP auditors on 12 December 2022.

Change of trustees and directors

Sirko Geist, CFO and Director resigned on 18 October 2022 following his appointment as Executive position within the DKMS Group in Germany.

Jérôme-Oliver Quella was appointed as CFO and Director on 01 December 2022.

Trustees' responsibilities statement

The Trustees (who are also directors of DKMS Foundation for the purposes of company law) are responsible for preparing the trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the trustees to prepare financial statements for each financial year. Under company law the trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period.

In preparing these financial statements, the trustees are required to:

- Select suitable accounting policies and then apply them consistently;
- Observe the methods and principles in the Charities Statement of Recommended Practice (SORP);
- Make judgments and accounting estimates that are reasonable and prudent; and
- Prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in operation.

Disclosure of information to auditors


Each of the persons who are trustees at the time when this trustees' report is approved has confirmed that:

- So far as that trustee is aware, there is no relevant audit information of which the charitable company's auditors are unaware, and
- That trustee has taken all the steps that ought to have been taken as a trustee in order to be aware of any relevant audit information and to establish that the charitable company's auditors are aware of that information.

This report was approved by the trustees on 17 July and signed on their behalf on 21 September 2023 by:

Jérôme-Oliver Quella

Trustee



Independent auditors' report to the members and trustees of DKMS Foundation

Opinion

In our opinion, DKMS Foundation's financial statements (the 'financial statements'):

- Give a true and fair view of the state of the charitable company's affairs as at 31 December 2022 and of its incoming resources and application of resources, including its income and expenditure, and cash flows for the year then ended;
- Have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards, comprising FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', and applicable law); and
- Have been prepared in accordance with the requirements of the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and regulation 8 of The Charities Accounts (Scotland) Regulations 2006 (as amended).

We have audited the financial statements, included within the Annual Report and Financial Statements (the 'Annual Report'), which comprise: the balance sheet as at 31 December 2022; the statement of financial activities (incorporating income and expenditure account) and the statement of cashflows for the year then ended; and the notes to the financial statements, which include a description of the significant accounting policies.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) ('ISAs (UK)') and applicable law. Our responsibilities under ISAs (UK) are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Independence

We remained independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, which includes the FRC's Ethical Standard and we have fulfilled our other ethical responsibilities in accordance with these requirements.

Conclusions relating to going concern

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from the date on which the financial statements are authorised for issue.

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

However, because not all future events or conditions can be predicted, this conclusion is not a guarantee as to the charitable company's ability to continue as a going concern.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Independent auditors' report to the members and trustees of DKMS Foundation

Reporting on other information

The other information comprises all of the information in the Annual Report other than the financial statements and our auditors' report thereon. The trustees are responsible for the other information. Our opinion on the financial statements does not cover the other information and, accordingly, we do not express an audit opinion or, except to the extent otherwise explicitly stated in this report, any form of assurance thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated. If we identify an apparent material inconsistency or material misstatement, we are required to perform procedures to conclude whether there is a material misstatement of the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report based on these responsibilities.

With respect to the Trustees' Report, we also considered whether the disclosures required by the UK Companies Act 2006 have been included.

Based on our work undertaken in the course of the audit, the Companies Act 2006 and The Charities Accounts (Scotland) Regulations 2006 (as amended) require us also to report certain opinions and matters as described on the next page.

Trustees' Report

In our opinion, based on the work undertaken in the course of the audit the information given in the Trustees' Report for the financial year for which the financial statements are prepared is consistent with the financial statements and the Trustees' Report have been prepared in accordance with applicable legal requirements.

In addition, in light of the knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we are required to report if we have identified any material misstatements in the Trustees' Report. We have nothing to report in this respect.

Responsibilities for the financial statements and the audit

Responsibilities of the trustees for the financial statements

As explained more fully in the trustees' responsibilities statement, the trustees are responsible for the preparation of the financial statements in accordance with the applicable framework and for being satisfied that they give a true and fair view. The trustees are also responsible for such internal control as they determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Independent auditors' report to the members and trustees of DKMS Foundation

Auditors' responsibilities for the audit of the financial statements

We have been appointed as auditors under section 44(1) of the Charities and Trustee Investment (Scotland) Act 2005 and under the Companies Act 2006 and report in accordance with the Acts and relevant regulations made or having effect there under.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion.

Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

Based on our understanding of the charitable company and industry, we identified that the principal risks of non-compliance with laws and regulations related to Health and Safety regulations and employment law, and we considered the extent to which non-compliance might have a material effect on the financial statements. We also considered those laws and regulations that have a direct impact on the financial statements such as the

Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and regulation 8 of The Charities Accounts (Scotland) Regulations 2006 (as amended). We evaluated management's incentives and opportunities for fraudulent manipulation of the financial statements (including the risk of override of controls), and determined that the principal risks were related to manipulation of financial performance. Audit procedures performed included:

- Enquiries of management around known or suspected instances of non-compliance with laws and regulations, claims, litigation, and instances of fraud;
- Understanding of management's controls designed to prevent and detect irregularities;
- Review of board minutes;
- Identifying and testing journal entries to assess whether any of the journals appeared unusual, for example unexpected account combinations impacting revenue; and
- Incorporating an element of unpredictability into our testing plan.

There are inherent limitations in the audit procedures described above. We are less likely to become aware of instances of non-compliance with laws and regulations that are not closely related to events and transactions reflected in the financial statements. Also, the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery or intentional misrepresentations, or through collusion.

A further description of our responsibilities for the audit of the financial statements is located on the FRC's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditors' report.

Independent auditors' report to the members and trustees of DKMS Foundation

Use of this report

This report, including the opinions, has been prepared for and only for the charitable company's members and trustees as a body in accordance with section 44(1) (c) of the Charities and Trustee Investment (Scotland) Act 2005 and the Companies Act 2006 and regulations made under those Acts (regulation 10 of The Charities Accounts (Scotland) Regulations 2006 (as amended) and Chapter 3 of Part 16 of the Companies Act 2006) and for no other purpose. We do not, in giving these opinions, accept or assume responsibility for any other purpose or to any other person to whom this report is shown or into whose hands it may come save where expressly agreed by our prior consent in writing.

Other required reporting

Matters on which we are required to report by exception

Under the Companies Act 2006 and The Charities Accounts (Scotland) Regulations 2006 (as amended) we are required to report to you if, in our opinion:

- We have not obtained all the information and explanations we require for our audit; or
- Adequate and proper accounting records have not been kept or returns adequate for our audit have not been received from branches not visited by us; or
- Certain disclosures of trustees' remuneration specified by law are not made; or
- The financial statements are not in agreement with the accounting records and returns.

We have no exceptions to report arising from this responsibility.

Entitlement to exemptions

Under the Companies Act 2006 we are required to report to you if, in our opinion, the trustees were not entitled to: prepare financial statements in accordance with the small companies' regime and take advantage of the small company's exemption from preparing a Strategic Report.

We have no exceptions to report arising from this responsibility.

N J Wakefield
Nicola Wakefield (Senior Statutory Auditor)
for and on behalf of Mazars LLP
Chartered Accountants and Statutory Auditors,
Sutton, Surrey

29 September 2023

DKMS Foundation: Statement of financial activities

(Incorporating income and expenditure account)
for the year 31 December 2022

		Unrestricted funds 2022	Total funds 2022	Total funds 2021
	Note	£	£	£
Income from				
Donations and legacies	2	3,603,214	3,603,214	2,608,270
Charitable activities	3	6,971,070	6,971,070	6,381,655
Total Income		10,574,284	10,574,284	8,989,925
Expenditure on				
Raising funds	4	1,188,144	1,188,144	521,982
Charitable activities	5, 6 and 9	8,339,439	8,339,439	8,244,207
	7, 18	9,527,583	9,527,583	8,766,189
Net Income/(expenditure) before other recognised gains and losses		1,046,701	1,046,701	223,736
		1,046,701	1,046,701	223,736
Reconciliation of funds				
Total funds brought forward		1,181,420	1,181,420	957,684
Total funds carried forward		2,228,121	2,228,121	1,181,420

All activities relate to continuing operations.

The notes on pages 16 to 28 form part of these financial statements.

DKMS Foundation: Balance Sheet

As at 31 December 2022

		2022		2021	
	Note	£	£	£	£
Fixed assets					
Tangible assets	12		59,165		111,986
Investments	13		1		1
			59,166		111,987
Current assets					
Inventory	14	285,015		180,086	
Debtors	15	1,313,149		1,171,084	
Cash at bank and in hand	21	1,749,940		1,017,723	
		3,348,104		2,368,893	
Creditors: amounts falling due within one year	16	(1,179,149)		(1,299,460)	
Net current assets			2,168,955		1,069,433
Net assets			2,228,121		1,181,420
Charity Funds					
Unrestricted funds	18		2,228,121		1,181,420
Total funds	19		2,228,121		1,181,420

The company's financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The trustees consider that the company is entitled to exemption from the requirement to have an audit under the provisions of section 477 of the Companies Act 2006 ("the Act") and members have not required the company to obtain an audit for the year in question in accordance with section 476 of the Act. However, an audit is required in accordance with section 144 of the Charities Act 2011.

The trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.

The financial statements were approved and authorised for issue by the trustees on 17 July and signed on their behalf on 21 September 2023 by:

Jérôme-Oliver Quella
Trustee

The notes on pages 16 to 28 form part of these financial statements.

DKMS Foundation: Statement of cash flows

For the year ended 31 December 2022

		2022	2021
	Note	£	£
Cash flows from operating activities			
Net cash provided by operating activities	20	749,434	281,170
Cash flows from investing activities			
Purchase of tangible fixed assets		(17,217)	(35,950)
Net cash used in investing activities		(17,217)	(35,950)
Change in cash and cash equivalents in the year		732,217	245,820
Cash and cash equivalents brought forward		1,017,723	771,903
Cash and cash equivalents carried forward	21	1,749,940	1,017,723

The notes on pages 16 to 28 form part of these financial statements.

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2022

01. Accounting Policies

1.1 Basis of preparation of financial statements

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

DKMS Foundation meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

The financial statements are presented in pound sterling (£).

1.2 Going concern

The trustees of the ultimate parent company review the company's activities and 3 year business plan each year and establish and approve funding level required to enable the company to achieve its goals and meet its business commitments and liabilities.

The trustees have approved arrangement to continue funding the charitable company's main activities from its principal, DKMS Gemeinnutzige GmbH until the company becomes financially independent to meet all its liabilities for a period not less than twelve months from the date these financial statements are approved. Accordingly, they continue to adopt going concern basis in preparing the financial statements.

1.3 Company status

The charitable company is limited by guarantee. The members of the company are the trustees named on page 55. In the event of the company being wound up, the liability in respect of the guarantee is limited to £10 per member of the company.

1.4 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the trustees in furtherance of the general objectives of the company and which have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the company for particular purposes. The costs of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2022

1.5 Income

All income is recognised once the charitable company has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably. Money donation income is recognised when the income is credited into the company's account and revenue for clinical services is recognised after services are delivered.

Donated services or facilities are recognised when the charitable company has control over the item, any conditions associated with the donated item have been met, the receipt of economic benefit from the use by the charitable company of the item is probable and that economic benefit can be measured reliably. In accordance with the Charities SORP (FRS 102). General volunteer time is not recognised. Further information about volunteer contribution is included in the trustees' report.

On receipt, donated professional services and donated facilities are recognised on the basis of the value of the gift to the charitable company which is the amount the charitable company would have been willing to pay to obtain services or facilities of equivalent economic benefit on the open market; a corresponding amount is then recognised in expenditure in the period of receipt.

Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

1.6 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to make payment to a third party, it is probable that settlement will be required and the amount of the obligation can be measured reliably.

All expenditure is accounted for on an accruals basis. All expenses including support costs and governance costs are allocated to the applicable expenditure headings:

- Costs of generating funds comprise the costs associated with attracting voluntary income.
- Charitable expenditure comprises those costs incurred by the charitable company in the delivery of its activities and services for its beneficiaries. It includes both costs that can be allocated directly to such activities and those costs of an indirect nature necessary to support them.

- Governance costs include those costs associated with meeting the constitutional and statutory requirements of the charitable company and include the audit fees and costs linked to the strategic management of the charitable company.
- All costs are allocated between the expenditure categories of the statement of financial activities on a basis designed to reflect the use of the resource. Costs relating to a particular activity are allocated directly; others are apportioned on an appropriate basis. Staff costs are allocated based on staff numbers, premises costs are allocated based on space occupied.

1.7 Tangible fixed assets and depreciation

Tangible fixed assets are carried at cost, net of accumulated depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost of fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

- Leasehold improvements - over period of lease (4 years) straight line.
- Office equipment - 33.33% per annum straight line.
- Computer equipment - 33.33% per annum straight line.

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2022

1.8 Investments

Investments are a form of basic financial instrument and are initially recognised at their transaction value. Investments in subsidiary companies are stated at cost less diminution in value.

1.9 Interest receivable

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the company; this is normally upon notification of the interest paid or payable by the Bank.

1.10 Debtors

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

1.11 Cash at bank and in hand

Cash at bank and in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

1.12 Creditors and provisions

Creditors and provisions are recognised where the charitable company has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due.

1.13 Pensions

The charitable company operates a defined contribution pension scheme and the pension charge represents the amount payable by the charitable company in respect of the year.

1.14 Financial instruments

The charitable company has applied Sections 11 and 12 of (FRS 102) in respect of financial instruments.

Financial assets and financial liabilities are recognised when the charitable company becomes party to the contractual provisions of the instrument. Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the charitable company after deducting all of its liabilities.

The charitable company's policies for its major classes of financial assets and financial liabilities are set out below.

Financial assets

Basic financial assets, including trade and other debtors, cash and bank balances, related charity working capital balances, and related charity financing are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest for a similar debt instrument. Financing transactions are those in which payment is deferred beyond normal business terms or is financed at a rate of interest that is not a market rate.

Such assets are subsequently carried at amortised cost using the effective interest method, less any impairment.

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2022

Financial liabilities

Basic financial liabilities, including trade and other creditors, bank loans and loans from related charities, are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Financing transactions are those in which payment is deferred beyond normal business terms or is financed at a rate of interest that is not a market rate.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Impairment of financial assets

Financial assets measured at cost and amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss is recognised in the profit and loss account.

For financial assets measured at cost less impairment, the impairment loss is measured as the difference between the asset's carrying amount and the best estimate of the amount the charitable company would receive for the asset if it were to be sold at the reporting date.

For financial assets measured at amortised cost, the impairment loss is measured as the difference between the asset's carrying amount and the present value of estimated cash flows discounted at the asset's original effective interest rate. If the financial asset has a variable interest rate, the discount rate for measuring any impairment loss is the current effective interest rate determined under the contract.

If there is a decrease in the impairment loss arising from an event occurring after the impairment was recognised, the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been had the impairment not previously been recognised. The impairment reversal is recognised in profit or loss.

Derecognition of financial assets and financial liabilities

Financial assets are derecognised when (a) the contractual rights to the cash flows from the asset expire or are settled, or (b) substantially all the risks and rewards of the ownership of the asset are transferred to another party or (c) despite having retained some significant risks and rewards of ownership, control of the asset has been transferred to another party who has the practical ability to unilaterally sell the asset to an unrelated third party without imposing additional restrictions.

Financial liabilities are derecognised when the liability is extinguished, that is when the contractual obligation is discharged, cancelled or expires.

Critical accounting estimates and areas of judgment

Management does not consider there to be any key judgements or estimates made in the preparation of the financial statements.

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2022

02. Donations and legacies

	Unrestricted funds 2022	Total funds 2022	Total funds 2021
	£	£	£
Donation income	1,932,099	1,932,099	475,451
International donation income	19,882	19,882	300,000
Funding for donor recruitment activities from DKMS Gemeinnutzige GmbH	1,651,233	1,651,233	1,825,114
Other income	-	-	7,705
Total donations and legacies	3,603,214	3,603,214	2,608,270
Total 2021	<u>2,608,270</u>	<u>2,608,270</u>	

03. Charitable activities

	Unrestricted funds 2022	Total funds 2022	Total funds 2021
	£	£	£
Income from service provision	6,971,070	6,971,070	6,381,655
Total 2021	<u>6,381,655</u>	<u>6,381,655</u>	

In the year ended 31 December 2022 and 2021 all income related to unrestricted funds.

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2022

04. Raising funds

	Unrestricted funds 2022	Total funds 2022	Total funds 2021
	£	£	£
Salaries, national insurance and pensions	336,699	336,699	333,167
Other staff costs and training	27,301	27,301	10,455
Premises costs	60,032	60,032	58,061
Publicity & Awareness costs	626,982	626,982	9,341
Postage, support and stationery	1,593	1,593	1,794
Other admin costs	130,313	130,313	89,671
Travel costs	4,795	4,795	272
(Gain)/Loss on foreign exchange	(8,786)	(8,786)	10,739
Depreciation	9,215	9,215	8,482
	<u>1,188,144</u>	<u>1,188,144</u>	<u>521,982</u>
Total 2021	<u>521,982</u>	<u>521,982</u>	

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2022

05. Direct costs

	Recruitment of Donors	Raising Awareness	Donor Request Management	Total 2022	Total 2021
	£	£	£	£	£
Other direct costs	237,726	129,058	2,384,558	2,751,342	2,920,685
Other staff costs and training	262	47,001	177	47,440	23,121
Premises cost	65,465	112,157	114,461	292,083	282,422
Publicity cost	65,819	250,538	(48,576)	267,781	289,522
(Gain)/Loss on foreign exchange	(9,348)	(16,026)	(18,697)	(44,071)	53,867
Postage, support and stationery	197,626	288,543	117,002	603,171	582,477
Travel costs	14,866	3,071	33,522	51,459	2,080
Donor typing costs	1,651,232	-	-	1,651,232	1,741,345
Salaries, national insurance and pensions	241,453	372,823	632,961	1,247,237	1,295,116
Depreciation	9,805	16,809	19,611	46,225	42,545
	2,474,906	1,203,974	3,235,019	6,913,899	7,233,180
Total 2021	<u>2,658,100</u>	<u>1,203,574</u>	<u>3,371,506</u>	<u>7,233,180</u>	

In the year ended 31 December 2022 and 2021 all costs of direct charitable activities related to unrestricted funds.

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2022

06. Support costs

	Recruitment of Donors	Raising Awareness	Donor Request Management	Total 2022	Total 2021
	£	£	£	£	£
Legal and professional fees	11,669	19,989	19,785	51,443	26,013
(Gain)/Loss on foreign exchange	(2,952)	(5,061)	(5,904)	(13,917)	17,011
Other staff costs and training	37,400	64,114	74,799	176,313	60,936
Premises costs	21,727	37,218	36,837	95,782	92,652
Travel costs	4,806	8,239	9,612	22,657	319
Other support costs	39,392	67,529	78,785	185,706	87,779
Postage, Support and stationery	335	574	669	1,578	4,447
Admin costs	718	1,232	1,437	3,387	9,588
Salaries, national insurance and pensions	177,270	303,891	354,539	835,700	654,460
Depreciation	3,096	5,308	6,193	14,597	13,435
Total 2022	293,461	503,033	576,752	1,373,246	966,640
Total 2021	206,792	354,464	405,384	966,640	

In the year ended 31 December 2022 and 2021 all support related to unrestricted funds.

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2022

07. Analysis of expenditure by expenditure type

	Staff Costs 2022	Depreciation 2022	Other Costs 2022	Total 2022	Total 2021
	£	£	£	£	£
Expenditure on raising voluntary income	336,699	9,215	842,230	1,188,144	628,834
Costs of raising funds	336,699	9,215	842,230	1,188,144	628,834
Recruitment of donors	418,722	12,902	2,336,744	2,768,368	1,123,868
Raising awareness	676,714	22,117	1,008,176	1,707,007	3,192,209
Donor request management	987,500	25,804	2,798,466	3,811,770	3,776,891
Charitable activities	2,082,936	60,823	6,143,386	8,287,145	8,092,968
Expenditure on governance	-	-	52,294	52,294	44,387
Total 2022	2,419,635	70,038	7,037,910	9,527,583	8,766,189
Total 2021	<u>2,282,743</u>	<u>64,461</u>	<u>6,418,985</u>	<u>8,766,189</u>	

Expenditure on raising voluntary income has not been allocated to specific activities as all costs relate to general charitable activities.

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2022

08. Analysis of expenditure by activities

	Activities undertaken directly 2022	Support costs 2022	Total 2022	Total 2021
	£	£	£	£
Recruitment of donors	2,474,906	293,461	2,768,367	1,123,869
Raising awareness	1,203,974	503,033	1,707,007	3,192,209
Donor request management	3,235,019	576,752	3,811,771	3,776,890
Total 2022	6,913,899	1,373,246	8,287,145	8,092,968
Total 2021	7,157,735	935,233	8,092,968	

In the year ended 31 December 2022 and 2021 all costs of direct charitable activities related to unrestricted funds.

09. Governance costs

	Unrestricted funds 2022	Total funds 2022	Total funds 2021
	£	£	£
Auditors' remuneration	27,600	27,600	23,000
Legal and professional fees	24,694	24,694	21,387
Total	52,294	52,294	44,387

In the year ended 31 December 2022 and 2021 all governance costs related to unrestricted funds.

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2022

10. Net income

This is stated after charging:

	2022	2021
	£	£
Depreciation of tangible fixed assets		
- Owned by the charity	70,038	64,719
Auditors' remuneration - audit	27,600	23,000
- Non-audit services Taxation advice	21,221	15,000

During the year, no trustees received any remuneration (2021- £Nil).

During the year, no trustees received any benefits in kind (2021 - £Nil).

During the year, no trustees received any reimbursement of expenses (2021 - £Nil).

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2022

11. Staff Costs

Staff costs were as follows:

	2022	2021
	£	£
Salaries	2,198,589	1,992,059
Social security costs	235,156	201,512
Pension costs	80,122	82,196
Total	<u>2,513,867</u>	<u>2,275,767</u>

The average monthly number of employees was: 51 (2021: 50) and the average monthly number of employees during the year.

Full time equivalents was as follows (including part-time and fixed period temporary staff):

	2022	2021
	No.	No.
Donor recruitment	7	7
Fundraising	5	5
Communications	8	12
Medical	16	14
Administration	15	12
Total	<u>51</u>	<u>50</u>

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2022

The number of higher paid employees was:

	2022	2021
	No.	No.
In the band £60,001 - £70,000	2	2
In the band £70,001 - £80,000	2	1
In the band £80,001 - £90,000	0	1
In the band £90,001 - £100,000	1	0
In the band £100,001 - £110,000	0	0
In the band £110,001 - £120,000	0	0
In the band £120,001 - £130,000	1	1
In the band £130,001 - £140,000	0	0
In the band £140,001 - £150,000	0	0
In the band £150,001 - £160,000	1	0
Total	<u>7</u>	<u>5</u>

The charitable company trustees were not paid nor received any other benefits from employment with the charitable company in the year (2021: £Nil) neither were they reimbursed expenses during the year (2021: £Nil). No charitable company trustee received payment for professional or other services supplied to the charitable company (2021: £Nil).

The key management personnel of the charitable company are the trustees, the Chief Executive Officer and the heads of departments. There are 6 heads of department (2021: 6), four of whom received remuneration in excess of £60,000 during the year (2021: 5). The total employee benefits of the key management personnel of the charitable company were £590,985 (2021: £571,266).

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2022

12. Tangible assets

	Office Equipment	Computer Equipment	Leasehold Improvements	Total
Cost	£	£	£	£
At 1 January 2022	70,434	171,328	228,855	470,617
Additions	999	16,218	-	17,217
Disposals	(1,633)	(20,673)	-	(22,306)
At 31 December 2022	69,800	166,873	228,855	465,528
Accumulated Depreciation				
At 1 January 2022	56,666	128,437	173,528	358,631
Charge for the year	6,442	30,399	33,197	70,038
Release on disposal	(1,633)	(20,673)	-	(22,306)
At 31 December 2022	61,475	138,163	206,725	406,363
Net book value				
At 31 December 2022	8,325	28,710	22,130	59,165
At 31 December 2021	13,768	42,891	55,327	111,986

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2022

13. Investments

Shares in Group Undertakings

	£
Costs and net book value	
At 31 December 2022 and 31 December 2021	<u><u>1</u></u>

The company's wholly owned subsidiary, Delete Blood Cancer UK Marketing Limited, registered at Ashburnham House, Castle Row, Horticultural Place, London W4 4JQ is a dormant company. Its net liability position at 31 December 2022 £10,245 (2021: £10,245) is represented by amounts due to parent company and is fully provided for in the accounts of the parent company.

14. Inventory

Inventory costs were as follows:

	2022	2021
	£	£
Materials stock	241,509	155,634
Work in progress costs	43,506	24,452
Total	<u><u>285,015</u></u>	<u><u>180,086</u></u>

Inventories are valued at lower of cost and net realisable value. Work in progress costs are reimbursable costs incurred for active stem cell collections awaiting to be billed.

15. Debtors

	2022	2021
	£	£
Due within one year		
Trade debtors	1,062,565	870,208
Amounts owed by group undertakings	10,245	10,245
Amounts owed by related charity	36,735	110,005
Other debtors	5,621	1,245
Prepayments and accrued income	197,983	179,381
Total	<u><u>1,313,149</u></u>	<u><u>1,171,084</u></u>

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2022

16. Creditors: Amounts falling due within one year

	2022	2021
	£	£
Trade creditors	385,315	349,404
Amounts owed to related charity	59,050	30,807
Other creditors	63,401	22,217
Other taxation and social security	67,672	62,586
Accruals	603,711	834,446
Total	<u>1,179,149</u>	<u>1,299,460</u>

17. Financial instruments

	2022	2021
	£	£
Financial assets		
Financial assets that are debt instruments measured at amortised cost	1,115,166	991,703
Financial liabilities		
Financial liabilities measured at amortised cost	(444,365)	(380,211)
Total	<u>670,801</u>	<u>611,492</u>

Financial assets measured at amortised cost include trade debtors, amounts owed by group companies, other debtors and amounts owed by related charity.

Financial liabilities include trade creditors and amounts owed to a related charity.

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2022

18. Summary of funds

	2022	2021
	£	£
At 1 January	1,181,420	957,684
Income for year	10,574,284	8,989,925
Resource expended	(9,527,583)	(8,766,189)
At 31 December	2,228,121	1,181,420

19. Analysis of net assets between funds

Analysis of net assets between funds - current year:

	Unrestricted funds 2022	Total funds 2022
	£	£
Tangible fixed assets	59,165	59,165
Fixed asset investments	1	1
Current assets	3,348,104	3,348,104
Creditors due within one year	(1,179,149)	(1,179,149)
Total	2,228,121	2,228,121

Analysis of net assets between funds - prior year:

	Unrestricted funds 2021	Total funds 2021
	£	£
Tangible fixed assets	111,986	111,986
Fixed asset investments	1	1
Current assets	2,368,893	2,368,893
Creditors due within one year	(1,299,460)	(1,299,460)
Total	1,181,420	1,181,420

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2022

20. Reconciliation of net movement in funds to net cash flow from operating activities

	2022	2021
	£	£
Net income/(expenditure) for the year (as per Statement of Financial activities)	1,046,701	223,736
Adjustment for		
Depreciation charges	70,038	64,461
(Increase)/Decrease in debtors	(142,065)	706,925
(Decrease) in creditors	(120,311)	(677,537)
(Increase) in Inventory	(104,929)	(35,815)
Total	<u>749,434</u>	<u>281,770</u>

21. Analysis of cash and cash equivalents

	2022	2021
	£	£
Cash at bank in hand	1,749,940	1,017,723
Total	<u>1,749,940</u>	<u>1,017,723</u>

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2022

22. Operating lease commitments

At 31 December 2022 the total of the charity's future minimum lease payments under non-cancellable operating leases was:

	2022	2021
	£	£
Within 1 year	214,541	285,022
Between 2 and 5 years	3,097	217,638
Over 5 years	-	-
Total	217,638	502,660

Lease payments recognised as an expense amounted to **£282,183** (2021: £282,183).

The company entered into a new 4 year lease ending 30 September 2023 for its current office premises at annual rent of £281,925 including a 6 month rent-free period at the start of the lease and a 3 year lease ending October 2024 for purchase of operating equipment at annual rent of £3,097.

The Superior leaseholders are in negotiations with the freehold landlords for renewal of their lease for these premises and have indicated to DKMS that they would correspondingly offer the charitable company a new lease for a further period. Negotiations have progressed positively and are at final stages.

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2022

23. Related party transactions

The company has taken advantage of the exemption contained in FRS 102 section 33 “Related Party Disclosures” from disclosing transactions with entities which are a wholly owned part of the group.

Transactions with other related parties are as follows:

Name (relationship)	Transaction	Amount		Amount due from/ (to) related party	
		2022	2021	2022	2021
		£	£	£	£
DKMS Gemeinnutzige GmbH (Common Trustees)	Donated services	1,651,233	1,825,114	-	83,930
DKMS Gemeinnutzige GmbH (Common Trustees)	Intercompany recharges	349,474	249,463	(52,617)	(30,141)
DKMS Life Science Lab (Common Trustees)	Intercompany service provision	-	161	-	-
DKMS Registry Gemeinnutzige GmbH	Intercompany service provision	77,119	54,339	(5,676)	(7,050)
DKMS USA (Common Trustees)	Intercompany service provision	68,120	667	(744)	(667)
DKMS USA (Common Trustees)	International money donation	19,882	300,000	-	-
DKMS BMST (India)	Intercompany support services	-	-	11,785	11,785
DKMS Foundation NPC (South Africa)	Intercompany service provision	38,310	14,290	24,950	14,290

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2022

Amounts owed to related parties are unsecured, interest free and due for repayment within one year.

DKMS Gemeinnutzige GmbH is the Controlling company and exercises full control over the charitable company through its common trustees who are also directors of the company. The controlling company recharges the charitable company actual or appropriately apportioned costs it incurs in providing support to the latter.

The controlling company DKMS Gemeinnutzige GmbH entered into a contract with DKMS Life Science Lab whereby DKMS Foundation receives typing services for no consideration from 01 January 2021.

DKMS Life Science Lab is one of the leading HLA laboratories and provides this service for all DKMS entities.

24. Post balance sheet events

The UK Board approved a strategic project to increase registrations from diverse ethnic minority communities in India in 2023 and to extend it to the Republic of South Africa thereafter. This will help increase the number of registered donors from these communities and help find more matching donors for the Indian and African diaspora globally.

25. Controlling party

The trustees are the immediate controlling party and DKMS Gemeinnutzige GmbH is the ultimate parent. The principal address of the ultimate parent is Kressbach 1, 72072 Tübingen, Germany.

Copies of the group financial statements are available at www.dkms.de.

Ways you can support us

Organise a donor registration event

Organise an event to encourage your friends, family or colleagues to register as potential blood stem cell donors.

Create a bespoke partnership

DKMS can provide your company with networking and marketing opportunities aligned with our purposes and shared values.

Payroll giving

Donate to DKMS through your company's Payroll Giving Scheme if employees are paid through PAYE.

The 2K Club

Join our club of corporate supporters whose contribution goes towards helping the more than 2,000 people in the UK searching for a matching blood stem cell donor each year.

Sponsored activities

From local 10k runs and marathons to multi-day cycle trips, challenge yourself and get fit!

Fundraising events

Whether holding a bake sale, organising a music night or giving up a vice, every penny you raise helps in the fight against blood cancer.

Daredevil challenges

If you fancy standing on top of a plane, jumping out of one, or filling your run with obstacles, we have something for everyone.

Giving in memory

Many people choose to remember a loved one by fundraising for DKMS. We'll help you through the process to make sure their memory lives on through our work.



Trustees

Dr E Neujahr
B J Abel
S Geist
J-O Quella
Dr A H Schmidt
S Schumacher

Principal staff

Stephan Schumacher, Country Manager, UK

Registered company number

08151279 (England & Wales)

Charity registered number

1150056 (England & Wales)

SC046917 (Scotland)

Registered office

Ashburnham House, Castle Row,
Horticultural Place
London W4 4JQ

Company secretary

B J Abel

Independent auditors

Mazars LLP
6 Sutton Plaza
Sutton Court Road
Sutton
Surrey
SM1 4FS

Bankers

Barclays Bank plc
74 Shepherds Bush Green
Shepherds Bush
London W12 8QB

Commerzbank AG
30 Gresham Street
London EC2V 7PG

105,703

Transplants for people in need*

11.7m

Potential donors registered*

21

Lifesaving blood stem cell
donations each day*

*Global DKMS statistics as of 31 December 2022

DKMS is the trading name of DKMS Foundation, a company limited by guarantee registered in England and Wales (08151279) and a charity registered in England and Wales (1150056) and Scotland (SC046917).

DKMS FOUNDATION

England & Wales - Charity number 1150056

Accounts

DKMS Foundation
ANNUAL REPORT
AND FINANCIAL
STATEMENTS

YEAR ENDING 31 DECEMBER 2021


BLOOD CANCER



Our Vision:

To delete blood cancer.



Our Mission:

To give as many blood cancer patients as possible a second chance at life.



Our Purpose:

To raise awareness of blood cancer and blood disorders, recruit and retain potential blood stem cell donors to provide a second chance at life, raise funds to match donor registration costs, and improve blood cancer therapies by our own research.

Contents

Trustee's introduction	3
Achievements	4
DKMS donor contribution	6
Stem cell donor recruitment	8
The power of partnerships	11
Achieving success during unprecedented times	12
Fundraising in 2021	14
Success stories	18
Trustees' Report	20
Independent auditors' report to the members and Trustees of DKMS Foundation	26
Financial statements	29
Reference and administrative details	48



Trustee's introduction

As we began to emerge from the early stages of the pandemic, navigating the continued ripple effects on our services caused by Covid-19 and the changing priorities in the UK and international healthcare systems, one thing remains unchanged: blood cancer continues to have a profound and debilitating effect on the lives of people from all communities. Therefore, throughout 2021 DKMS continued to do everything possible to overcome obstacles and unforeseen circumstances and deliver the best services possible for patients who found themselves in need of a blood stem cell transplant.

As a strategically-critical arm of a global organisation, DKMS UK was able to continue to deliver essential life-saving services and expand upon a foundation that will provide for patients for years to come. By continuing to recruit and register a diverse pool of potential blood stem cell donors and arrange blood stem cell donations, DKMS has been able to provide treatment to those in need and hope to the innumerable friends and family who fear for their loved ones. Despite the challenging circumstances, DKMS remained firm in their promise to never settle for anything less than the best when it comes to serving our patients and donors.

Beyond the maintenance of day-to-day operations, DKMS also continued to evolve and develop successfully as an organisation during the course of 2021. Though it was difficult to register as many new potential stem cell donors as in previous years, due to limited opportunities to run face-to-face recruitment events and the inevitable shift of public focus during

a global pandemic, you will be pleased to learn we still added nearly 90,000 people to the UK blood stem cell donor register, moving ever closer to one million available donors. The importance of new donors was reinforced by the nearly 350 blood stem cell donations that DKMS helped arrange during the year, a record number for the UK. We draw deep inspiration from this achievement, not simply for the sum total, but rather from the knowledge that each and every donation represents a second chance at life for a patient in the UK or around the world.

As always, an enormous debt of thanks is owed to our blood stem cell donors, volunteers, and fundraising supporters who have all worked closely with our committed staff to overcome seemingly insurmountable obstacles and achieve remarkable things. Their dedication and passion for the cause ensures that we never take no as an answer.

Stephan Schumacher
Trustee DKMS Foundation

A young girl with dark hair, wearing a colorful patterned dress, is blowing bubbles. Several bubbles are floating in the air around her. The background is a dark, textured wall.

339

second chances at life

Livia found a donor through DKMS

Achievements

During 2021 we continued to work in line with the key priorities established in 2019, which will guide our work through to 2023. We reviewed and reconfirmed our priorities to ensure focus remained on delivering the best and most innovative services and support for our incredible blood stem cell donors, fundraisers, volunteers and patients.

Saving more lives

2021 was a record-breaking year for DKMS UK, with the organisation's donors and staff helping to give 339 second chances at life via blood stem cell donations – a massive increase from the 273 achieved in 2020. Last year, DKMS globally facilitated stem cell transplants for 527 UK patients, with 98 donations coming from DKMS UK.

This accomplishment is a real testament to the passion, commitment, and fortitude of our donors. So many of them were willing to overcome challenging situations, often related to fast-changing pandemic health or travel restrictions, to selflessly donate their stem cells to those in need.

Increasing the number of lives that can be saved is absolutely dependent on continuing to build the donor pool by recruiting new people to the UK stem cell donor register. A further 87,000 new potential donors were registered, bringing us close to 900,000 total donors since DKMS first started working in the UK.

We hope to reach our first million registrations in 2022.

It costs DKMS £40 to register each donor, so fundraising is pivotal to our continuing to do more for patients with blood cancer.

By growing our fundraising income, we will be able to register more donors and give more people with blood cancer a second chance at life.

Better chances for those who have fewer chances

During 2021, an external agency was commissioned to research the needs of racial and ethnic minority communities, with a focus on how best to engage, build, and maintain better relationships with these groups. This will improve our work with transplant patients and help target blood stem cell donor recruitment from selected communities, including from South Asian, African, and Caribbean groups. The research findings have provided us with the knowledge and tools to more effectively communicate with these communities.

The best support for donors

Major steps were taken to improve the journey for our blood stem cell donors, supporters, and stakeholders. Some of the more significant changes include:

- » Delivering new, more user-friendly communications and packaging for confirmatory typing activities (the information and medical assessment kits we send to donors when they are first identified as a potential match),
- » digitising blood stem cell donor registration cards, and
- » using innovative tools to speed up the process for donors, while also reducing our carbon footprint and cutting unnecessary costs.

Achievements (CONTINUED)

Increasing our Income

The successes of 2021, including the increase in our blood stem cell donation services, reductions in costs and efficiency savings, have moved DKMS UK closer to a position of being sustainable. However, this is still not enough.

We want to increase income so we can support more blood stem cell donations and transplants, including in countries such as India and South Africa where there is currently no donor register or where access to transplantation is limited due to high costs, limited availability of qualified clinicians, or both.

Building a community of support

Building a vibrant community of committed and engaged support for DKMS UK is vital to achieving our long-term goals. With this goal in mind, we were pleased to take major steps forward during 2021. A new volunteer development programme was launched to better support existing volunteers, recruit new ones, and establish volunteering hubs in different areas of the UK. All of these efforts will continue to further blood stem cell donor recruitment and fundraising initiatives, while increasing engagement with our passionate and dedicated volunteers.

Fundraising supporters exceeded our expectations over the last year, with more and more people taking part in community and challenge events, finding new and creative ways in which to support our work. We continue to be deeply grateful for their committed efforts, which have been above and beyond what we could hope for.

Relationships were built and strengthened with new and existing companies that support our work, continuing strong collaborations with over 60 businesses into the new year.

We were glad to have the opportunity to work more closely with a number of stem cell collection centres and their clinicians to prepare for growth in future years.

Ultimately, none of this year's achievements would be possible without a committed and talented staff. Therefore, staff welfare, care, and support were prioritised in the organisation's plans.

Due to the ongoing and unprecedented volume of work, we are exceptionally proud that during the pandemic no staff were furloughed and that employees have been able to migrate to a more flexible hybrid office-home working environment that is coming into fuller effect during 2022.

Digital first

The desire to digitise more of DKMS' processes remains as strong as ever and 2021 saw significant improvements across the organisation. We have transitioned to more systems becoming digital or automated, including reducing physical postage, automating key notifications, and using online platforms for core services or support. The year ahead offers bigger opportunities, as e-registration for face-to-face donor recruitment events will be introduced.

Not only do these changes improve the quality of our work, they also bring operational efficiencies and reduce our carbon footprint.




Donor contribution, globally and locally


Global breakdown of where DKMS UK sends stem cells




DKMS UK Collections by donor age



DKMS UK Collections by donor gender



DKMS UK Collections by donor ethnicity



*British, Irish and Northern European

**Minority Ethnic Backgrounds

Source for all data in this section: DKMS UK 2021 Donor Collections

Contribution to the Aligned Stem Cell Registry

The UK's aligned stem cell registry is made up of donors recruited by Anthony Nolan, DKMS, NHS Blood and Transplant and the Welsh Blood Service. The registry coordinates requests for UK donors from both national and international transplant hospitals.

Aligned Stem Cell Registry and DKMS UK donors by ethnicity

	2020/1 (registry)	April 2021 DKMS
BINE*	1,658,500	623,730
MEB**	268,000	236,990
Unknown	151,000	13,323
Total	2,105,000	874,043

Registered donors in the UK Aligned Stem Cell Registry 2021





Chart shows the number of registered potential blood stem cell donors.

***WBMDR: Welsh Bone Marrow Donor Registry
 ****NHSBT: NHS Blood and Transplant
 Source for all data in this section: State of the Registry report 2021





2,000

requested a home swab kit
for Libby

Stem cell donor recruitment

Remaining patient-centric

We launched a programme to further engage patients and patient families with our work. The programme started with research to better understand their experience of working with DKMS and their thoughts on what we could do to better support them.

One interesting piece of feedback received from most of the patients spoken to was that DKMS gives patients and their families hope at a very difficult time.

The insight also highlighted several things we can do to better support our patients including providing a forum for patients to talk to each other. As a result, we have set up a closed Facebook group for patients and their family members.

We will continue to deliver other initiatives in the coming years.

Many of the ways of working introduced in 2020 were built on in 2021. Patient-led appeals and online registration events (called virtual drives, or V-drives) were the focus of activity for the first three-quarters of the year.

We launched 105 V-drives in 2021, including 49 in partnership with our corporate supporters, resulting in over 30,000 people registering as potential blood stem cell donors and raising £18,668 in fundraising donations, exceeding expected outcomes. 20 people who registered via V-drives have gone on to donate their stem cells.

DKMS' social media activities continued to deliver good levels of impact and contribute significantly to the number of donors recruited (60% of the total). We were fortunate enough to be able to share some particularly powerful patient stories, resulting in high levels of engagement. 13-year-old Libby, who had aplastic anaemia, is a great example of the online community coming together to help spread the word about what's needed. Within three days, Libby's patient appeal resulted in 2,000 people requesting a home swab kit.

By sharing a variety of content, including patient stories, statistics on the ongoing impact of the pandemic on our work and the inequality of access to donors for certain ethnic communities, some great successes can be noted. 100 pieces of national media coverage were secured of which six were on broadcast media - the highest so far for DKMS in any year.

We continued to work with celebrity supporter Al Murray. In November, alongside DKMS' CEO, Al was interviewed by BBC News and 16 regional TV and radio stations, which resulted in more than 1,700 people starting the registration process in the 48 hours following the interview being aired.



3,387

donors registered within a 48 hour period for Esha



Stem Cell donor recruitment

In-person opportunities

As restrictions started to ease across the UK, some face-to-face registration drives were held in locations where people were already gathering. In September, DKMS UK was approached by the family of four-year-old Esha, who had acute myeloid leukaemia (AML), to run registration drives in temples across London. Over a matter of days, the family had arranged for more than 20 drives to be held in the temples, resulting in 3,387 donors being registered within a 48-hour period. The family also shared their story via social media which saw a further 3,281 people register as potential blood stem cell donors.

We also worked with Everton FC to deliver a two-day donor recruitment event at the team's stadium, Goodison Park. The drive was in support of former player Gary Stevens, whose four-year-old son, Jack, was searching for a blood stem cell donor. Sadly, little Jack died not long after this event but his legacy remains in the hundreds of donors who registered as a result of seeing or hearing his story.

Jack's appeal has also led to the development of a model for working with other sports clubs and associations, which DKMS will focus on in the coming years.

Levelling up access to donors

Work to increase the chances available to all patients continued. At the end of December 2021, a further 10,000 donors had been recruited from the black African and Caribbean and Asian communities in the UK.

The breakdown of DKMS' donor database at the end of December 2021 is shown below.

13,441

African-Caribbean

29,255

Mixed

78,271

Asian

750,330

British Irish and European

24,223

Middle Eastern/Mediterranean

3,304

Other/unknown



Although engagement continues with specific ethnic communities, we're aware that more needs to be done to achieve parity of access for all, so this will continue to be a focus for DKMS' work in 2022.

Angelina and Shola, blood stem cell donors

The power of partnerships

Thanks to our many recruitment partners, in particular those listed below, who have continued to support our mission, DKMS is exploring new ways to work together to recruit more people onto the donor database.

10,000 Donors	ACLT	
AME-BCT (Asian and Middle Eastern Blood Cancer Trust)	Jain and Hindu Organ Donation Steering Group	Jaskomal Foundation
Kevin Kararwa Leukaemia Trust	Love Hope Strength	Race Against Blood Cancer
Sue Harris Trust	Team Margot	Upahaar



Throughout 2021, DKMS continued to work with the Women's Institute (WI) to support its efforts in raising awareness of the need for blood stem cell donors. We value this important relationship and the WI's continued support.



Oakmere Women's Institute

Achieving success during unprecedented times

Although the UK embarked on a successful Covid-19 vaccination campaign which allowed public life to reopen, for blood stem cell donors there were still many restrictions that had to stay in place to ensure donor and patient safety.

However, despite the effects of these restrictions, the DKMS UK team was determined to continue finding solutions so that donations could be completed and blood cancer and blood disorder patients would receive the treatment they desperately needed.

A new record for second chances at life

In 2021, 3,085 DKMS UK donors were selected as a potential match for patients. 339 donors went on to donate. This included 34 by bone marrow donation and 305 by PBSC (peripheral blood stem cell) donation. This was an all-time record for DKMS UK with more second chances at life given in one year than ever before.



A mark of quality

The quality of our processes has always been core to DKMS' success. In March 2021, this was recognised when we received Qualification status with the World Marrow Donor Association (WMDA). This accreditation was a significant milestone. The accreditation is important as it acts as a stamp of approval, shown to transplant centres and search coordinators searching for donors.

Learning from our colleagues abroad

Taking learning from other DKMS entities, we aligned our donor processes to deliver improved donor care and business efficiency in our work.

Listening, learning and striving to make a difference

Helping donors to proceed with their donation is a core element of what happens at DKMS, so we continually seek solutions to give an easier, better quality experience for donors. Staying involved in the latest developments in the medical community, as well as listening to the donors, several new ways were developed to help our donors and community.

A new welcome pack for potential lifesavers

The new Lifesaver Pack (the welcome pack mailed to donors when they are identified as a potential match) went live in August. There has been a positive impact from this, including donors sharing the pack on social media which, in turn, has helped to raise the profile of the DKMS brand.





An improvement to pre-donation injections

In April 2021, a medicine called Zarzio became DKMS' primary drug of choice used to stimulate the bone marrow to produce stem cells and release them into the bloodstream; an essential pre-donation step for those donating by PBSC.

Zarzio is an easier drug to administer and has provided an uplift in donors self-injecting, which has been particularly useful during the pandemic restrictions. It is estimated there will be a cost saving of approximately £200,000 thanks to this change.

Family assistance

In some cases, for patients worldwide that had a stem cell donor match in their family, the pandemic meant that these family members were not able to travel to donate. In 2021, we supported three family donations where lockdown or travel restrictions did not permit travel by finding ways to transport the required stem cells across borders.

In 2021 our international Patient Aid programme continued to grow. The aim of this programme is to make treatment more available to those in developing economies who would otherwise struggle to access it, or have that access denied entirely. Four families were supported to proceed with stem cell treatment during this financial year. We will work tirelessly to secure further funds to ensure we're able to help increasing numbers of families.

Published works

DKMS UK was actively involved (working with the UK aligned stem cell register) and listed as a co-author for the following two papers published in 2021.

- » 'The Impact of Covid-19 pandemic on unrelated donor and donor cord provision to Transplant Centres during the first wave of the pandemic. The UK Aligned Stem-cell Donor Registry experience' (currently being peer-reviewed)
- » 'SARS-CoV-2 respiratory screening of asymptomatic stem cell donors on day of collection; to test or not to test.' (accepted for publication in Bone Marrow Transplantation)



Fundraising in 2021

DKMS' fundraising activities generate incredible stories of daredevil feats and endurance challenges, helping to raise awareness of blood cancer and blood disorders, and highlighting our lifesaving work.

Corporate Partnerships

Working with companies with a strong sense of social responsibility, be it through a shared purpose or shared values – aids the DKMS cause and mission. By delivering jointly organised events and activities, companies are able to see the lasting impact of their partnership with DKMS, for example when their staff members are selected as donors or when they directly contribute towards a patient appeal.

Donor Drives

Online registrations continued in 2021, with new bespoke online pages set up for each company we worked with. This enabled employees to register online and DKMS to give feedback to companies on how many of their workforce had joined the fight against blood cancer. In 2021, 49 virtual donor drives were set up with our corporate partners. We would like to thank all those companies who supported us to make this happen.

CT Business Travel

On the back of a new contract with CT Business Travel who help arrange travel and accommodation for our donors, the company agreed to waive £2,000 of DKMS donor booking fees and committed to raising money by holding a company donor registration event and publicising our partnership to their client base... with a little help from their Wellness Director, Willow the Dog!

Hanbury Manor Golf Course

Hanbury Manor Golf Club near Ware selected DKMS to be its 2021 Charity of the Year Partner because one of its members, Nigel Ovenden, was diagnosed with multiple myeloma in September 2020. The club has done an incredible job in supporting Nigel and DKMS to raise awareness about the importance of registering as a potential blood stem cell donor, as well as the need to raise money to cover donor registration costs. The total they had raised by the end of the year was almost £25,000.

Serco

The Serco Surface Finish team at RAF Brize Norton refurbished a 1956 Chevrolet truck, raising an amazing £800. Serco has been supporting DKMS since 2018 and has raised over £3,000 to date.

The London Stock Exchange Group

The London Stock Exchange Group (LSEG) recently supported DKMS and one of their employees, Gareth Walker. Nearly two years ago, Gareth's son, Henry died of aplastic anaemia. Gareth said: "In order that something positive might come out of something so utterly heart-breaking, and in an effort to prevent other people and their loved ones from having to go through the same ordeal as Henry, I want to get the word out about the blood stem cell donor register and stem cell donation. If we know about it, we can do something about it." An amazing 189 LSEG employees registered as potential lifesavers.

We greatly appreciate the support every company has given to DKMS in what has been another challenging year. Their support has enabled us to continue to aid people facing blood cancer and to help them have a second chance at life.

Trusts and foundations

Trusts and foundations are playing an increasingly important role in DKMS voluntary funding and we would especially like to thank:

- » C A Rookes
- » Edith Murphy Foundation
- » The Hobson Charity
- » ING Bank
- » Leonard Curtis
- » PF Charitable Trust
- » RZK Foundation



Community Fundraising

Our amazing fundraising community continued to show their dedication to DKMS during 2021. Hundreds of runners, walkers, skydivers, bakers, gamers and countless others raised nearly £190,000 over the year. This was an amazing outcome for DKMS – nearly doubling the expected income from this area of fundraising at a time when other charities were publicly calling for more support. Thank you to everyone that gave their support this way in 2021.

Here are some examples of what our incredible supporters delivered:



Stand Out Supporter: Jordan Donovan

The brother of recent transplant recipient, Sheldon, and four of his friends braved a skydive to raise money for DKMS. By jumping from a plane 10,000 feet above Cornwall, the group raised over £5,500. Jordan said “I loved every second of it and can’t wait for the next fundraiser!”.



Stand Out Supporters: Dorset and Wiltshire Firefighters

An amazing group of ten firefighters took on the Bristol Half Marathon in memory of their friend and colleague Guy Tadman. Not content with the running challenge itself, they made it harder for themselves by running the 13.1 miles in their full firefighting kit, including breathing apparatus. In total they raised over £3,500.



Fantastic Fundraising Event: Wine and Cheese with DKMS

The first ever Wine and Cheese with DKMS event took place on 28 May, World Blood Cancer Day. The virtual event raised over £2,700 and was attended by around 200 to 300 people. Olly Smith, star of BBC’s Saturday Kitchen, provided lots of wine-tasting tips, answered audience questions and shared a few insider stories on finding the perfect wine and cheese pairing. As well as raising vital funds, a post-event survey revealed that 53% of participants had not heard of DKMS before the event and 13% went on to register as a blood stem cell donor following the event.



Wing walk to find lifesaving donors

DKMS’ theme for 2021’s Blood Cancer Awareness month (September) was ‘You’ve Got it in You’. The initiative urged people between the ages of 17 and 55 to make a difference by taking the first step to becoming a blood stem cell donor and a potential lifesaver.

As part of the month-long campaign, DKMS supporters Peter McCleave, Sally Hurman and Lisa Jackson completed a daring walk on the wing of a plane. The event, which took place in Essex, brought together three people with a personal connection to blood cancer, to highlight Peter’s search for a lifesaving blood stem cell donor.

The trio became a quartet when Jo Hill, the mother of former patient Finn, shaved her head for us. These four brave supporters managed to raise over £10,000 in total for DKMS. Peter, who has the blood cancer myeloma, said: “I’ve been searching for a match for four years now. If we can get more people to register with DKMS, that will help give me and other blood cancer patients a second chance at life.



End of Year Appeal

At the end of November, DKMS UK launched the Year End Appeal, which featured Alfie and his lifesaving donor, Christin. An email and social media posts encouraged supporters to watch a video featuring Lorna, Alfie's mum, and give a donation if they wished to. The campaign raised more than £16,000, making it one of the most successful Year End Appeals to date.



Better support for our supporters

In February, the fundraising team launched a useful new microsite. Provided by third party fundraising web specialist, Enthuse, the site serves as a platform not only for community fundraisers and corporate partners to raise funds and awareness through the challenges they set themselves, but also to collect donations for virtual drives.

Since launch, the Enthuse microsite has helped DKMS raise more than £93,000 in under a year. More details on this can be found at: dkms.enthuse.com.

Whilst all DKMS entities faced unprecedented challenges with fundraising, they came together for a week in May to share learning and seek solutions to the global challenges. Topics discussed included acquisition of new regular givers and retention of givers, digital peer-to-peer fundraising, and best and worst practice to share insight and lessons learned. This inspired ideas about other opportunities to raise money and new ways of engaging more supporters.

Volunteering Stories

There are currently 50 volunteers registered with DKMS and six volunteering hubs across the UK. Due to the pandemic, our volunteers weren't able to deliver as many physical donor recruitment drives as hoped, but they helped promote a number of V-drives and attracted a total of 223 new donors to the register.

In December our amazing volunteers were invited to celebrate their work over the year, at our lunchtime quarterly meeting. Lorna Gray, one of our volunteers, had a good reason for missing out on the meeting - she was donating her blood stem cells for the second time in two years.

“

It's a privilege to have the potential to help a stranger who is in an unfortunate health position. We are only asked to donate something we can make up again for ourselves, so why would you not? The whole experience was simple and made easier by the information given by my donation coordinator. During this last couple of years, we have all done many swabs but the DKMS registration swab is by far the easiest and most beneficial you can do.”

- Lorna Gray





Success stories

Black donors working with DKMS for Black History Month

In October, as the focus for our Black History Month outreach, DKMS adopted Black History Month Magazine's theme 'Proud to Be', aiming to raise awareness of blood stem cell donation among black African and Caribbean communities and position it as a positive experience.


Blood stem cell donors Angelina, Julius and Shola teamed up with DKMS to urgently call for more black blood stem cell donors. For those with blood cancer or a blood disorder diagnosis, a blood stem cell donation from a genetically similar person can be the only option for survival. Currently, people from black, Asian or other minority ethnic backgrounds have a 37% chance of finding the best possible stem cell donor match, compared to 70% for people from Northern European backgrounds.

The trio said: "We chose to become blood stem cell donors because we all understood how important it is for black African or Caribbean people to be on the register. As it stands, blood cancer patients from backgrounds similar to us have a far harder task to find a potential lifesaver".

Our Black History Month donor outreach resulted in an increase in people from black African and Caribbean communities joining the register in October, and contributed to our continuing efforts to diversify the register.

37%

chance of finding the best stem cell donor match, compared to 70% for Northern Europeans



Success stories

“You’re like my brother, you saved my life”

The moment a patient meets their lifesaver is always so special.

Alex, from the UK, registered because his friend Peter McCleave – mentioned on page 15 – is still seeking a match and Alex hoped he might be the one to help. He wasn’t a match for Peter, unfortunately, but he did match with someone else. His blood stem cells were an excellent match for Patrick, who lives in the US.

Because of the pandemic it wasn’t possible for them to meet in person but a Zoom call meant they were able to meet virtually for the first time. ITV News Granada Reports captured the moment and in an emotional exchange, Patrick told Alex: “I had trouble sleeping

last night, I was so excited to meet you. I find myself getting a little emotional. I keep thinking: Alex, what if you didn’t do it? I’m so grateful. I thank you, we’re joined at the hip now. But you’re like my brother, you saved my life and I love you.”

Since the story was featured, over 2,000 people have joined the blood stem cell register. Through Peter’s own website, 10000donors.com, he has helped to register over 90,000 blood stem cell donors, far exceeding his original goal. Seventeen of these so far were found to be a match for a patient in need and went on to donate. Alex was one of them.

17

people from the 10,000 donors campaign have already donated

TRUSTEES' REPORT

Preparation of report

As the company qualifies as small under section 383 of the Companies Act 2006, the strategic report required of medium and large companies under The Companies Act 2006 (Strategic Report and Director's Report) Regulations 2013 is not required.

DKMS Foundation (referred to hereinafter as 'DKMS UK') is incorporated as a charitable company limited by guarantee and is a registered charity in England and Wales, and in Scotland. It is governed by its Memorandum and Articles of Association, and the work, management, finances and strategy of the Charity are overseen by a Board of Trustees, who are also the Company Directors.

DKMS UK is connected through common Trustees to DKMS gemeinnützige GmbH ('DKMS'), and its related charities.

The Trustees who held office during the financial year and at the date of the report are set out on page 50.

A minimum of two Trustees at any one time are required by the Articles of Association. There is no maximum limit required by the Articles. At every Annual General Meeting (AGM) one-third of the Trustees retire by rotation, but are eligible for re-election. There is no restriction on the term of tenure as a Trustee. Trustees do not receive remuneration for their duties.

Purpose

DKMS UK's charitable purposes are set out in its Memorandum of Association as follows:

"The preservation and protection of good health and the relief of sickness of individuals who are suffering from any kind of blood cancer."

The aims of DKMS UK are to:

- raise awareness of blood stem cell donation;
- increase the number and diversity of registered potential blood stem cell donors in the UK; and
- provide more second chances at life for those with blood cancer or blood disorders whose survival depends upon being matched with an unrelated blood stem cell donor.

Public benefit

DKMS UK raises awareness of blood cancers and blood disorders in the UK, including the life-changing impact of a diagnosis, in order that increasing numbers of the general public know about the need for more people to

register as a potential blood stem cell donor. Increasing the number and diversity of potential blood stem cell donors is vital in increasing the life chances of blood cancer and disorder patients who are in need of a blood stem cell transplant. At present, only 3% of the UK population are registered as donors compared to much higher levels in some other countries.

Registering more potential blood stem cell donors means that we are able to provide more second chances at life by finding and supporting an unrelated blood stem cell donor who can and will donate their stem cells for a patient in need of a life-saving blood stem cell transplant.

Through recruiting, registering and supporting blood stem cell donors to be part of life-saving treatments, we deliver significant public benefit to patients and their families and to the National Health Service, which arranges treatment and care for those patients.

The Trustees review the aims, objectives and activities of DKMS UK each year, ensuring the Charity remains focused on its stated purpose. This report looks at what DKMS UK has achieved and the outcomes of its work in the reporting period.

The Trustees have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing the Charity's aims and objectives and in planning its future activities. In particular, the Trustees consider how planned activities will contribute to the aims and objectives that have been set.

Board and management operations and structure of Board of Trustees

The Board of Trustees meets twice a year to review DKMS UK's work, finances and services, and to agree the strategic goals for the Charity.

Recruitment and appointment of new Trustees

Trustees are appointed on the basis of their relevant skills and experience. The ongoing Trustees are responsible for the induction of any new Trustees, which involves an awareness of a Trustee's responsibilities, the governing document, administrative procedures, the history, approach and current business plan of DKMS UK.

The Trustees will also make available a welcome pack to include copies of the previous year's annual report and financial statements, a brief history of the charitable company and a copy of the governing document. The pack will also include a copy of the Charity Commission guidance 'The essential Trustee: What you need to know. What you need to do.'

TRUSTEES' REPORT

While DKMS UK is connected through common Trustees to DKMS gemeinnützige GmbH ('DKMS'), it aims to recruit additional Trustees that can broaden and support its representation in the UK.

Management and organisation

Day-to-day operation of the Charity, and strategy implementation, is delegated to the Chief Executive Officer, supported by the Senior Leadership Team (SLT). In the absence of the CEO, Stephan Schumacher, Trustee oversees the work of the SLT.

The Senior Leadership Team comprises:

- Chief Executive Officer
Jonathan Pearce (until 04 April 2022)
- Head of Communications and Engagement
Reshna Radiven
- Head of Customer Service
Natalie Carr
- Head of Donor Request Management
Helen Kelly
- Head of Finance
Hasnein Alidina
- Head of Fundraising
Caroline Richardson
- HR Manager
Regina Salih

Related parties

The only related parties are considered to be the Trustees and those connected with the Trustees, including their close family, business and other charity interests. There have been no transactions with related parties, other than the reimbursement of reasonable travel expenses for the purposes of attendance at Board meetings and other relevant organisational activities.

Remuneration

In order to recruit and retain staff of the calibre it requires, DKMS UK's pay policy is to remunerate staff at levels above the voluntary sector median rate, but below the private sector market rate. The Charity has an organisational salary structure based upon a job evaluation study and external salary benchmarking that took place in 2018. New roles are assessed against the job evaluation criteria and placed in a corresponding grade in the structure.

The salary structure's pay levels are reviewed at least annually by the CEO to ensure that salary scales are aligned with those for similar positions in the external market. A review of salaries normally takes place annually, and is usually implemented in January. If changes are to be made, staff are advised in writing of the amount and the date from which it takes effect. A salary review does not imply an increase and in making any pay award the review will be based on the organisation's financial health and achievements.

With reference to the National Council of Voluntary Organisation's 2014 inquiry into executive pay (NCVO, **Report of the Inquiry into Charity Senior Executive Pay and Guidance for Trustees on Setting Remuneration**), the Board of Trustees is committed to including the following information within its annual statutory report and financial statements:

- A summary statement of the Charity's remuneration policy and approach to senior executive pay.
- Disclosures on the number of staff in receipt of more than £60,000 per annum (in bands of £10,000), and the collective total benefits (including pension payments and employer's national insurance) paid to 'key management personnel' (which we have defined as the Senior Leadership Team), in line with the accounting Statement of Recommended Practice 2019 for charities. Given the Charity's size, the Board of Trustees does not believe it is appropriate to disclose the actual/personal salary of any individual member of staff, including senior executives, to the public.
- Disclosures on pensions and other staff benefits (see subsequent notes to the financial statements).

Our approach to fundraising

We continue to uphold the highest standards in how we communicate with our fundraising donors and supporters and ensure that our fundraising practices meet the requirements of the recommended Codes of Practice.

We treat our donors and supporters with great respect and gratitude that befits a community of people and organisations that make our work possible.

Key aspects of our approach to fundraising include:

- Registration with the Fundraising Regulator, which maintains the standards for charitable fundraising and ensures that fundraising is respectful, open, honest and accountable to the public. It also takes complaints about fundraising, investigates cases and adjudicates on fundraising practice.
- Ensuring our fundraising approach is aligned with the Charity's governing objectives.

TRUSTEES' REPORT

- We have a complaints policy, which outlines our commitment to resolving fundraising complaints as promptly and amicably as possible. It also sets out our process for handling any complaints received. As per our policy, complaints will be reported and referred to the Fundraising Regulator if a resolution with the complainant cannot be reached or if the complaint is about a breach of any aspect of the Code of Fundraising Practice.
- In 2021 we did not receive any complaints across the organisation. Trustees are updated on a bi-annual basis with regards to the number of complaints we have handled in the year.
- We raise funds through individual giving requests (cash appeals, regular donation asks and online giving), community, challenge events, corporate and trust fundraising.
- We do not carry out any telephone, face-to-face or door-to-door fundraising.
- We do not use third party agencies to make fundraising requests, although we do use them for fulfilment purposes, e.g. acquisition of charity place challenge events, processing direct debits or distribution of fundraising direct mail. In such situations, legal agreements are in place. In no other circumstance do we swap or share data and we never sell data.
- All fundraising activity complies with the UK General Data Protection Regulation (GDPR) and associated legislation and guidance.
- Promotional goods sent out for fundraising purposes, and use of our logo on external fundraising materials, is subject to approval. Official stationery, such as our letterhead, is never sent out for external use.

Risk assessment and management

DKMS UK operates a risk assessment and management framework that reviews major risk areas on a quarterly basis.

The CEO and individual members of the SLT take responsibility for the day-to-day management and oversight of the above risk areas. The Trustees review the assessments and mitigating actions at their Board meetings and consider the following areas to be the major risks related to DKMS UK's operations and activities.

MEDICAL SAFETY OF DONORS DURING THE BLOOD STEM CELL COLLECTION PROCESS

Although the medical process and procedure for blood stem cell donation and collection is safe, well-established and regulated, there will always be some safety risks and

DKMS UK acknowledges these and takes them seriously. The risks to the safety of our donors before, during and after the donation process, as well as any risks to transplant patients from the collection of poor-quality stem cell product are managed and mitigated in the following ways:

- Working in line with approved and regularly reviewed Standard Operating Procedures that comply with domestic and international standards and regulations, and that include clear identification and reporting mechanisms for Serious Adverse Events and Reactions and Quality Incidents.
- Working only with experienced, trusted and appropriately regulated medical partners and services. These relationships in turn are governed via established legal contracts and service protocols and regular service reviews.
- Ensuring a thorough quality assurance system is in place within the organisation, including compliance with the World Marrow Donor Association (WMDA) standards (qualification for which was achieved and approved in March 2021).
- Ensuring ongoing training, support and continuing professional development for all staff involved in the blood stem cell registration and donation process.

DATA MANAGEMENT AND PROTECTION

The collection, processing, storage and security of our blood stem cell donors' personal data and genetic information is of paramount importance and so represents a major risk in the event of mismanagement, loss or misuse of that data. The potential damage to individual donors through a data breach, let alone the damage to DKMS UK's and the DKMS Group's reputation and activities in working with patients, donors, supporters and stakeholders would be catastrophic. We manage and mitigate these risks through:

- Adherence to and compliance with strong information security and data protection policies and practices throughout the whole DKMS Group.
- Ensuring data processing and third parties and protocols are in place with suppliers and partners.
- Regular training and reviews for staff, volunteers and donor registration partners.
- Blood stem cell donor recruitment.

Effective and high-quality blood stem cell donor recruitment is essential to ensuring we meet the needs of patients and transplant centres looking for a match. If we fail to ensure we recruit sufficient numbers of

TRUSTEES' REPORT

donors with a diverse range of backgrounds, and also with accurate and regularly updated personal health and genetic information and contact details, then we risk not being able to save the lives of more blood cancer and blood disorder patients. We manage and mitigate this risk by ensuring we have:

- Clear and compelling communications and explanations about the registration process and the need for blood stem cell donors.
- Effective quality check and review processes.
- Quality programmes to enhance the health and contact information we have on the priority groups among our blood stem cell donors.
- A system for prioritisation for recruiting, retaining and supporting potential and actual blood stem cell donors.

FINANCIAL RISKS

There are a number of areas of financial risk faced by DKMS UK:

- Failure to achieve budgeted income levels.
- Inadequate financial controls or fraud.
- Poor financial management, including credit risk management, pricing risk and foreign exchange and liquidity risks.

These risks are managed and mitigated in the following ways:

- Strong planning, budgeting and monitoring processes in relation to income streams, including fundraising.
- Strong internal financial controls and data security.
- Regular reviews of fraud risks.
- Close interaction, support and cross-checking with the international financial management and controlling teams in Germany.
- Vetting by DKMS Germany of international health services, registries and companies involved in stem cell transplantation, so that stringent assessments on credit risk are carried out and appropriate financial terms agreed for all DKMS companies within the Group.
- Ensuring pricing of products and services is set at reasonable and affordable levels, that recognise the Group's role as a healthcare service provider with a primary objective of saving lives. Pricing levels are based on a production cost structure and also acknowledge differences in international economies, as well as the need to ensure patient treatments are not jeopardised by costs.

- Maintaining good cash flow and financial management systems in order to manage fluctuations in the major trading currencies in which DKMS UK deals.
- Cash flow projections are prepared as part of the Charity's strategic planning, while liquidity levels are monitored internally on a daily basis as well as reported to central management and Trustees at each reporting period.
- DKMS UK is not indebted to any external lenders outside the DKMS global group and does not have any borrowing obligations. Adequate balances are maintained in all currencies to ensure sufficient funding is available to meet commitments.

LOGISTICAL AND SUPPLY LINE BUSINESS CONTINUITY AND RESILIENCE

Ensuring we have reliable, efficient and cost-effective methods for transporting our swab packs, blood samples and collected blood stem cells is crucial to the successful achievement of our organisational goals and objectives to save more lives, as is having a well-stocked and maintained supply line, resources and medicines. To manage and mitigate the risks of business-critical supplies and logistical arrangements we have:

- Implemented strong review processes for stock control and order processing.
- Made alternative arrangements and contingency plans for business continuity and disaster recovery scenarios.
- Developed contingency plans to provide for business periods where we are working at higher than normal levels of activity or volume (e.g. when running successful campaigns).

CONSEQUENCES FOR DKMS UK OF THE UK EXIT FROM THE EU

DKMS UK did not experience any major effects on its activities following the UK's exit from the EU and leaving the single market and customs union. The charity has a diverse customer base across wide geographical areas and continues to trade in all three major trading currencies – namely the British pound sterling, Euro and US dollar.

Significant operational developments in the year

As reported in our previous Annual Report the Controlling company DKMS gemeinnützige GmbH entered into a contract with DKMS Life Science Lab whereby DKMS UK receives HLA and CMV (human leukocyte antigen and cytomegalovirus, two key pieces of information gathered from new donor registration swabs) for no consideration from 1 January 2021.

TRUSTEES' REPORT

DKMS gemeinnützige GmbH and its related entities also implemented its strategic decision to simplify its pricing structure for stem cell treatment to its customers with effect from 21 April 2021. This has been received favourably by Registries and Transplant Centres.

Post-balance sheet events

The war in Ukraine is likely to increase costs of stem cell extraction and delivery in the short term. The Charity and its controlling company is financially able to cover the extra costs. The situation is still in its early days and the management team and the Trustees will continue to monitor the situation as it develops and take measures to ensure the safety and wellbeing of our donors and giving blood cancer patients a second chance at life.

Financial review

GOING CONCERN

The Board of Trustees of the ultimate parent company approved an arrangement to continue funding DKMS UK's main activities to meet all its liabilities from its principal, DKMS gemeinnützige GmbH for a period not less than 12 months from the date these financial statements are approved. Accordingly, the Trustees continue to adopt a going concern basis in preparing the financial statements.

The company's business activities in 2022 show positive results to budget and the trend is expected to continue for rest of the year with the company's funding requirements expected to remain well within the amounts approved by the board for next three years.

The charitable company's net current assets at 31 December 2021 were £1,069,433 (2020: £817,186). Further details regarding the adoption of the going concern basis can also be found in the Accounting Policies on page 32.

FINANCIAL RESULTS

DKMS UK received donations totalling £2,608,270 (2020: £4,079,333) of which £775,451 (2020: £939,538) was donated funds, £1,825,114 (2020: £3,139,795) was donated services from DKMS in Germany and other income £7,705 (2020: £nil).

The year posed different challenges than that experienced in 2020. The charity company's net income for the year amounted to £223,736 (2020: loss £346,067) mainly from increased activity in stem cell transplants in the year as the success of vaccination programme against the Covid-19 virus and its variants in the UK and in many other countries made patient treatment more readily available and generated income of £6,381,655 (2020: £4,841,811). However, the uncertainty, constantly changing and longer long lockdowns and travel restrictions created greater

challenges for online and face-to-face donor registration meetings resulting in lower register donor numbers. Money donation income was also adversely affected once again by cancellation of the annual UK Gala with lost revenue of almost £1,550,000 (2020: £1,200,000).

RESERVES POLICY

DKMS UK's aim is to gradually grow its unrestricted funds and achieve full financial independence. While the Charity is growing its income base and cash flow, it continues to receive funding for its main activities from its principal, DKMS gemeinnützige GmbH. The Trustees have approved for this arrangement to continue for the foreseeable future and until DKMS UK becomes financially independent to meet all its liabilities for at least 12 months. As at 31 December 2021 DKMS UK's unrestricted funds were £1,181,420 (2020: £957,684).

PRINCIPAL FUNDING

In the period under review, DKMS UK's principal funding has come from donations from DKMS in Germany. In the meantime, the charitable company continues to grow its fee income from referral of potential blood stem cell donors and management of stem cell or bone marrow collections and establishing a broader base of additional funding sources to grow its voluntary donation income.

However, the charitable company developed a fundraising strategy to raise additional funding through voluntary donations and events. Another source of fundraising is fees earned for the referral of potential blood stem cell donors and the management of stem cell or bone marrow collection.

FUTURE DEVELOPMENTS

DKMS remains on track to increase the number of blood stem cell donations to exceed 400 per year within two years, but realises the need to continue adding new blood stem cell donors to the UK register to support this aim.

Recruitment must remain targeted, particularly focusing on those from ethnic minority communities, as those groups will help increase our overall number of matched donors, and move us closer to levelling up access to transplantation.

Fundraising work is planned to grow significantly over the next three years to support our expansion, with important areas for future growth being community-based and volunteer-led programmes, along with an expanded corporate support programme. This support is vital to achieve our aim of finding a matching donor for every stem cell transplant patient that needs one and where required covering the costs of the transplant.

TRUSTEES' REPORT

Trustees' responsibilities statement

The Trustees (who are also directors of DKMS Foundation for the purposes of company law) are responsible for preparing the Trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial year. Under company law the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period.

In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities Statement of Recommended Practice (SORP);
- make judgments and accounting estimates that are reasonable and prudent;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in operation.

DISCLOSURE OF INFORMATION TO AUDITORS

Each of the persons who are Trustees at the time when this Trustees' report is approved has confirmed that:

- so far as that Trustee is aware, there is no relevant audit information of which the charitable company's auditors are unaware, and
- that Trustee has taken all the steps that ought to have been taken as a Trustee in order to be aware of any relevant audit information and to establish that the charitable company's auditors are aware of that information.

This report was approved by the Trustees on 4 July 2022 and signed on their behalf on 20 September 2022 by:



S. Geist
Trustee

INDEPENDENT AUDITORS' REPORT TO THE MEMBERS AND TRUSTEES OF DKMS FOUNDATION

OPINION

In our opinion, DKMS Foundation's financial statements (the 'financial statements'):

- give a true and fair view of the state of the charitable company's affairs as at 31 December 2021 and of its incoming resources and application of resources, including its income and expenditure, and cash flows for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards, comprising FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', and applicable law); and
- have been prepared in accordance with the requirements of the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and regulation 8 of The Charities Accounts (Scotland) Regulations 2006 (as amended).

We have audited the financial statements, included within the Annual Report and Financial Statements (the 'Annual Report'), which comprise: the balance sheet as at 31 December 2021; the statement of financial activities (incorporating income and expenditure account) and the statement of cashflows for the year then ended; and the notes to the financial statements, which include a description of the significant accounting policies.

BASIS FOR OPINION

We conducted our audit in accordance with International Standards on Auditing (UK) ('ISAs (UK)') and applicable law. Our responsibilities under ISAs (UK) are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

INDEPENDENCE

We remained independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, which includes the FRC's Ethical Standard and we have fulfilled our other ethical responsibilities in accordance with these requirements.

CONCLUSIONS RELATING TO GOING CONCERN

Based on the work we have performed, we have not identified any material uncertainties relating to events

or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from the date on which the financial statements are authorised for issue.

In auditing the financial statements, we have concluded that the Trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

However, because not all future events or conditions can be predicted, this conclusion is not a guarantee as to the charitable company's ability to continue as a going concern.

Our responsibilities and the responsibilities of the Trustees with respect to going concern are described in the relevant sections of this report.

REPORTING ON OTHER INFORMATION

The other information comprises all of the information in the Annual Report other than the financial statements and our auditors' report thereon. The Trustees are responsible for the other information. Our opinion on the financial statements does not cover the other information and, accordingly, we do not express an audit opinion or, except to the extent otherwise explicitly stated in this report, any form of assurance thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated. If we identify an apparent material inconsistency or material misstatement, we are required to perform procedures to conclude whether there is a material misstatement of the financial statements or a material misstatement of the other information.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report based on these responsibilities.

With respect to the Trustees' Report, we also considered whether the disclosures required by the UK Companies Act 2006 have been included.

Based on our work undertaken in the course of the audit, the Companies Act 2006 and The Charities Accounts (Scotland) Regulations 2006 (as amended) require us also to report certain opinions and matters as described on the next page.

INDEPENDENT AUDITORS' REPORT TO THE MEMBERS AND TRUSTEES OF DKMS FOUNDATION

Trustees' Report

In our opinion, based on the work undertaken in the course of the audit the information given in the Trustees' Report for the financial year for which the financial statements are prepared is consistent with the financial statements and the Trustees' Report have been prepared in accordance with applicable legal requirements.

In addition, in light of the knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we are required to report if we have identified any material misstatements in the Trustees' Report. We have nothing to report in this respect.

RESPONSIBILITIES FOR THE FINANCIAL STATEMENTS AND THE AUDIT

Responsibilities of the Trustees for the financial statements

As explained more fully in the Trustees' Responsibilities statement, the Trustees are responsible for the preparation of the financial statements in accordance with the applicable framework and for being satisfied that they give a true and fair view. The Trustees are also responsible for such internal control as they determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Auditors' responsibilities for the audit of the financial statements

We have been appointed as auditors under section 44(1) of the Charities and Trustee Investment (Scotland) Act 2005 and under the Companies Act 2006 and report in accordance with the Acts and relevant regulations made or having effect there under.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement

when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

Based on our understanding of the charitable company and industry, we identified that the principal risks of non-compliance with laws and regulations related to Health and Safety regulations and employment law, and we considered the extent to which non-compliance might have a material effect on the financial statements. We also considered those laws and regulations that have a direct impact on the financial statements such as the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and regulation 8 of The Charities Accounts (Scotland) Regulations 2006 (as amended). We evaluated management's incentives and opportunities for fraudulent manipulation of the financial statements (including the risk of override of controls), and determined that the principal risks were related to manipulation of financial performance. Audit procedures performed included:

- Enquiries of management around known or suspected instances of non-compliance with laws and regulations, claims, litigation, and instances of fraud;
- Understanding of management's controls designed to prevent and detect irregularities;
- Review of board minutes;
- Identifying and testing journal entries to assess whether any of the journals appeared unusual, for example unexpected account combinations impacting revenue; and
- Incorporating an element of unpredictability into our testing plan.

INDEPENDENT AUDITORS' REPORT TO THE MEMBERS AND TRUSTEES OF DKMS FOUNDATION

There are inherent limitations in the audit procedures described above. We are less likely to become aware of instances of non-compliance with laws and regulations that are not closely related to events and transactions reflected in the financial statements. Also, the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery or intentional misrepresentations, or through collusion.

A further description of our responsibilities for the audit of the financial statements is located on the FRC's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditors' report.

Use of this report

This report, including the opinions, has been prepared for and only for the charitable company's members and Trustees as a body in accordance with section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and the Companies Act 2006 and regulations made under those Acts (regulation 10 of The Charities Accounts (Scotland) Regulations 2006 (as amended) and Chapter 3 of Part 16 of the Companies Act 2006) and for no other purpose. We do not, in giving these opinions, accept or assume responsibility for any other purpose or to any other person to whom this report is shown or into whose hands it may come save where expressly agreed by our prior consent in writing.

Other required reporting

MATTERS ON WHICH WE ARE REQUIRED TO REPORT BY EXCEPTION

Under the Companies Act 2006 and The Charities Accounts (Scotland) Regulations 2006 (as amended) we are required to report to you if, in our opinion:

- we have not obtained all the information and explanations we require for our audit; or
- adequate and proper accounting records have not been kept or returns adequate for our audit have not been received from branches not visited by us; or
- certain disclosures of Trustees' remuneration specified by law are not made; or
- the financial statements are not in agreement with the accounting records and returns.

We have no exceptions to report arising from this responsibility.

ENTITLEMENT TO EXEMPTIONS

Under the Companies Act 2006 we are required to report to you if, in our opinion, the Trustees were not entitled to: prepare financial statements in accordance with the small companies' regime and take advantage of the small company's exemption from preparing a Strategic Report.

We have no exceptions to report arising from this responsibility.



Matthew Kaye (Senior Statutory Auditor)

for and on behalf of PricewaterhouseCoopers LLP
Chartered Accountants and Statutory Auditors, Glasgow
20 September 2022.

STATEMENT OF FINANCIAL ACTIVITIES

(INCORPORATING INCOME AND EXPENDITURE ACCOUNT) FOR THE YEAR ENDED 31 DECEMBER 2021

	Note	Unrestricted funds 2021 £	Total funds 2021 £	Total funds 2020 £
Income from:				
Donations and legacies	2	2,608,270	2,608,270	4,079,333
Charitable activities	3	6,381,655	6,381,655	4,841,812
Total Income		8,989,925	8,989,925	8,921,145
Expenditure on:				
Raising funds	4	521,982	521,982	459,047
Charitable activities	5, 6 and 9	8,244,207	8,244,207	8,808,165
	7, 18	8,766,189	8,766,189	9,267,212
Net income/(expenditure) before other recognised gains and losses		223,736	223,736	(346,067)
Reconciliation of funds:				
		223,736	223,736	(346,067)
Total funds brought forward		957,684	957,684	1,303,751
Total funds carried forward		1,181,420	1,181,420	957,684

All activities relate to continuing operations.

The notes on pages 32 to 48 form part of these financial statements.

BALANCE SHEET

AS AT 31 DECEMBER 2021

		2021		2020	
	Note	£	£	£	£
Fixed assets					
Tangible assets	12		111,986		140,497
Investments	13		1		1
			<u>111,987</u>		<u>140,498</u>
Current assets					
Inventory	14	180,086		144,271	
Debtors	15	1,171,084		1,878,009	
Cash at bank and in hand	21	1,017,723		771,903	
		<u>2,368,893</u>		<u>2,794,183</u>	
Creditors: amounts falling due within one year	16	(1,299,460)		(1,976,997)	
Net current assets			1,069,433		817,186
Net assets			<u>1,181,420</u>		<u>957,684</u>
Charity Funds					
Unrestricted funds	18		1,181,420		957,684
Total funds	19		<u>1,181,420</u>		<u>957,684</u>

The company's financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The Trustees consider that the company is entitled to exemption from the requirement to have an audit under the provisions of section 477 of the Companies Act 2006 ('the Act') and members have not required the company to obtain an audit for the year in question in accordance with section 476 of the Act. However, an audit is required in accordance with section 144 of the Charities Act 2011.

The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.

The financial statements were approved and authorised for issue by the Trustees on 4 July 2022 and signed on their behalf on 20 September 2022 by:



S. Geist
Trustee

The notes on pages 32 to 48 form part of these financial statements.

STATEMENT OF CASH FLOWS

FOR THE YEAR ENDED 31 DECEMBER 2021

	Note	2021 £	2020 £
Cash flows from operating activities			
Net cash provided by operating activities	20	<u>281,770</u>	<u>15,937</u>
Cash flows from investing activities			
Purchase of tangible fixed assets		<u>(35,950)</u>	<u>(17,425)</u>
Net cash used in investing activities		<u>(35,950)</u>	<u>(17,425)</u>
Change in cash and cash equivalents in the year			
Cash and cash equivalents brought forward		<u>771,903</u>	<u>773,391</u>
Cash and cash equivalents carried forward	21	<u><u>1,017,723</u></u>	<u><u>771,903</u></u>

The notes on pages 32 to 48 form part of these financial statements.

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 31 December 2021

1. Accounting Policies

1.1 Basis of preparation of financial statements

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

DKMS Foundation meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

The financial statements are presented in pound sterling (£).

1.2 Going concern

The Trustees of the ultimate parent company review the company's activities and 3-year business plan each year and establish and approve funding level required to enable the company to achieve its goals and meet its business commitments and liabilities.

The Board of Trustees of the ultimate parent company approved arrangement to continue funding the charitable company's main activities from its principal, DKMS gemeinnützige GmbH until the company becomes financially independent to meet all its liabilities for a period not less than twelve months from the date these financial statements are approved. Accordingly, the Trustees continue to adopt going concern basis in preparing the financial statements.

1.3 Company status

The charitable company is limited by guarantee. The members of the company are the Trustees named on page 50. In the event of the company being wound up, the liability in respect of the guarantee is limited to £10 per member of the company.

1.4 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the company and which have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the company for particular

purposes. The costs of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

1.5 Income

All income is recognised once the charitable company has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably. Money donation income is recognised when the income is credited into the company's account and revenue for clinical services is recognised after services are delivered.

Donated services or facilities are recognised when the charitable company has control over the item, any conditions associated with the donated item have been met, the receipt of economic benefit from the use by the charitable company of the item is probable and that economic benefit can be measured reliably. In accordance with the Charities SORP (FRS 102). General volunteer time is not recognised. Further information about volunteer contribution is included in the Trustees' report.

On receipt, donated professional services and donated facilities are recognised on the basis of the value of the gift to the charitable company which is the amount the charitable company would have been willing to pay to obtain services or facilities of equivalent economic benefit on the open market; a corresponding amount is then recognised in expenditure in the period of receipt.

Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

1.6 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to make payment to a third party, it is probable that settlement will be required and the amount of the obligation can be measured reliably.

All expenditure is accounted for on an accruals basis. All expenses including support costs and governance costs are allocated to the applicable expenditure headings:

- Costs of generating funds comprise the costs associated with attracting voluntary income.
- Charitable expenditure comprises those costs incurred by the charitable company in the delivery of its activities and services for its beneficiaries. It includes both costs that can be allocated directly to such activities and those costs of an indirect nature necessary to support them.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2021

- Governance costs include those costs associated with meeting the constitutional and statutory requirements of the charitable company and include the audit fees and costs linked to the strategic management of the charitable company.
- All costs are allocated between the expenditure categories of the statement of financial activities on a basis designed to reflect the use of the resource. Costs relating to a particular activity are allocated directly; others are apportioned on an appropriate basis. Staff costs are allocated based on staff numbers, premises costs are allocated based on space occupied.

1.7 Tangible fixed assets and depreciation

Tangible fixed assets are carried at cost, net of accumulated depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost of fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

- Leasehold improvements – over period of lease (four years) straight line.
- Office equipment – 33.33% per annum straight line.
- Computer equipment – 33.33% per annum straight line.

1.8 Investments

Investments are a form of basic financial instrument and are initially recognised at their transaction value. Investments in subsidiary companies are stated at cost less diminution in value.

1.9 Interest receivable

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the company; this is normally upon notification of the interest paid or payable by the bank.

1.10 Debtors

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

1.11 Cash at bank and in hand

Cash at bank and in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

1.12 Creditors and provisions

Creditors and provisions are recognised where the charitable company has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due.

1.13 Pensions

The charitable company operates a defined contribution pension scheme and the pension charge represents the amount payable by the charitable company in respect of the year.

1.14 Financial instruments

The charitable company has applied Sections 11 and 12 of (FRS 102) in respect of financial instruments.

Financial assets and financial liabilities are recognised when the charitable company becomes party to the contractual provisions of the instrument. Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the charitable company after deducting all of its liabilities.

The charitable company's policies for its major classes of financial assets and financial liabilities are set out below.

Financial assets

Basic financial assets, including trade and other debtors, cash and bank balances, related charity working capital balances, and related charity financing are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest for a similar debt instrument. Financing transactions are those in which payment is deferred beyond normal business terms or is financed at a rate of interest that is not a market rate.

Such assets are subsequently carried at amortised cost using the effective interest method, less any impairment.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2021

Financial liabilities

Basic financial liabilities, including trade and other creditors, bank loans and loans from related charities, are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Financing transactions are those in which payment is deferred beyond normal business terms or is financed at a rate of interest that is not a market rate.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Impairment of financial assets

Financial assets measured at cost and amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss is recognised in the profit and loss account.

For financial assets measured at cost less impairment, the impairment loss is measured as the difference between the asset's carrying amount and the best estimate of the amount the charitable company would receive for the asset if it were to be sold at the reporting date.

For financial assets measured at amortised cost, the impairment loss is measured as the difference between the asset's carrying amount and the present value of estimated cash flows discounted at the asset's original effective interest rate. If the financial asset has a

variable interest rate, the discount rate for measuring any impairment loss is the current effective interest rate determined under the contract.

If there is a decrease in the impairment loss arising from an event occurring after the impairment was recognised, the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been had the impairment not previously been recognised. The impairment reversal is recognised in profit or loss.

Derecognition of financial assets and financial liabilities

Financial assets are derecognised when (a) the contractual rights to the cash flows from the asset expire or are settled, or (b) substantially all the risks and rewards of the ownership of the asset are transferred to another party or (c) despite having retained some significant risks and rewards of ownership, control of the asset has been transferred to another party who has the practical ability to unilaterally sell the asset to an unrelated third party without imposing additional restrictions.

Financial liabilities are derecognised when the liability is extinguished, that is when the contractual obligation is discharged, cancelled or expires.

1.15 Critical accounting estimates and areas of judgment

Management does not consider there to be any key judgements or estimates made in the preparation of the financial statements.

2. Donations and legacies

	Unrestricted funds 2021 £	Total funds 2021 £	Total funds 2020 £
Donation income	475,451	475,451	693,838
International donation income	300,000	300,000	245,700
Funding for donor recruitment activities from DKMS gemeinnützige GmbH	1,825,114	1,825,114	3,139,795
Other income	7,705	7,705	-
Total donations and legacies	<u>2,608,270</u>	<u>2,608,270</u>	<u>4,079,333</u>
Total 2020	<u>4,079,333</u>	<u>4,079,333</u>	

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2021

3. Charitable activities

	Unrestricted funds 2021 £	Total funds 2021 £	Total funds 2020 £
Income from service provision	<u>6,381,655</u>	<u>6,381,655</u>	<u>4,841,812</u>
Total 2020	<u>4,841,812</u>	<u>4,841,812</u>	

In the year ended 31 December 2021 and 2020 all income related to unrestricted funds.

4. Raising funds

	Unrestricted funds 2021 £	Total funds 2021 £	Total funds 2020 £
Salaries, national insurance and pensions	333,167	333,167	306,647
Other staff costs and training	10,455	10,455	9,036
Premises costs	58,061	58,061	55,971
Publicity costs (income)	9,341	9,341	(2,344)
Postage, support and stationery	1,794	1,794	2,121
Other admin costs	89,671	89,671	73,979
Travel costs	272	272	287
Loss on foreign exchange	10,739	10,739	1,862
Depreciation	8,482	8,482	11,488
Total 2021	<u>521,982</u>	<u>521,982</u>	<u>459,047</u>
Total 2020	<u>459,047</u>	<u>459,047</u>	

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2021

5. Direct costs

	Recruitment of donors	Raising awareness	Donor Request Management	Total funds	Total funds
	2021	2021	2021	2021	2020
	£	£	£	£	£
Other direct costs	229,391	98,142	2,593,152	2,920,685	2,348,760
Other staff costs and training	21,882	509	730	23,121	20,316
Premises cost	63,334	108,506	110,582	282,422	184,826
Publicity cost	69,793	210,942	8,787	289,522	305,256
Loss on foreign exchange	11,426	19,588	22,853	53,867	6,672
Postage, support and stationery	233,378	240,273	108,826	582,477	706,203
Travel costs	160	1,920	-	2,080	4,233
Donor typing costs	1,741,184	161	-	1,741,345	3,179,578
Salaries, national insurance and pensions	278,527	508,062	508,527	1,295,116	1,142,156
Depreciation	9,025	15,471	18,049	42,545	41,154
	<u>2,658,100</u>	<u>1,203,574</u>	<u>3,371,506</u>	<u>7,233,180</u>	<u>7,939,154</u>
Total 2020	<u>3,852,792</u>	<u>1,584,072</u>	<u>2,502,290</u>	<u>7,939,154</u>	

In the year ended 31 December 2021 and 2020 all costs of direct charitable activities related to unrestricted funds.
In the year ended 31 December 2021 and 2020 all income related to unrestricted funds.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2021

6. Support costs

	Recruitment of donors	Raising awareness	Donor Request Management	Total funds	Total funds
	2021	2021	2021	2021	2020
	£	£	£	£	£
Legal and professional fees	5,901	10,108	10,004	26,013	21,855
Loss on foreign exchange	3,608	6,186	7,217	17,011	3,013
Other staff costs and training	12,926	22,159	25,851	60,936	41,074
Premises costs	21,017	36,002	35,633	92,652	107,162
Travel costs	68	116	135	319	1,305
Other support costs	18,620	31,920	37,239	87,779	86,287
Postage, Support and stationery	943	1,617	1,887	4,447	9,160
Admin costs	2,034	3,486	4,068	9,588	(5,095)
Salaries, national insurance and pensions	138,825	237,985	277,650	654,460	564,114
Depreciation	2,850	4,885	5,700	13,435	18,586
	<u>206,792</u>	<u>354,464</u>	<u>405,384</u>	<u>966,640</u>	<u>847,461</u>
Total 2020	<u>201,537</u>	<u>243,368</u>	<u>402,556</u>	<u>847,461</u>	

In the year ended 31 December 2021 and 2020 all income related to unrestricted funds.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2021

7. Analysis of expenditure by expenditure type

	Staff costs 2021 £	Depreciation 2021 £	Other costs 2021 £	Total funds 2021 £	Total funds 2020 £
Expenditure on raising voluntary income	<u>333,167</u>	<u>8,482</u>	<u>180,333</u>	<u>521,982</u>	459,047
Costs of raising funds	<u>333,167</u>	<u>8,482</u>	<u>180,333</u>	<u>521,982</u>	459,047
Recruitment of donors	417,353	11,874	694,641	1,123,868	2,040,820
Raising awareness	746,047	20,356	2,532,659	3,299,062	3,840,949
Donor request management	786,176	23,749	2,966,965	3,776,890	2,904,845
Charitable activities	<u>1,949,576</u>	<u>55,979</u>	<u>6,194,265</u>	<u>8,199,820</u>	<u>8,786,615</u>
Expenditure on governance	0	0	44,387	44,387	21,550
Total 2021	<u>2,282,743</u>	<u>64,461</u>	<u>6,418,985</u>	<u>8,766,189</u>	<u>9,267,212</u>
Total 2020	<u>2,012,919</u>	<u>71,226</u>	<u>7,183,067</u>	<u>9,267,212</u>	

In the year ended 31 December 2021 and 2020 all costs of direct charitable activities related to unrestricted funds.

Expenditure on raising voluntary income has not been allocated to specific activities as all costs relate to general charitable activities.

8. Analysis of expenditure by activities

	Activities undertaken directly 2021 £	Support costs 2021 £	Total funds 2021 £	Total funds 2020 £
Recruitment of donors	917,078	206,791	1,123,869	2,040,820
Raising awareness	2,944,597	354,465	3,299,062	3,840,950
Donor request management	3,371,506	405,384	3,776,890	2,904,845
Total 2021	<u>7,233,182</u>	<u>966,640</u>	<u>8,199,821</u>	<u>8,786,615</u>
Total 2020	<u>7,939,152</u>	<u>847,463</u>	<u>8,786,615</u>	

In the year ended 31 December 2021 and 2020 all costs of direct charitable activities related to unrestricted funds.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2021

9. Governance costs

	Unrestricted funds 2021 £	Total funds 2021 £	Total funds 2020 £
Auditors' remuneration	23,000	23,000	20,950
Legal and professional fees	21,387	21,387	600
Total	<u>44,387</u>	<u>44,387</u>	<u>21,550</u>

In the year ended 31 December 2021 and 2020 all costs of direct charitable activities related to unrestricted funds.

10. Net resources expended

This is stated after charging:	2021 £	2020 £
Depreciation of tangible fixed assets:		
- owned by the charity	64,719	71,226
Auditors' remuneration - audit	23,000	21,939
- Non audit services - Taxation advice	<u>15,000</u>	<u>10,640</u>

During the year, no Trustees received any remuneration (2020 - £Nil).

During the year, no Trustees received any benefits in kind (2020 - £Nil).

During the year, no Trustees received any reimbursement of expenses (2020 - £Nil).

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2021

11. Staff costs

Staff costs were as follows:	2021	2020
	£	£
Salaries	1,992,059	1,755,341
Social security costs	201,512	171,521
Pension costs	82,196	83,524
Total	2,275,767	2,010,386

The average monthly number of employees was: 50 (2020: 45) and the average monthly number of employees during the year expressed as follows.

Full-time equivalents was as follows (including part-time and fixed period temporary staff):

	2021	2020
	No.	No.
Donor recruitment	7	9
Fundraising	5	5
Communications	12	7
Medical	14	13
Administration	12	11
Total	50	45

The number of higher paid employees was:

	2021	2020
	No.	No.
In the band £60,001 - £70,000	2	2
In the band £70,001 - £80,000	1	0
In the band £80,001 - £90,000	1	0
In the band £90,001 - £100,000	0	0
In the band £100,001- £110,000	0	0
In the band £110,001- £120,000	0	0
In the band £120,001- £130,000	1	1
Total	5	3

The charitable company Trustees were not paid or received any other benefits from employment with the charitable company in the year (2020: £Nil) neither were they reimbursed expenses during the year (2020: £Nil). No charitable company Trustees received payment for professional or other services supplied to the charitable company (2020: £Nil).

The key management personnel of the charitable company are the Trustees, the Chief Executive Officer and the heads of departments. There are 6 heads of department (2020: 7), five of whom received remuneration in excess of £60,000 during the year (2020: 3). The total employee benefits of the key management personnel of the charitable company were £571,266 (2020: £516,792).

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2021

12. Tangible assets

	Office equipment £	Computer equipment £	Leasehold improvements £	Total funds £
Cost				
At 1 January 2021	69,500	136,312	228,855	434,667
Additions	934	35,016	-	35,950
At 31 December 2021	<u>70,434</u>	<u>171,328</u>	<u>228,855</u>	<u>470,617</u>
Accumulated Depreciation				
At 1 January 2021	50,282	103,557	140,331	294,170
Charge for the year	6,384	24,880	33,197	64,461
At 31 December 2021	<u>56,666</u>	<u>128,437</u>	<u>173,528</u>	<u>358,631</u>
Net book value				
At 31 December 2021	<u>13,768</u>	<u>42,891</u>	<u>55,327</u>	<u>111,986</u>
At 31 December 2020	<u>19,218</u>	<u>32,755</u>	<u>88,524</u>	<u>140,497</u>

13. Investments

	Shares in Group undertakings £
Costs	
At 31 December 2021 and 31 December 2020	<u>1</u>

The company's wholly owned subsidiary, Delete Blood Cancer UK Marketing Limited, registered at Ashburnham House, Castle Row, Horticultural Place, London W4 4JQ is a dormant company. Its net liability position at 31 December 2021 £10,245 (2020: £10,245) is represented by amounts due to parent company and is fully provided for in the accounts of the parent company.

14. Inventory

Inventory costs were as follows:	2021	2020
	£	£
Materials stock	155,634	129,903
Work in progress costs	24,452	14,368
Total	<u>180,086</u>	<u>144,271</u>

Inventories are valued at lower of cost and net realisable value. Work in progress costs are reimbursable costs incurred for active stem cell collections awaiting to be billed.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2021

15. Debtors

	2021	2020
	£	£
Due within one year		
Trade debtors	884,498	701,885
Amounts owed by group undertakings	10,245	10,245
Amounts owed by related charity	95,715	984,975
Other debtors	1,245	4,445
Prepayments and accrued income	179,381	176,459
Total	1,171,084	1,878,009

16. Creditors: amounts falling due within one year

	2021	2020
	£	£
Trade creditors	349,404	325,906
Amounts owed to related charity	30,807	213,039
Other creditors	22,217	415,615
Other taxation and social security	62,586	57,773
Accruals	834,446	964,664
Total	1,299,460	1,976,997

17. Financial Instruments

	2021	2020
	£	£
Financial assets		
Financial assets that are debt instruments measured at amortised cost	991,703	1,701,550
Financial liabilities		
Financial liabilities measured at amortised cost	(380,211)	(538,946)
Total	611,492	1,162,604

Financial assets measured at amortised cost include trade debtors, amounts owed by group companies, other debtors and amounts owed by related charity.

Financial liabilities include trade creditors and amounts owed to a related charity.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2021

18. Summary of funds

	2021	2020
	£	£
At 1 January	957,684	1,303,751
Income for year	8,989,925	8,921,145
Resource expended	(8,766,189)	(9,267,212)
At 31 December	<u>1,181,420</u>	<u>957,684</u>

19. Analysis of net assets between funds

Analysis of net assets between funds - current year

	Unrestricted funds 2021 £	Total funds 2021 £
Tangible fixed assets	111,986	111,986
Fixed asset investments	1	1
Current assets	2,368,893	2,368,893
Creditors due within one year	(1,299,460)	(1,299,460)
Total	<u>1,181,420</u>	<u>1,181,420</u>

Analysis of net assets between funds - prior year

	Unrestricted funds 2020 £	Total funds 2020 £
Tangible fixed assets	140,497	140,497
Fixed asset investments	1	1
Current assets	2,794,183	2,794,183
Creditors due within one year	(1,976,997)	(1,976,997)
Total	<u>957,684</u>	<u>957,684</u>

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2021

20. Reconciliation of net movement in funds to net cash flow from operating activities

	2021	2020
	£	£
Net income/(expenditure) for the year (as per Statement of Financial activities)	223,736	(346,067)
Adjustment for:		
Depreciation charges	64,461	71,226
Decrease/(Increase) in debtors	706,925	(276,613)
(Decrease)/Increase in creditors	(677,537)	481,603
(Increase)/Decrease in inventory	(35,815)	85,788
Total	<u>281,770</u>	<u>15,937</u>

21. Analysis of cash and cash equivalents

	2021	2020
	£	£
Cash at bank and in hand	1,017,723	771,903
Total	<u>1,017,723</u>	<u>771,903</u>

22. Operating lease commitments

At 31 December the total of the charity's future minimum lease payments under non-cancellable operating leases was:

	2021	2020
	£	£
Within 1 year	285,022	281,925
Between 2 and 5 years	217,638	493,369
Over 5 years	-	-
Total	<u>502,660</u>	<u>775,294</u>

Lease payments recognised as an expense amounted to £282,183 (2020: £218,171).

The company entered into a new 4-year lease ending 30 September 2023 for its current office premises at annual rent of £281,925 including a 6-month rent-free period at the start of the lease and a 3-year lease ending October 2024 for purchase of operating equipment at annual rent of £3,097.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2021

23. Related party transactions

The company has taken advantage of the exemption contained in FRS 102 section 33 'Related Party Disclosures' from disclosing transactions with entities which are a wholly owned part of the group.

Transactions with other related parties are as follows:

Name (relationship)	Transaction	Amount		Amount due from/(to) related party	
		2021	2020	2021	2020
		£	£	£	£
DKMS gemeinnützige GmbH (Common Trustees)	Donated services	1,825,114	3,139,795	83,930	921,171
DKMS gemeinnützige GmbH (Common Trustees)	Intercompany recharges	249,463	195,217	(30,141)	62,503
DKMS Life Science Lab (Common Trustees)	Intercompany recharges	161	2,686,250	-	(211,958)
DKMS Registry gemeinnützige GmbH	Intercompany recharges	54,339	-	(7,050)	-
DKMS USA (Common Trustees)	Intercompany recharges	667	-	(667)	1,301
DKMS USA (Common Trustees)	International money donation	300,000	245,700	-	-
DKMS BMST (India)	Intercompany support services	-	-	11,785	-
DKMS Foundation NPC (South Africa)	Intercompany service provision	14,290	-	14,290	-

Amounts owed to related parties are unsecured, interest free and due for repayment within one year.

DKMS gemeinnützige GmbH is the Controlling company and exercises full control over the charitable company through its common Trustees who are also directors of the company. The controlling company recharges the charitable company actual or appropriately apportioned costs it incurs in providing support to the latter.

The controlling company DKMS gemeinnützige GmbH entered into a contract with DKMS Life Science Lab whereby DKMS Foundation receives typing services for no consideration from 1 January 2021.

DKMS Life Science Lab is one of the leading HLA laboratories and provides this service for all DKMS entities.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2021

24. Post balance sheet events

The war in Ukraine is likely to increase costs of stem cell extraction and delivery in the short term. The Charity and its controlling company is financially able to cover the extra costs. The situation is still in its early days and the management team and the Trustees will continue to monitor the situation as it develops and take measures to ensure the safety and wellbeing of our donors and giving blood cancer patients a second chance at life.

25. Controlling party

The Trustees are the immediate controlling party and DKMS gemeinnützige GmbH is the ultimate parent. The principal address of the ultimate parent is Kressbach 1, 72072 Tübingen, Germany.

Copies of the group financial statements are available at www.dkms.de.

REFERENCE AND ADMINISTRATIVE DETAILS OF THE COMPANY, ITS TRUSTEES
AND ADVISERS FOR THE YEAR ENDED 31 DECEMBER 2021

Trustees

Dr E Neujahr
B J Abel
S Geist
Dr A H Schmidt
S Schumacher

Principal staff

Jonathan Pearce, CEO (until 4 April 2022)
Stephan Schumacher, Trustee

Registered company number

08151279 (England & Wales)

Charity registered number

1150056 (England & Wales)
SC046917 (Scotland)

Registered office

Ashburnham House, Castle Row, Horticultural Place
London, W4 4JQ

Company secretary

B J Abel

Independent auditors

PricewaterhouseCoopers LLP
141 Bothwell Street
Glasgow, G2 7EQ

Bankers

Barclays Bank plc
74 Shepherds Bush Green
Shepherds Bush
London W12 8QB

Commerzbank AG
30 Gresham Street
London EC2V 7PG



*Global DKMS statistics as
of 31 December 2021

DKMS FOUNDATION

England & Wales - Charity number 1150056

Accounts

LIFESAVING IN LOCKDOWN

DKMS FOUNDATION

ANNUAL REPORT
AND FINANCIAL
STATEMENTS

YEAR ENDING 31 DECEMBER 2020

OUR VISION:

Anyone with blood cancer or a blood disorder is given a second chance of life.

OUR MISSION:

To provide a matching donor for every blood cancer patient in need of a blood stem cell donation.

OUR PURPOSE:

To raise awareness of blood cancer and blood disorders, recruit and retain potential blood stem cell donors to provide a second chance of life, raise funds to match donor registration costs, and improve blood cancer therapies by our own research.

CONTENTS

CEO's introduction	2
Trustees' Report	
Achievements	3
Our donor contribution, globally and locally	5
Keeping calm and carrying on through COVID-19	6
Supporting more donors, saving more lives	7
Harnessing the power of digital	8
Putting patients at the heart of our work	9
Fundraising in 2020	11
Improving the experience of our donors and supporters	15
Environmental impact	16
Future plans	16
DKMS donor: Robert's story	17
DKMS patient: Alfie meets his lifesaver	18
Governance	19
Trustees' responsibilities statement	24
Independent auditors' report to the members and trustees of DKMS Foundation	25
Statement of financial activities	28
Balance sheet	29
Statement of cash flows	30
Notes to the financial statements for the year ended 31 December 2020	31
Reference and administrative details	47

CEO'S INTRODUCTION

In a year affected by a pandemic, any and every achievement should be celebrated, especially when we remember the loss of life and damage to livelihoods experienced by so many around the world. We began the year with high hopes and big ambitions, but by the end of March our plans were in disarray as, in common with the rest of the world, we adapted at speed to a changing and challenging environment, ensuring that we were able to continue our vital work of recruiting blood stem cell donors to be potential lifesavers for blood cancer and blood disorder patients in need of a transplant.

As an organisation working within the healthcare system, we were classed as an essential service and continued to work throughout the pandemic and associated lockdowns. We've been proud of how our staff, volunteers, supporters, stakeholders and suppliers have worked with us to ensure we save as many lives as possible, overcoming incredible barriers and obstacles along the way.

Working within a national ecosystem for stem cell registration and donation, as well as an international environment, there have been aspects of the pandemic that have brought us all closer together and created an added urgency and understanding as to what it is to be in need of help and support in life-threatening situations. Because of the pandemic we are stronger as an organisation and as a community, and we have evolved and innovated in a way that would have been unimaginable at the beginning of 2020.

Read on to learn more about our work over the past year, and the incredible contribution our blood stem cell donors have made in unbelievable circumstances.

With thanks and congratulations to each and every one, and all of those who have supported them to help save a life.



A handwritten signature in black ink that reads "Jonathan Pearce". The signature is fluid and cursive, with a long, sweeping underline that extends to the right.

Jonathan Pearce
CEO, DKMS Foundation

ACHIEVEMENTS

In 2019, we established eight key priorities for DKMS UK to guide our work between 2020 and 2023. Below we've set out our progress against each of these priorities.

1 KEY PRIORITY 1 MORE SECOND CHANCES OF LIFE

During 2020, we succeeded in creating 253 second chances of life from our donors' blood stem cell donations. Although this was below our original target and our previous year's figures, it was inevitable once the pandemic struck and the country went into lockdown. That we were able to continue working at all is the real achievement, and is testament to the commitment, determination and creativity of our blood stem cell donors, our staff and volunteers, and the healthcare professionals in the hospitals with which we work to carry out our stem cell collections and where patients receive their transplants.

With hospitals and other healthcare settings being overwhelmed with responding to the pandemic, and transport networks virtually closed, the challenges to supporting donors with health assessments, blood checks and tests, travel to hospital for their donations and then transport of their stem cells nationally and internationally, at one point almost seemed insurmountable. Yet by working together, both nationally with the other members of the UK aligned stem cell register and internationally among the DKMS Group, we were able to find innovative solutions to even the most intractable problems.

These solutions included setting up a transport hub near Heathrow, using cargo flights and seeking travel permissions for blood stem cell donors from governments and national executives for extenuating circumstances. The list of small and great solutions is almost endless and representative of DKMS UK's determination to achieve its mission, however difficult it may have seemed. You will find many more examples within the other pages of this report.

At the other end of the process of saving lives - recruiting new potential donors to the stem cell registry - we were equally challenged. Our original target for 2020 of recruiting 210,000 new donors seemed completely out of reach when the country went into lockdown, so we were extremely proud when the year ended to have added nearly 170,000 donors - not so far short of what we originally set out to achieve. Once again we are indebted to our supporters, who responded to our 'Lifesavers in Lockdown' campaigns and also the innovation of virtual donor drives - a digital replacement for the physical, face-to-face donor recruitment events that we were forced to abandon in a world of social distancing.

2 KEY PRIORITY 2 BETTER CHANCES FOR THOSE WHO CURRENTLY HAVE FEWER CHANCES

We know that not everyone has the same chance of finding a matching blood stem cell donor, so it is an important part of DKMS UK's mission to address that. During 2020, we researched and analysed the ethnic and racial diversity of our current register of donors, and used this to develop a strategy to recruit donors from under-represented communities, as well as to increase and over-represent donors from all ethnic and racial backgrounds.

We have also identified an external partner to research and develop stronger and better engagement and retention strategies with specific communities. Although there is an international aspect to solving this issue, we are committed to playing our national part in this and expect to see the first fruits of our labours in 2021.

3 KEY PRIORITY 3 THE BEST SUPPORT FOR THE BEST DONORS

During 2020 we devoted much of our time to reviewing and improving our 'customer journeys' so that all donors have an optimal experience when they register with DKMS UK. There is a long way to go, as we know there are so many opportunities to improve and modernise the contacts and interactions we have with our donors, supporters and stakeholders. In response to this, we have identified a portfolio of projects that will improve our donors' and supporters' experience, whether that's through online registration to be a donor, or email, and phone contact, or messaging with DKMS staff, as well as making us more efficient and cost-effective.

ACHIEVEMENTS (CONTINUED)

4

KEY PRIORITY 4

BEING FINANCIALLY SUSTAINABLE

DKMS UK is funded by a combination of three main income streams: revenue from agreed medical fees, clinical and transport services we provide regarding our stem cell donations and collections; fundraising income; and financial support from our parent organisation in relation to the HLA typing and laboratory costs we incur during stem cell donor registration. It is our longer-term aim to achieve financial sustainability and although this was slowed down by a year of pandemic, we have identified financial strategies and plans to realise this goal in the years to come.

5

KEY PRIORITY 5

BUILDING A COMMUNITY OF SUPPORT

Building a vibrant community of committed and engaged support around DKMS UK is vital to achieving our long-term goals. There are so many aspects to this, but key developments in 2020 included the creation of a long-term volunteer plan, so that we can build our volunteer hubs to support both our fundraising and donor recruitment work. Our corporate networks too are vital and we're pleased that we have recruited more staff and resources for this area of work. Indeed, the pandemic saw us create partnerships with new companies in sectors where we had not previously worked.

The healthcare sector is clearly of particular importance to us, and we have started to build stronger networks and relationships with hospitals and transplant centres, so that we will be able to support the set-up of new stem cell collection centres to increase the number of lives we can potentially save. The pandemic delayed plans to work with new hospitals as collection centres, but as the country emerges from the latest lockdown we are confident those new centres are not too far away.

6

KEY PRIORITY 6

BEING AN EXCELLENT EMPLOYER

Staff welfare, care and support are crucial to achieving our organisational objectives, as are effective HR frameworks. We have invested in new staff and new systems during 2020, so that we have a suitable performance management framework for all staff, improved home-working systems, and revised organisational policies on all aspects of our work. We learned from the pandemic and moved from an office to a predominantly home-working situation with all staff, and have consulted them to understand how future working arrangements could and should look, with overwhelming support for a move to a more flexible working environment.

7

KEY PRIORITY 7

REDUCING OUR ENVIRONMENTAL IMPACT

As an organisation, DKMS UK is committed to reducing its carbon footprint. As a first step, we carried out an environmental audit during 2020, clearly identifying the main sources and volumes of our carbon emissions over the year to 31 December 2019. We have used this as a baseline to map ways to reduce our footprint, set targets and implement a plan for greener working and operations.

8


KEY PRIORITY 8

DIGITAL FIRST

Again, the pandemic had an unforeseen consequence of speeding up our plans to digitise as much of our work as we possibly can. The creation of virtual donor drives is one big example, as is the progress we've made in establishing an e-registration system for donor recruitment when we do return to face-to-face events. Elsewhere, the organisation is committed to digital systems and services over paper as a default approach and we have succeeded in changing paper-based systems and moving to digital/online platforms wherever the opportunity arises.

OUR DONOR CONTRIBUTION, GLOBALLY AND LOCALLY

Global breakdown of where DKMS UK sends blood stem cells



DKMS UK’s registered donors make up over one-third of the UK Aligned Registry (see pie chart). However, our donors’ blood stem cells are sent far and wide, as shown in the map above, 22% being used for patients within the UK. As for donors provided by DKMS entities based outside the UK, 449 were matched with UK patients last year.

Looking at the combined global register, 28% of all potential blood stem cell donors worldwide are registered by DKMS globally, a significant contribution towards the global effort of helping those with blood cancer or a blood disorder.

Map data source: DKMS 2020 KPI report

Registered donors in the UK Aligned Stem Cell Registry




Chart shows the number of registered potential blood stem cell donors.
 NHSBT: NHS Blood and Transplant
 WBMDR: Welsh Bone Marrow Donor Registry
 Source: State of the register (2020-2021)

KEEPING CALM AND CARRYING ON THROUGH COVID-19

2020 was a year that none of us will forget. Those involved in the logistics of blood stem cell donation were faced with significant challenges in delivering unrelated stem cell donations to patients worldwide. These included international border closures, flight cancellations, mandatory testing for SARs-CoV-2, a 95% increase in cryopreservation requests and the inability to perform blood draws.

Over the following months, DKMS worked hard to overcome many of these challenges. This was made possible by the close relationships between our colleagues in the UK and DKMS' global medical teams, and with our partners in the UK aligned stem cell register. New processes were developed and rolled out, many of which are still in place today as the pandemic continues to affect the UK.

Changes we have successfully implemented include:



Offering home Covid test kits to donors so that they can be tested for Covid during their donation journey, ensuring that public health and safety as well as the safety of our donors and patients remain a priority.



Working closely with our UK aligned stem cell register partners to secure UK travel exemptions for donors, and national and international couriers, so that they can legally and safely travel for their donation or for the purpose of transporting stem cells.



Working closely with the UK aligned stem cell register to set up a Heathrow Hub - an area at London's Heathrow airport for the exchange of stem cells between couriers at the UK border.



Developing a new stage for donors at confirmatory typing, called a Health and Availability Check, as an alternative to collecting blood draws at their GP. This meant donors could still move forward in their donation journey providing vital information to the patient's team from the comfort of their home, with no need to travel.



In some cases, for patients worldwide who had a match in their family, the pandemic meant that these family members were not able to travel to donate. In 2020, we supported four families by helping with travel and logistics so that they could proceed with their donation.



Maria Schmiing, volunteer stem cell courier



LATAM Cargo pilots carrying a blood stem cell donation

SUPPORTING MORE DONORS, SAVING MORE LIVES

Against the odds, DKMS was successful in delivering some key projects. Below are some of the highlights of the progress made by our team, and the achievements of the donors they worked with.

DURING THE COURSE OF 2020:

2,663

donors were supported through confirmatory typing

253

of these potential donors went on to donate

13

were bone marrow donations

240

were peripheral blood stem cell (PBSC) collections

15

plus donor leukocyte infusion (DLI) donations



STREAMLINING THE DONOR JOURNEY

We moved the coordination and management of UK workups – the stage of the donor journey that involves going from confirmatory typing to actual donation – for UK patients from the charity Anthony Nolan to DKMS UK from 1 July 2020. A new contract was created that better reflected the partnership between the two charities. This new way of working allows us to provide a more seamless journey for our donors.



OFFERING UK DONORS WORLDWIDE

As of 21 October 2020, DKMS donors from the UK became accessible via the global DKMS Registry. With this move, DKMS UK offered a free confirmatory typing service to transplant centres across the world (excluding USA, Germany and the UK). This update helps us to offer better access to a second chance at life for everyone, everywhere.

HARNESSING THE POWER OF DIGITAL




DKMS was fortunate to have some rich and engaging content to share. As a result, we achieved some incredible communication successes, despite the challenges of sharing our key messages when the world was primarily focused on the latest developments in the global pandemic.



We reached some key milestones for social media, gaining in excess of 24,000 followers on Instagram. Two of our highest performing appeals on Instagram were for patients Liya and Evie, with in excess of 1,000 likes in one day.



Through 2020, we worked tirelessly on preparing the new DKMS UK website. After working with stakeholders to develop user journey maps and a planned structure, the teams focused on reviewing and developing content. The website, which launched in January 2021, offers users an easy-to-navigate website regardless of the device being used. The new design also offers a more engaging and user-friendly experience.



PUTTING PATIENTS AT THE HEART OF OUR WORK

2020 saw some new initiatives being introduced at DKMS that have enabled us to provide better support to people in need of a blood stem cell transplant.

We have always worked closely with patients, helping them to share their stories and deliver activities to increase awareness of the need for blood stem cell donors. Last year, aiming to deepen our relationships further, we established a new cross-organisation team – the Patient Campaign Team (PCT) – which is now responsible for the management of all patient-related activities. Bringing together individuals from across the organisation who work with patients, we are able to offer patients and their families a more unified and efficient experience of working with DKMS.

Through the work of the PCT, patient campaigns now involve a more holistic approach to press coverage, social media and fundraising events, enabling us to provide the best support possible to those searching for their perfect match.

We are also able to see the real-time impact of our social media activities on the registration of potential blood stem cell donors. Throughout the year, we shared patient appeals via our social media channels and over the year, saw 118,327 (72%) donors recruited as a result of these appeals. We were fortunate enough to be able share some particularly powerful patient stories, resulting in high levels of engagement. Within 48 hours of launch, one of our patient appeals resulted in 35,000 starting the registration process and requesting a home swab kit.

By sharing a variety of content including patient stories, statistics on the impact of the pandemic on our work and the inequality of access to donors for certain ethnic communities, we achieved some great successes. We achieved 2,595 pieces of media coverage – the highest in any single year for DKMS.

As with most other organisations, the Covid-19 pandemic forced us to change the way we operate. As a result of lockdowns and the cancellation of all large gatherings, our planned donor recruitment events – also called ‘donor drives’ – were cancelled. To manage any fall-out from cancelled events, and in support of our aim to be a ‘digital first’ organisation, we launched virtual donor drives (v-drives) in March 2020; working across departments to launch them within a month.



V-drives provide a tailored online landing page for anyone who wants to support DKMS’ aim to register potential blood stem cell donors – be that a patient’s family, a group of volunteers, or a company/organisation. The DKMS team prepares the page, based on information and photographs provided by the patient, partner or supporter, and then provides a unique link to the page for them to share with their network. This means we can share more detailed updates on the numbers of donors recruited and funds raised, directly linked to the patient appeal.

We launched 53 v-drives in 2020, including 19 set up by our volunteer hubs, and 15 by partner charities, resulting in 41,255 people registering as potential blood stem cell donors and raising £61,159 in fundraising donations, exceeding our expected outcomes from face-to-face events.

PUTTING PATIENTS AT THE HEART OF OUR WORK (CONTINUED)

In order to increase the chances available to all patients, DKMS has been looking to increase the diversity of those on our register. At the end of December 2020, the ethnic breakdown of our donor database was as shown in the pie chart. The categories used are those required by the UK aligned stem cell register (for HLA, or tissue, matching purposes) and so may be different to other ethnic and racial categorisations.

Although we are engaging more with specific ethnic communities, greater work will be done to achieve parity of access.

We'd like to extend our thanks to our many recruitment partners who have continued to support our mission, working with us to find ways to recruit more donors on the DKMS donor database.


- ACLT (Afro-Caribbean Leukaemia Trust)
- AME-BCT (Asian and Middle Eastern Blood Cancer Trust)
- Jaskomal Foundation
- Kevin Kararwa Leukaemia Trust
- Love Hope Strength
- Race Against Blood Cancer
- Team Margot
- Upahaar

INFLUENCING THE INFLUENCER

Through 2020, DKMS has been working with the Women's Institute (WI) to support them to raise awareness of the need for blood stem cell donors. The WI chose blood stem cell donation as their resolution for 2020, electing to support our work to increase awareness across the UK of the need for blood stem cell donors.

We have participated in zoom meetings, sharing information and patient stories, and jointly developed communications to be shared with local WI groups. Through the year, we worked with 17 WI groups. Our aim was to encourage WI members to support our work, and to also encourage their family members and friends to sign up as potential stem cell donors.

Racial and ethnic breakdown of DKMS UK donor database (December 2020)



FUNDRAISING IN 2020

We are proud to say that DKMS has continued in its mission to support people with blood cancer and provide as many people as possible with a second chance of life, despite the challenges presented by 2020.

In fact, it's been a really significant year, as in March 2020, DKMS celebrated a huge milestone: 10 million potential donors registered worldwide. DKMS UK has made a significant contribution to this target - an achievement only made possible thanks to voluntary financial donations and the support of the trusts and foundations who supported our cause and enabled DKMS to continue its mission.

We would like to highlight just how important the following Trusts' support has been to us:

- Basil Samuel Charitable Trust
- C A Rookes
- [Doris Field](#)
- Frances & Augustus Newman Foundation
- [ING](#)
- Lord Leverhulme's Charitable Trust
- RZK Foundation
- The Barbour Foundation
- [TJX](#)

COMMUNITY FUNDRAISING



STAND OUT SUPPORTER: GINNY WALKER

Ben Walker was only 12 years old when he died in 2019, following a relapse of acute myeloid leukaemia (AML). Despite this tragic loss, his family was incredibly grateful to the stranger who donated their blood stem cells to Ben in 2018 and gave them more precious time to make memories together.

Ben's mum, Ginny, has since dedicated herself to raising awareness and nearly £3,000 for DKMS. Throughout 2020, even as we all dealt with the difficulties of the pandemic, Ginny took on two incredible physical challenges. She ran 120 miles in a single month, and dyed her hair red, to raise £1,500. But she didn't stop there. She also committed to walking 480 miles, virtually, to Santiago de Compostela to raise funds for DKMS.

Ginny is truly inspiring and everyone at DKMS is incredibly grateful for her support. Her fundraising efforts so far will fund the addition of 75 potential lifesavers to the blood stem cell registry, and provide more people diagnosed with blood cancer with a second chance of life.



STAND OUT SUPPORTER: SALLY HURMAN

Sally Hurman is a social media influencer, mother of three and the wife of Gavin, who has a diagnosis of lymphoma. As if all of that wasn't enough, Sally took part in an incredible fundraising feat to mark Blood Cancer Awareness Month in September 2020.

Unleashing her inner daredevil, Sally completed a 170 metre abseil down the Spinnaker Tower in Portsmouth. She more than doubled her original fundraising target of £1,000, which brings her total raised to more than £12,000 since she first started supporting us two years ago. As well as throwing herself off tall buildings, Sally sells beautiful necklaces, has organised raffles at blogging events and donated items to auction, all in support of DKMS.

Sally's fundraising efforts have not gone unnoticed. She beat an overwhelming number of entries to be shortlisted at the Third Sector Excellence Awards 2020 in the Volunteer of the Year category. We very much appreciate that she continues to raise awareness of blood cancer and DKMS among her 88,000 social media followers.

COMMUNITY FUNDRAISING (CONTINUED)



STAND OUT SUPPORTER: PETER MCCLAVE

Peter McCleave (Pete), a 43-year-old husband, father to two young boys, and a man who is searching for a potential lifesaver, continues to support DKMS to register more potential donors and raise vital funds to support our work.

Through the pandemic, Pete has been shielding and at times has been separated from his family. Despite this, he has continued to support our work, by joining zoom meetings with potential corporate partners and Women's Institute and sharing his story to inspire people to support DKMS.



STAND OUT SUPPORTER: AL MURRAY

We are delighted to say that we won a Third Sector Excellence Award for Charity Champion for our work with comedian Al Murray.

Al has been a supporter of DKMS since 2019 and continued to help us raise funds through sponsored events throughout 2020, including a sponsored beard shave and a live broadcast quiz night.

FUNDRAISING AT WORK

We are truly thankful for the support companies have given DKMS throughout this unprecedented year, enabling us to continue to support people facing blood cancer.

VIRTUAL DONOR RECRUITMENT EVENTS

Government restrictions during the Covid-19 pandemic meant that DKMS was unable to hold physical donor registration events at companies. In response to this, we developed virtual recruitment events (also known as v-drives) so that employees could register through a landing page, dedicated to the company, from the comfort of their own home. We would like to thank all those companies, including Google and Amazon, who supported our v-drives throughout 2020.



APOLLO MOTOR GROUP

The third largest independent accident repair group in the UK, Apollo Motor Group campaigned tirelessly to support Luke Hope, an Apollo Academy apprentice who was diagnosed with blood cancer and was searching for a matching blood stem cell donor. Managing Director, Bradley Eyles, rallied his networks and raised over £6,000 for DKMS. In addition, 119 people registered as potential blood stem cell donors through the dedicated Apollo Motor Group virtual donor drive page.

ICELAND FOODS CHARITABLE FOUNDATION

Iceland Foods Charitable Foundation made a generous £10,000 donation in support of Luke Hope, enabling DKMS to register 250 new potential lifesavers.

Luke was first diagnosed with blood cancer when he was employed at his local Iceland store before he started his apprenticeship with Apollo Motor Group. Despite leaving the business, the company continued to support Luke and his family in raising awareness of his story and encouraging people to register to become potential donors.

NEW £2K CLUB MEMBERS

MNU Ltd, Airsweb Ltd and 4Wall Entertainment UK Ltd became the newest members of the DKMS £2K Club. Their generous donations of £2,000 each will fund registrations of new potential lifesavers.

FORD MOBILITY

In December, employees of Ford Mobility donated their last hour of pay for the year to DKMS, for the second year in a row, in support of a colleague who was affected by blood cancer. They raised a total of £288.



OAKMERE WEALTH MANAGEMENT





Six employees from Northwich-based Oakmere Wealth Management smashed their planned 874 mile #Lifesaversinlockdown challenge for DKMS. Managing Director, Carla Brown, and five of her colleagues - Louise Gilbody, Jackie Phillips, Jacky Roberts, Rachel Whittaker and Penny Williams - completed 1,046.14 miles (172 miles more than their target distance) for their virtual Lands End to John O' Groats charity challenge, raising over £2,000.

IMPROVING THE EXPERIENCE OF OUR DONORS AND SUPPORTERS

We undertook a restructure in the last year to separate our data and customer support teams, to place a greater emphasis on delivering consistently on our service standards and to better meet the expectations of our donors and supporters.

A working group was set up to identify and implement improvements. The team has reviewed all of our key customer journeys, from recruitment onto the database via donor recruitment events or via our website, through to blood stem cell donation.

Key successes of the working group so far include:

-  We have identified better use of technology that will enable us to deliver better customer service.
-  For many people who are searching for a matching donor, time is of the essence. We have been working with our fulfilment company to reduce dispatch times for swab packs, particularly during periods of high demand.
-  We are beginning to identify improvements to increase how many swab kits are returned to us.
-  Donor recruitment event boxes have been developed. These boxes are provided to event hosts, providing them with everything that they need to run a registration event. We have also changed our courier to allow easier delivery and returns of the boxes.

The Customer Service team faced additional challenges during the last year due to the reduction in office-based staff. Other teams stepped in order to allow DKMS UK to process returned swab kits and send them on for processing in our laboratory in Germany without delay.

Additionally, we created a Brexit contingency plan for sending swabs to the laboratory, which was deployed when international borders were closed due to Covid-19 in December 2020. This contingency plan has meant our potential donors are registered with minimal delay.



ENVIRONMENTAL IMPACT

As part of DKMS' commitment to the environment, we embarked on a project to understand our carbon footprint. We collated data from the financial year 2019 to complete a carbon footprint assessment to Greenhouse Gas Protocol Corporate Standard. As an organisation, we have taken responsibility for carbon generated from our recruitment, marketing, fundraising, logistical and stem cell donation activities.

After completion of the assessment, we know the activities and areas of our organisation which contribute to our environmental footprint. A working group has been set up to identify projects and to create a strategy to reduce our environmental impact in financial year 2021 and beyond, across all scopes contained in the carbon footprint measurement.

FUTURE PLANS

Our future plans remain aligned with our key priorities. On current trends, by the end of 2023 we should achieve a primary goal of giving at least 500 second chances of life per year to people with blood cancer and blood disorders. Yet that is not enough for DKMS UK and our current planning is focusing on prioritising and targeting our audiences, donors, supporters and stakeholders, so that we exceed those targets.

While we will maintain our existing broad donor recruitment and registration policies, ranging from the age of 17 to 55, within that we aim to focus on donors more likely to be selected for donation or those where there is an urgent demand or need. This means certain aspects of our donor recruitment and management will focus on younger donors and those from specific ethnic communities, while we continue to engage and work with our wider donor community to help support this prioritisation in any way they can.

We also plan to improve further the quality of the personal and health information we hold on our donors so that they are more likely to be selected as a matching donor. This means thorough and detailed quality programmes that will help us gather the cytomegalovirus (CMV) status of donors where we don't have it, as well as ensuring contact details and health information for preferred donors are fully up-to-date and accurate. CMV is a common virus that rarely causes problems in healthy people, but is an important risk factor for blood cancer patient teams considering a potential donor.

We also know that to support our planned growth in potential and actual blood stem cell donors we need to work with more hospitals as stem cell collection centres in the future. Our current plans include establishing contractual relationships with a minimum of two new hospitals each year. We aim to provide more support, including education and training, to hospitals and healthcare practitioners working in blood stem cell donation and transplant.

To achieve this we need to continue to invest in and support new staff and ways of working, including increased digitisation and efficiencies. While we can support some of this with fees from our services, we also know that we need to increase our fundraising levels, hence why we will continue to increase staff and invest in resources that will enable us to achieve our ambitious targets.

Behind all this lies an awareness of the need for blood stem cell transplants in the UK of about 2,000 patients per year, including a significant number who are unable to find a matching donor. We will not rest until we meet that need.

DKMS DONOR: ROBERT'S STORY

Robert Keown suffered every parent's worst nightmare when his teenage daughter Adelle died of blood cancer in 2020. Determined to help others in a similar situation, he went on to provide a potentially lifesaving blood stem cell donation to a complete stranger who is also fighting the disease that claimed the life of his daughter.

Adelle, who Robert describes as 'sassy, with a heart of gold' was just fifteen when she was diagnosed with leukaemia in 2018 - just four months after her best friend tragically died of the same condition.

Robert said: "We were devastated and heart-broken. Overwhelmed and in disbelief, we wondered how could this happen. We always tried to protect our children, but we couldn't protect her against this."

Adelle was told her only hope of beating the disease was to receive a blood stem cell transplant from a matching donor. Sadly, no suitable match was found within the family so they turned to the register hoping to find the lifeline Adelle so desperately needed, signing themselves up as potential donors at the same time.

Adelle eventually found a match and had a donation from a stranger who had signed up as a potential lifesaver with DKMS, and she enjoyed a cancer-free year in 2019.

After a brave fight against her aggressive leukaemia, Adelle died peacefully in July 2020, at the age of eighteen.

Less than four months after Adelle died, Robert received a phone call from DKMS, and was told he had been matched with a patient fighting blood cancer. He was asked if he would be willing to donate his blood stem cells in a transplant identical to Adelle's.

Robert said: "When I heard the voice on the phone telling me I had matched with someone just like Adelle, I couldn't speak. I was in shock and crying. I was so overwhelmed because I know what it's like to be on the other side waiting for a match."


"As a father, I was told I needed to rely on a complete stranger to save my child's life. I felt useless. But Adelle's donor gave us precious extra time with our daughter. Then I was given the chance to be someone else's hero. It was the easiest yes I've ever had to say."

“

It was an honour to donate my stem cells. And you're so well looked after by everyone at DKMS and the staff at the clinic. I honestly couldn't thank them all enough. My whole experience has been amazing.”



Robert donating his blood stem cells



Robert and Adelle

“HE’S HERE BECAUSE OF YOU. THANK YOU FOR SAVING MY ANGEL”

Mum of two, Lorna, went through the emotional experience of meeting the woman who saved her five-year-old son Alfie’s life.

Alfie Commons, from Nottingham, was just seven months old when he was diagnosed with an aggressive form of leukaemia.

Lorna said: “Our world completely fell apart. My innocent baby had cancer. Chemotherapy was failing, and we were told Alfie’s only chance of survival was to have a bone marrow transplant from a matching donor. Nobody in the family was a match, so we were relying on a total stranger.”

Meanwhile, 1,243km away in Schwerin, Germany, 35-year-old school teacher Christin Bouvier, who had been registered as a potential donor with DKMS for some years, received a letter telling her she had been matched with a patient in urgent need.

After a donation of her bone marrow, Christin said: “When they told me that the recipient was a baby, I just cried. After the anesthetic wore off, I called DKMS as I needed to know more. They told me that Alfie was a small baby and living in the UK. I still can’t describe that moment but tears of joy ran down my face. It’s a moment that is always with me and whenever I feel down, I think back to it as it always brings me so much happiness!”

In February 2020, DKMS arranged for Alfie and Lorna to meet Christin for the very first time, in a special event at Chiswick Town Hall, next door to DKMS UK’s London headquarters. The event was attended by the Mayor of Hounslow, and a specially invited audience of DKMS supporters and staff.

Lorna said: “As a family, we owe so much to Christin, words of thanks will never feel enough. I wanted to meet Christin from the very start and this meeting was so special and exciting. Alfie and Christin share a special bond, she is now part of him, and part of our lives.”

“

To be a donor, and to have had the chance to save a life, has been one of the best moments of my life. I will always be wedded to Alfie; he is such a special, brave boy. Donating the bone marrow was such an easy process, and nothing compared to what Alfie and his family went through. I was able to help them during this terrible time and to help Alfie fight cancer. So far, this is the best thing that I have done in my entire life.”



Alfie and Lorna meet Christin

GOVERNANCE

Preparation of report

As the company qualifies as small under section 383 of the Companies Act 2006, the strategic report required of medium and large companies under The Companies Act 2006 (Strategic Report and Director's Report) Regulations 2013 is not required.

DKMS Foundation (referred to hereinafter as 'DKMS UK') is incorporated as a charitable company limited by guarantee and is a registered charity in England and Wales, and in Scotland. It is governed by its Memorandum and Articles of Association, and the work, management, finances and strategy of the Charity are overseen by a Board of Trustees, who are also the Company Directors.

DKMS UK is connected through common trustees to DKMS Gemeinnützige GmbH ('DKMS'), and its related charities.

The Trustees who held office during the financial year and at the date of the report are set out on page 47. A minimum of two Trustees at any one time are required by the Articles of Association. There is no maximum limit required by the Articles. At every Annual General Meeting (AGM) one-third of the Trustees retire by rotation, but are eligible for re-election. There is no restriction on the term of tenure as a Trustee. Trustees do not receive remuneration for their duties.

Purpose

DKMS UK's charitable purposes are set out in its Memorandum of Association as follows:

"The preservation and protection of good health and the relief of sickness of individuals who are suffering from any kind of blood cancer."

The aims of DKMS UK are to:

- raise awareness of blood stem cell donation;
- increase the number and diversity of registered potential blood stem cell donors in the UK; and
- provide more second chances of life for those with blood cancer or blood disorders whose survival depends upon being matched with an unrelated blood stem cell donor.

Public benefit

DKMS UK raises awareness of blood cancers and blood disorders in the UK, including the life-changing impact of a diagnosis, in order that increasing numbers of the general public know about the need for more people to register as a potential blood stem cell donor. Increasing the number and diversity of potential blood stem cell

donors is vital in increasing the life chances of blood cancer and disorder patients who are in need of a blood stem cell transplant. At present, only 2% of the UK population are registered as donors compared to much higher levels in some other countries.

Registering more potential blood stem cell donors means that we are able to provide more second chances of life by finding and supporting an unrelated blood stem cell donor who can and will donate their stem cells for a patient in need of a life-saving blood stem cell transplant.

Through recruiting, registering and supporting blood stem cell donors to be part of life-saving treatments, we deliver significant public benefit to patients and their families and to the National Health Service, which arranges treatment and care for those patients.

The Trustees review the aims, objectives and activities of DKMS UK each year, ensuring the Charity remains focused on its stated purpose. This report looks at what DKMS UK has achieved and the outcomes of its work in the reporting period.

The Trustees have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing the Charity's aims and objectives and in planning its future activities. In particular, the Trustees consider how planned activities will contribute to the aims and objectives that have been set.

Board and management operations and structure of Board of Trustees

The Board of Trustees meets twice a year to review DKMS UK's work, finances and services, and to agree the strategic goals for the Charity.

Recruitment and appointment of new Trustees

Trustees are appointed on the basis of their relevant skills and experience. The ongoing Trustees are responsible for the induction of any new Trustees, which involves an awareness of a Trustee's responsibilities, the governing document, administrative procedures, the history, approach and current business plan of DKMS UK. The Trustees will also make available a welcome pack to include copies of the previous year's annual report and financial statements, a brief history of the charitable company and a copy of the governing document. The pack will also include a copy of the Charity Commission guidance 'The Essential Trustee: What you need to know' and 'Charities and Public Benefit'.

While DKMS UK is connected through common trustees to DKMS Gemeinnützige GmbH ('DKMS'), it aims to recruit additional Trustees in 2021 in order to broaden UK representation on the Board.

Management and organisation

Day-to-day operation of the Charity, and strategy implementation, is delegated to the Chief Executive Officer, supported by the Senior Leadership Team (SLT).

The Senior Leadership Team comprises:

- Chief Executive Officer
Jonathan Pearce
- Head of Communications and Engagement
Reshna Radiven
- Head of Customer Service
Julie Roberts
- Head of Donor Request Management
Helen Kelly
- Head of Finance
Hasnein Alidina
- Head of Fundraising
Caroline Richardson
- Head of Improvement and Innovation
Candy Stern
- HR Manager
Regina Salih

Related parties

The only related parties are considered to be the Trustees and those connected with the Trustees, including their close family, business and other charity interests. There have been no transactions with related parties, other than the reimbursement of reasonable travel expenses for the purposes of attendance at Board meetings and other relevant organisational activities.

Remuneration

In order to recruit and retain staff of the calibre it requires, DKMS UK's pay policy is to remunerate staff at levels above the voluntary sector median rate, but below the private sector market rate. The Charity has an organisational salary structure based upon a job evaluation study and external salary benchmarking that took place in 2018. New roles are assessed against the job evaluation criteria and placed in a corresponding grade in the structure.

The salary structure's pay levels are reviewed at least annually by the CEO to ensure that salary scales are aligned with those for similar positions in the external market.

A review of salaries normally takes place annually, and is usually implemented in January. If changes are to be made, staff are advised in writing of the amount and the date from which it takes effect. A salary review does not imply an increase and in making any pay award the review will be based on the organisation's financial health and achievements.

With reference to the National Council of Voluntary Organisation's 2014 inquiry into executive pay (NCVO, 'Report of the Inquiry into Charity Senior Executive Pay and Guidance for Trustees on Setting Remuneration'), the Board of Trustees is committed to including the following information within its annual statutory report and financial statements:

- A summary statement of the Charity's remuneration policy and approach to senior executive pay.
- Disclosures on the number of staff in receipt of more than £60,000 per annum (in bands of £10,000), and the collective total benefits (including pension payments and employer's national insurance) paid to 'key management personnel' (which we have defined as the Senior Leadership Team), in line with the accounting Statement of Recommended Practice 2019 for charities. Given the Charity's size, the Board of Trustees does not believe it is appropriate to disclose the actual/personal salary of any individual member of staff, including senior executives, to the public.
- Disclosures on pensions and other staff benefits (see subsequent notes to the financial statements).

Our approach to fundraising

We continue to uphold the highest standards in how we communicate with our fundraising donors and supporters and ensure that our fundraising practices meet the requirements of the recommended Codes of Practice. We treat our donors and supporters with great respect and gratitude that befits a community of people and organisations that make our work possible.

Key aspects of our approach to fundraising include:

- Registration with the Fundraising Regulator, which maintains the standards for charitable fundraising and ensures that fundraising is respectful, open, honest and accountable to the public. It also takes complaints about fundraising, investigates cases and adjudicates on fundraising practice.

- Ensuring our fundraising approach is aligned with the Charity's governing objectives.
- We have a complaints policy, which outlines our commitment to resolving fundraising complaints as promptly and amicably as possible. It also sets out our process for handling any complaints received. As per our policy, complaints will be reported and referred to the Fundraising Regulator if a resolution with the complainant cannot be reached or if the complaint is about a breach of any aspect of the Code of Fundraising Practice.
- In 2020 we did not receive any complaints across the organisation. Trustees are updated on a bi-annual basis with regards to the number of complaints we have handled in the year.
- We raise funds through individual giving requests (cash appeals, regular donation asks and online giving), community, challenge events, corporate and trust fundraising.
- We do not carry out any telephone, face-to-face or door-to-door fundraising.
- We do not use third party agencies to make fundraising requests, although we do use them for fulfilment purposes, e.g., acquisition of charity place challenge events, processing direct debits or distribution of fundraising direct mail. In such situations, legal agreements are in place. In no other circumstance do we swap or share data and we never sell data.
- All fundraising activity complies with EU General Data Protection Regulation (GDPR) introduced in May 2018.
- Promotional goods sent out for fundraising purposes and use of our logo on external fundraising materials is subject to approval. Official stationery, such as our letterhead, is never sent out for external use.

Risk assessment and management

DKMS UK operates a risk assessment and management framework that reviews major risk areas on a quarterly basis.

The CEO and individual members of the Senior Leadership Team take responsibility for the day-to-day management and oversight of the above risk areas. The Trustees review the assessments and mitigating actions at their Board meetings and consider the following areas to be the major risks related to DKMS UK's operations and activities.

MEDICAL SAFETY OF DONORS DURING THE BLOOD STEM CELL COLLECTION PROCESS

Although the medical process and procedure for blood stem cell donation and collection is safe, well-established and regulated, there will always be some safety risks and DKMS UK acknowledges these and takes them seriously. The risks to the safety of our donors before, during and after the donation process, as well as any risks to transplant patients from the collection of poor quality stem cell product are managed and mitigated in the following ways:

- Working in line with approved and regularly reviewed Standard Operating Procedures that comply with domestic and international standards and regulations, and that include clear identification and reporting mechanisms for Serious Adverse Events and Reactions and Quality Incidents.
- Working only with experienced, trusted and appropriately regulated medical partners and services. These relationships in turn are governed via established legal contracts and service protocols and regular service reviews.
- Ensuring a thorough quality assurance system is in place within the organisation, including compliance with the World Marrow Donor Association (WMDA) standards (qualification for which was achieved and approved in March 2021).
- Ensuring ongoing training, support and continuing professional development for all staff involved in the blood stem cell registration and donation process.
- Developing a strong UK-based Medical Advice and Support Service to support operational decisions, and to supplement the DKMS Group's global medical advice systems and services.

DATA MANAGEMENT AND PROTECTION

The collection, processing, storage and security of our blood stem cell donors' personal data and genetic information is of paramount importance and so represents a major risk in the event of mismanagement, loss or misuse of that data. The potential damage to individual donors through a data breach, let alone the damage to DKMS UK's and the DKMS Group's reputation and activities in working with patients, donors, supporters and stakeholders would be catastrophic. We manage and mitigate these risks through:

- Adherence to and compliance with strong information security and data protection policies and practices throughout the whole DKMS Group.

- Ensuring data processing and third parties and protocols are in place with suppliers and partners.
- Regular training and reviews for staff, volunteers and donor registration partners.
- Blood stem cell donor recruitment.

Effective and high quality blood stem cell donor recruitment is essential to ensuring we meet the needs of patients and transplant centres looking for a match. If we fail to ensure we recruit sufficient numbers of donors with a diverse range of backgrounds, and also with accurate and regularly updated personal health and genetic information and contact details, then we risk not being able to save the lives of more blood cancer and blood disorder patients. We manage and mitigate this risk by ensuring we have:

- Clear and compelling communications and explanations about the registration process and the need for blood stem cell donors.
- Effective quality check and review processes.
- Quality programmes to enhance the health and contact information we have on the priority groups among our blood stem cell donors.
- A system for prioritisation for recruiting, retaining and supporting potential and actual blood stem cell donors.

LOGISTICAL AND SUPPLY LINE BUSINESS CONTINUITY AND RESILIENCE

Ensuring we have reliable, efficient and cost-effective methods for transporting our swab packs, blood samples and collected blood stem cells is crucial to the successful achievement of our organisational goals and objectives to save more lives, as is having a well-stocked and maintained supply line, resources and medicines. To manage and mitigate the risks of business critical supplies and logistical arrangements we have:

- Implemented strong review processes for stock control and order processing.
- Made alternative arrangements and contingency plans for business continuity and disaster recovery scenarios.
- Developed contingency plans to provide for business periods where we are working at higher than normal levels of activity or volume (e.g. when running successful campaigns).

FINANCIAL RISKS

There are a number of areas of financial risk faced by DKMS UK:

- Failure to achieve budgeted income levels.
- Inadequate financial controls or fraud.
- Poor financial management, including credit risk management, pricing risk and foreign exchange and liquidity risks.

These risks are managed and mitigated in the following ways:

- Strong planning, budgeting and monitoring processes in relation to income streams, including fundraising.
- Strong internal financial controls and data security.
- Regular reviews of fraud risks.
- Close interaction, support and cross-checking with the international financial management and controlling teams in Germany.
- Vetting by DKMS Germany of international health services, registries and companies involved in stem cell transplantation, so that stringent assessments on credit risk are carried out and appropriate financial terms agreed for all DKMS companies within the Group.
- Ensuring pricing of products and services is set at reasonable and affordable levels, that recognise the Group's role as a healthcare service provider with a primary objective of saving lives. Pricing levels are based on a production cost structure and also acknowledge differences in international economies, as well as the need to ensure patient treatments are not jeopardised by costs.
- Maintaining good cash flow and financial management systems in order to manage fluctuations in the major trading currencies in which DKMS UK deals. Cash flow projections are prepared as part of the Charity's strategic planning, while liquidity levels are monitored internally on a daily basis as well as reported to central management and trustees at each reporting period. DKMS UK is not indebted to any external lenders outside the DKMS global group and does not have any borrowing obligations. Adequate balances are maintained in all currencies to ensure sufficient funding is available to meet commitments.

CONSEQUENCES FOR DKMS UK OF THE UK EXIT FROM THE EU

DKMS UK has not experienced any major effects on its activities following the UK's exit from the EU, although the Charity's management and the Board of Trustees will continue to monitor any developments very closely.

DKMS UK's main product does not attract any customs duties or tariffs within the EU or in all other countries worldwide at present and the Board is of the opinion that this is unlikely to change.

At the time of writing this report, the British Pound has recently gained value in line with economic expectations of an early UK 'bounce back' due to its successful implementation of the Covid-19 vaccination programme. This has not affected DKMS UK's operations as the business has a diverse customer base across wide geographical areas and continues to trade in all three major trading currencies – namely the British pound sterling, Euro and US Dollar.

Post-balance sheet events

The Controlling company DKMS Gemeinnutzige GmbH is currently in the process of finalising a contract with DKMS Life Science Lab whereby DKMS UK will receive HLA and CMV (human leukocyte antigen and cytomegalovirus, two key pieces of information gathered from new donor registration swabs) for no consideration from 01 January 2021.

DKMS Gemeinnutzige GmbH and its related entities have taken a strategic decision to simplify its pricing structure for stem cell treatment to its customers. The aim is to make it more readily available at lower cost to blood cancer patients in segmented countries. The new simple pricing was implemented from 21 April 2021.

As part of this pricing model, DKMS companies also offer free search services to patients, transplant centres and health services in these countries from the same date. This offer removes financial and bureaucratic barriers to transplantation for patients and transplant centres via cost-free searches for potential donors, simplified processes and cost structures, and greater efficiencies. DKMS UK piloted the scheme from 21 October 2020 and results to date have been encouraging.

Financial review

A. GOING CONCERN

The Board of Trustees of the ultimate parent company has approved an arrangement to continue funding DKMS UK's main activities from its principal, DKMS Gemeinnutzige GmbH, to meet all its liabilities for a period not less than 12 months from the date these financial statements are approved. Accordingly, they continue to adopt a going concern basis in preparing the financial statements.

The company's business activities in 2021 show positive results to budget and recent business review and forecast reaffirms that this trend will continue for rest of the year. The company's funding requirements is expected to remain well within the amounts approved by the board for next 3 years.

The charitable company's net current assets at 31 December 2020 were £817,186 (2019: £1,109,452). Further details regarding the adoption of the going concern basis can also be found in the Accounting Policies on page 31.

B. FINANCIAL RESULTS

DKMS UK received donations totalling £4,079,333 (2019: £5,170,383), of which £939,538 (2019: £2,242,520) was donated funds and £3,139,795 (2019: £2,915,555) was donated services from DKMS in Germany.

DKMS UK's main fundraising activity, the UK Gala, was cancelled because of the Covid-19 pandemic, resulting in lost income of almost £1,200,000. DKMS UK's annual income from the referral of potential blood stem cell donors was £4,841,811 (2019: £5,270,405), the reduction on the previous year also a direct consequence of the pandemic. Despite these challenges, DKMS UK remained focused on its main objective of giving blood cancer and blood disorder patients a second chance of life by retaining its staff and achieving some savings in costs. Total costs for the year amounted to £9,267,212 (2019: £10,224,042), resulting in a net loss for the year of £346,067 (2019: net gain of £216,746).

C. RESERVES POLICY

DKMS UK's aim is to gradually grow its unrestricted funds and achieve full financial independence. While the Charity is growing its income base and cash flow, it continues to receive funding for its main activities from its principal, DKMS Gemeinnutzige GmbH. The Trustees have approved for this arrangement to continue for the foreseeable future and until DKMS UK becomes financially independent to meet all its liabilities for at least 12 months. As at 31 December 2020 DKMS UK's unrestricted funds were £957,684 (2019: £1,303,751).

D. PRINCIPAL FUNDING

In the period under review, DKMS UK's principal funding has come from donations from DKMS in Germany. However, the charitable company developed a fundraising strategy to raise additional funding through voluntary donations and events. Another source of fundraising is fees earned for the referral of potential blood stem cell donors and the management of stem cell or bone marrow collections.

TRUSTEES' RESPONSIBILITIES STATEMENT

The Trustees (who are also directors of DKMS Foundation for the purposes of company law) are responsible for preparing the Trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial year. Under company law the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities Statement of Recommended Practice (SORP);
- make judgments and accounting estimates that are reasonable and prudent;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in operation.

DISCLOSURE OF INFORMATION TO AUDITORS

Each of the persons who are Trustees at the time when this Trustees' report is approved has confirmed that:

- so far as that Trustee is aware, there is no relevant audit information of which the charitable company's auditor is unaware, and
- that Trustee has taken all the steps that ought to have been taken as a Trustee in order to be aware of any relevant audit information and to establish that the charitable company's auditors are aware of that information.

This report was approved by the Trustees on 25 June 2021 and signed on their behalf on 5 August 2021 by:



S Geist
Trustee

INDEPENDENT AUDITORS' REPORT TO THE MEMBERS AND TRUSTEES OF DKMS FOUNDATION

Report on the audit of the financial statements

OPINION

In our opinion, DKMS Foundation's financial statements (the "financial statements"):

- give a true and fair view of the state of the charitable company's affairs as at 31 December 2020 and of its incoming resources and application of resources, including its income and expenditure, and cash flows for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards, comprising FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", and applicable law); and
- have been prepared in accordance with the requirements of the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and regulation 8 of The Charities Accounts (Scotland) Regulations 2006 (as amended).

We have audited the financial statements, included within the Annual Report and Financial Statements (the "Annual Report"), which comprise: the balance sheet as at 31 December 2020; the statement of financial activities (incorporating income and expenditure account) and the statement of cashflows for the year then ended; and the notes to the financial statements, which include a description of the significant accounting policies.

BASIS FOR OPINION

We conducted our audit in accordance with International Standards on Auditing (UK) ("ISAs (UK)") and applicable law. Our responsibilities under ISAs (UK) are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Independence

We remained independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, which includes the FRC's Ethical Standard and we have fulfilled our other ethical responsibilities in accordance with these requirements.

CONCLUSIONS RELATING TO GOING CONCERN

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from the date on which the financial statements are authorised for issue.

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

However, because not all future events or conditions can be predicted, this conclusion is not a guarantee as to the charitable company's ability to continue as a going concern.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

REPORTING ON OTHER INFORMATION

The other information comprises all of the information in the Annual Report other than the financial statements and our auditors' report thereon. The trustees are responsible for the other information. Our opinion on the financial statements does not cover the other information and, accordingly, we do not express an audit opinion or, except to the extent otherwise explicitly stated in this report, any form of assurance thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated. If we identify an apparent material inconsistency or material misstatement, we are required to perform procedures to conclude whether there is a material misstatement of the financial statements or a material misstatement of the other information.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report based on these responsibilities.

With respect to the Trustees' Report, we also considered whether the disclosures required by the UK Companies Act 2006 have been included.

Based on our work undertaken in the course of the audit, the Companies Act 2006 and The Charities Accounts (Scotland) Regulations 2006 (as amended) require us also to report certain opinions and matters as described below.

Trustees' Report

In our opinion, based on the work undertaken in the course of the audit the information given in the Trustees' Report for the financial year for which the financial statements are prepared is consistent with the financial statements and the Trustees' Report have been prepared in accordance with applicable legal requirements.

In addition, in light of the knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we are required to report if we have identified any material misstatements in the Trustees' Report. We have nothing to report in this respect.

RESPONSIBILITIES FOR THE FINANCIAL STATEMENTS AND THE AUDIT

Responsibilities of the trustees for the financial statements

As explained more fully in the Trustees' responsibilities statement, the trustees are responsible for the preparation of the financial statements in accordance with the applicable framework and for being satisfied that they give a true and fair view. The trustees are also responsible for such internal control as they determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Auditors' responsibilities for the audit of the financial statements

We have been appointed as auditors under section 44(1) of the Charities and Trustee Investment (Scotland) Act 2005 and under the Companies Act 2006 and report in accordance with the Acts and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from

material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

Based on our understanding of the charitable company/ industry, we identified that the principal risks of non-compliance with laws and regulations related to Health and Safety regulations and employment law, and we considered the extent to which non-compliance might have a material effect on the financial statements. We also considered those laws and regulations that have a direct impact on the financial statements such as the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and regulation 8 of The Charities Accounts (Scotland) Regulations 2006 (as amended). We evaluated management's incentives and opportunities for fraudulent manipulation of the financial statements (including the risk of override of controls), and determined that the principal risks were related to manipulation of financial performance. Audit procedures performed included:

- Enquiries of management around known or suspected instances of non-compliance with laws and regulations, claims, litigation, and instances of fraud;
- Understanding of management's controls designed to prevent and detect irregularities;
- Review of board minutes;
- Identifying and testing journal entries to assess whether any of the journals appeared unusual, for example unexpected account combinations impacting revenue; and
- Incorporating an element of unpredictability into our testing plan.

There are inherent limitations in the audit procedures described above. We are less likely to become aware of instances of non-compliance with laws and regulations that are not closely related to events and transactions reflected in the financial statements. Also, the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery or intentional misrepresentations, or through collusion.

A further description of our responsibilities for the audit of the financial statements is located on the FRC's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditors' report.

Use of this report

This report, including the opinions, has been prepared for and only for the charitable company's members and trustees as a body in accordance with section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and the Companies Act 2006 and regulations made under those Acts (regulation 10 of The Charities Accounts (Scotland) Regulations 2006 (as amended) and Chapter 3 of Part 16 of the Companies Act 2006) and for no other purpose. We do not, in giving these opinions, accept or assume responsibility for any other purpose or to any other person to whom this report is shown or into whose hands it may come save where expressly agreed by our prior consent in writing.

Other required reporting

MATTERS ON WHICH WE ARE REQUIRED TO REPORT BY EXCEPTION

Under the Companies Act 2006 and The Charities Accounts (Scotland) Regulations 2006 (as amended) we are required to report to you if, in our opinion:

- we have not obtained all the information and explanations we require for our audit; or
- adequate and proper accounting records have not been kept or returns adequate for our audit have not been received from branches not visited by us; or
- certain disclosures of trustees' remuneration specified by law are not made; or
- the financial statements are not in agreement with the accounting records and returns.

We have no exceptions to report arising from this responsibility.

ENTITLEMENT TO EXEMPTIONS

Under the Companies Act 2006 we are required to report to you if, in our opinion, the trustees were not entitled to: prepare financial statements in accordance with the small companies' regime and take advantage of the small companies exemption from preparing a Strategic Report. We have no exceptions to report arising from this responsibility.



Matthew Kaye (Senior Statutory Auditor)

for and on behalf of PricewaterhouseCoopers LLP
Chartered Accountants and Statutory Auditors, Edinburgh.
5 August 2021

STATEMENT OF FINANCIAL ACTIVITIES

(INCORPORATING INCOME AND EXPENDITURE ACCOUNT)
FOR THE YEAR ENDED 31 DECEMBER 2020

	Note	Unrestricted funds 2020 £	Total funds 2020 £	Total funds 2019 £
Income from:				
Donations and legacies	2	4,079,333	4,079,333	5,170,383
Charitable activities	3	4,841,811	4,841,811	5,270,405
Total Income		8,921,145	8,921,145	10,440,788
Expenditure on:				
Raising funds	4	459,047	459,047	1,012,911
Charitable activities	5, 6 and 9	8,808,165	8,808,165	9,211,131
	7,18	9,267,212	9,267,212	10,224,042
Net (expenditure / income before other recognised gains and losses)		(346,067)	(346,067)	216,746
Reconciliation of funds:		(346,067)	(346,067)	216,746
Total funds brought forward		1,303,751	1,303,751	1,087,005
Total funds carried forward		957,684	957,684	1,303,751

All activities relate to continuing operations.

The notes on pages 31 to 45 form part of these financial statements.

BALANCE SHEET

AS AT 31 DECEMBER 2020

		2020		2019	
	Note	£	£	£	£
Fixed assets					
Tangible assets	12		140,497		194,298
Investments	13		1		1
			<u>140,498</u>		<u>194,299</u>
Current assets					
Inventory	14	144,271		230,058	
Debtors	15	1,878,009		1,601,397	
Cash at bank and in hand	21	771,903		773,391	
		<u>2,794,183</u>		<u>2,604,846</u>	
Creditors: amounts falling due within one year	16	(1,976,997)		(1,495,394)	
Net current assets			817,186		1,109,452
Net assets			<u>957,684</u>		<u>1,303,751</u>
Charity Funds					
Unrestricted funds	18		957,684		1,303,751
Total funds	19		<u>957,684</u>		<u>1,303,751</u>

The company's financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved and authorised for issue by the Trustees on 25 June 2021 and signed on their behalf on 5 August 2021 by:


S Geist
 Trustee

The notes on pages 31 to 45 form part of these financial statements.

STATEMENT OF CASH FLOWS

FOR THE YEAR ENDED 31 DECEMBER 2020

	Note	2020 £	2019 £
Cash flows from operating activities			
Net cash provided by operating activities	20	15,937	346,066
Cash flows from investing activities			
Purchase of tangible fixed assets		(17,425)	(191,764)
Net cash used in investing activities		<u>(17,425)</u>	<u>(191,764)</u>
Change in cash and cash equivalents in the year			
Cash and cash equivalents brought forward		773,391	619,089
Cash and cash equivalents carried forward	21	<u>771,903</u>	<u>773,391</u>

The notes on pages 31 to 45 form part of these financial statements.

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 31 December 2020

1. Accounting Policies

1.1 Basis of preparation of financial statements

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

DKMS Foundation meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

The financial statements are presented in pound sterling (£).

1.2 Going concern

The trustees of the ultimate parent company review the company's activities and 3 year business plan each year and establish and approve funding level required to enable the company to achieve its goals and meet its business commitments and liabilities.

The Trustees have approved arrangement to continue funding the charitable company's main activities from its principal, DKMS Gemeinnutzige GmbH, to meet all its liabilities for a period not less than twelve months from the date these financial statements are approved. Accordingly, they continue to adopt going concern basis in preparing the financial statements.

1.3 Company status

The charitable company is limited by guarantee. The members of the company are the Trustees named on page 47. In the event of the company being wound up, the liability in respect of the guarantee is limited to £10 per member of the company.

1.4 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the company and which have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the company for particular purposes.

The costs of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

1.5 Income

All income is recognised once the charitable company has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably. Money donation income is recognised when the income is credited into the company's account and revenue for clinical services is recognised after services are delivered.

Donated services or facilities are recognised when the charitable company has control over the item, any conditions associated with the donated item have been met, the receipt of economic benefit from the use by the charitable company of the item is probable and that economic benefit can be measured reliably, in accordance with the Charities SORP (FRS 102). General volunteer time is not recognised. Further information about volunteer contribution is included in the Trustees' Report.

On receipt, donated professional services and donated facilities are recognised on the basis of the value of the gift to the charitable company which is the amount the charitable company would have been willing to pay to obtain services or facilities of equivalent economic benefit on the open market; a corresponding amount is then recognised in expenditure in the period of receipt.

Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

1.6 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to make payment to a third party, it is probable that settlement will be required and the amount of the obligation can be measured reliably.

All expenditure is accounted for on an accruals basis. All expenses including support costs and governance costs are allocated to the applicable expenditure headings:

- Costs of generating funds comprise the costs associated with attracting voluntary income.
- Charitable expenditure comprises those costs incurred by the charitable company in the delivery of its activities and services for its beneficiaries. It includes both costs that can be allocated directly to such activities and those costs of an indirect nature necessary to support them.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020

- Governance costs include those costs associated with meeting the constitutional and statutory requirements of the charitable company and include the audit fees and costs linked to the strategic management of the charitable company.
- All costs are allocated between the expenditure categories of the statement of financial activities on a basis designed to reflect the use of the resource. Costs relating to a particular activity are allocated directly; others are apportioned on an appropriate basis. Staff costs are allocated based on staff numbers, premises costs are allocated based on space occupied.

1.7 Tangible fixed assets and depreciation

Tangible fixed assets are carried at cost, net of depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost of fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

- Leasehold improvements - over period of lease (4 years) straight line
- Office equipment - 33.33% per annum straight line
- Computer equipment - 33.33% per annum straight line

1.8 Investments

Investments are a form of basic financial instrument and are initially recognised at their transaction value. Investments in subsidiary companies are stated at cost less diminution in value.

1.9 Interest receivable

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the company; this is normally upon notification of the interest paid or payable by the bank.

1.10 Debtors

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

1.11 Cash at bank and in hand

Cash at bank and in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

1.12 Creditors and provisions

Creditors and provisions are recognised where the charitable company has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due.

1.13 Pensions

The charitable company operates a defined contribution pension scheme and the pension charge represents the amount payable by the charitable company in respect of the year.

1.14 Financial instruments

The charitable company has applied Sections 11 and 12 of FRS 102 in respect of financial instruments.

Financial assets and financial liabilities are recognised when the charitable company becomes party to the contractual provisions of the instrument. Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the charitable company after deducting all of its liabilities.

The charitable company's policies for its major classes of financial assets and financial liabilities are set out below.

Financial assets

Basic financial assets, including trade and other debtors, cash and bank balances, related charity working capital balances, and related charity financing are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest for a similar debt instrument. Financing transactions are those in which payment is deferred beyond normal business terms or is financed at a rate of interest that is not a market rate.

Such assets are subsequently carried at amortised cost using the effective interest method, less any impairment.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020

Financial liabilities

Basic financial liabilities, including trade and other creditors, bank loans and loans from related charities, are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Financing transactions are those in which payment is deferred beyond normal business terms or is financed at a rate of interest that is not a market rate.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Impairment of financial assets

Financial assets measured at cost and amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss is recognised in the profit and loss account.

For financial assets measured at cost less impairment, the impairment loss is measured as the difference between the asset's carrying amount and the best estimate of the amount the charitable company would receive for the asset if it were to be sold at the reporting date.

For financial assets measured at amortised cost, the impairment loss is measured as the difference between the asset's carrying amount and the present value of estimated cash flows discounted at the asset's

original effective interest rate. If the financial asset has a variable interest rate, the discount rate for measuring any impairment loss is the current effective interest rate determined under the contract.

If there is a decrease in the impairment loss arising from an event occurring after the impairment was recognised, the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been had the impairment not previously been recognised. The impairment reversal is recognised in profit or loss.

Derecognition of financial assets and financial liabilities

Financial assets are derecognised when (a) the contractual rights to the cash flows from the asset expire or are settled, or (b) substantially all the risks and rewards of the ownership of the asset are transferred to another party or (c) despite having retained some significant risks and rewards of ownership, control of the asset has been transferred to another party who has the practical ability to unilaterally sell the asset to an unrelated third party without imposing additional restrictions.

Financial liabilities are derecognised when the liability is extinguished, that is when the contractual obligation is discharged, cancelled or expires.

1.15 Critical accounting estimates and areas of judgment

Management does not consider there to be any key judgements or estimates made in the preparation of the financial statements.

2. Income from donations and legacies

	Unrestricted funds 2020 £	Total funds 2020 £	Total funds 2019 £
Donation income	693,838	693,838	2,004,333
International donation income	245,700	245,700	238,187
Funding for donor recruitment activities from DKMS Gemeinnutzige GmbH	3,139,795	3,139,795	2,915,555
Other income - cost reimbursement	-	-	3,078
Other income	-	-	9,230
Total donations and legacies	<u>4,079,333</u>	<u>4,079,333</u>	<u>5,170,383</u>
Total 2019	<u>5,170,383</u>	<u>5,170,383</u>	

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020

3. Income from charitable activities

	Unrestricted funds 2020 £	Total funds 2020 £	Total funds 2019 £
Income from service provision	<u>4,841,811</u>	<u>4,841,811</u>	<u>5,270,405</u>
Total 2019	<u>5,270,405</u>	<u>5,270,405</u>	

In the year ended 31 December 2020 and 2019 all income related to unrestricted funds.

4. Costs of generating voluntary income

	Unrestricted funds 2020 £	Total funds 2020 £	Total funds 2019 £
Salaries, national insurance and pensions	306,647	306,647	315,275
Other staff costs and training	9,036	9,036	18,598
Premises costs	55,971	55,971	47,190
Publicity costs	(2,344)	(2,344)	548,943
Postage, support and stationery	2,121	2,121	2,909
Other admin costs	73,979	73,979	57,607
Travel costs	287	287	6,537
Loss/(Gain) on foreign exchange	1,862	1,862	9,483
Depreciation	11,488	11,488	6,369
	<u>459,047</u>	<u>459,047</u>	<u>1,012,911</u>
Total 2019	<u>1,012,911</u>	<u>1,012,911</u>	

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020

5. Direct costs

	Recruitment of donors	Raising awareness	Donor Request Management 2020	Total funds 2020	Total funds 2019
	£	£	£	£	£
Other direct costs	154,760	355,794	1,838,206	2,348,760	2,107,290
Other staff costs and training	9,263	3,320	7,733	20,316	14,564
Premises cost	50,440	69,599	64,787	184,826	139,241
Publicity cost	24,296	277,346	3,614	305,256	563,009
Loss/(gain) on foreign exchange	1,540	1,796	3,336	6,672	41,557
Postage, support and stationery	166,065	404,690	135,448	706,203	680,932
Travel costs	2,736	233	1,264	4,233	41,384
Donor typing costs	3,179,578	0	0	3,179,578	3,594,871
Salaries, national insurance and pensions	254,617	460,214	427,325	1,142,156	1,068,660
Depreciation	9,497	11,080	20,577	41,154	27,910
	<u>3,852,792</u>	<u>1,584,072</u>	<u>2,502,290</u>	<u>7,939,154</u>	<u>8,279,418</u>
Total 2019	<u>4,874,306</u>	<u>892,673</u>	<u>2,512,439</u>	<u>8,279,418</u>	

In the year ended 31 December 2020 and 2019 all income related to unrestricted funds.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020

6. Support costs

	Recruitment of donors	Raising awareness	Donor Request Management 2020	Total funds 2020	Total funds 2019
	£	£	£	£	£
Legal and professional fees	6,055	8,460	7,340	21,855	-
Loss on foreign exchange	695	811	1,507	3,013	13,446
Other staff costs and training	9,479	11,058	20,537	41,074	107,306
Premises costs	29,688	41,482	35,992	107,162	58,574
Travel costs	301	351	653	1,305	16,533
Other support costs	19,912	23,231	43,144	86,287	75,702
Postage, Support and stationery	2,114	2,466	4,580	9,160	5,030
Admin costs	(1,176)	(1,372)	(2,547)	(5,095)	0
Salaries, national insurance and pensions	130,180	151,877	282,057	564,114	557,251
Depreciation	4,289	5,004	9,293	18,586	9,029
	<u>201,537</u>	<u>243,368</u>	<u>402,556</u>	<u>847,461</u>	<u>842,871</u>
Total 2019	<u>326,149</u>	<u>256,629</u>	<u>260,093</u>	<u>842,871</u>	

In the year ended 31 December 2020 and 2019 all income related to unrestricted funds.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020

7. Analysis of expenditure by expenditure type

	Staff costs 2020 £	Depreciation 2020 £	Other costs 2020 £	Total funds 2020 £	Total funds 2019 £
Expenditure on raising voluntary income	<u>306,647</u>	<u>11,488</u>	<u>140,912</u>	<u>459,047</u>	1,012,911
Costs of raising funds	<u>306,647</u>	<u>11,488</u>	<u>140,912</u>	<u>459,047</u>	1,012,911
Recruitment of donors	<u>384,798</u>	<u>13,786</u>	<u>1,642,236</u>	<u>2,040,820</u>	5,200,459
Raising awareness	<u>612,091</u>	<u>16,083</u>	<u>3,212,775</u>	<u>3,840,949</u>	1,149,301
Donor request management	<u>709,383</u>	<u>29,869</u>	<u>2,165,593</u>	<u>2,904,845</u>	2,772,529
Charitable activities	<u>1,706,272</u>	<u>59,738</u>	<u>7,020,604</u>	<u>8,786,614</u>	9,122,289
Expenditure on governance	0	0	21,550	21,550	88,842
Total 2020	<u>2,012,919</u>	<u>71,226</u>	<u>7,183,067</u>	<u>9,267,211</u>	
Total 2019	<u>1,941,185</u>	<u>43,307</u>	<u>8,239,550</u>	<u>10,224,042</u>	10,224,042

In the year ended 31 December 2020 and 2019 all income related to unrestricted funds.

Expenditure on raising voluntary income has not been allocated to specific activities as all costs relate to general charitable activities.

8. Analysis of expenditure by activities

	Activities undertaken directly 2020 £	Support costs 2020 £	Total funds 2020 £	Total funds 2019 £
Recruitment of donors	<u>1,839,282</u>	<u>201,538</u>	<u>2,040,820</u>	5,200,455
Raising awareness	<u>3,597,580</u>	<u>243,370</u>	<u>3,840,950</u>	1,149,302
Donor request management	<u>2,502,290</u>	<u>402,555</u>	<u>2,904,845</u>	2,772,532
Total 2020	<u>7,939,152</u>	<u>847,463</u>	<u>8,786,615</u>	9,122,289
Total 2019	<u>8,279,418</u>	<u>842,871</u>	<u>9,122,289</u>	

In the year ended 31 December 2020 and 2019 all costs of direct charitable activities related to unrestricted funds.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020

9. Governance costs

	Unrestricted funds 2020 £	Total funds 2020 £	Total funds 2019 £
Auditors' remuneration	20,950	20,950	23,843
Legal and professional fees	600	600	51,722
Travel costs	-	-	13,277
	<u>21,550</u>	<u>21,550</u>	<u>88,842</u>

In the year ended 31 December 2020 and 2019 all costs of direct charitable activities related to unrestricted funds.

10. Net resources expended

This is stated after charging:	2020 £	2019 £
Depreciation of tangible assets:		
- owned by the charity	71,226	43,307
Auditors' remuneration - audit	21,939	23,843
- Non audit services - Taxation advice	<u>10,640</u>	<u>6,000</u>

During the year, no trustees received any remuneration (2019 - £Nil).

During the year, no trustees received any benefits in kind (2019 - £Nil).

During the year, no trustees received any reimbursement of expenses (2019 - £Nil).

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020

11. Staff costs

Staff costs were as follows:	2020	2019
	£	£
Salaries	1,755,341	1,702,270
Social security costs	171,521	169,594
Pension costs	83,524	64,557
Total	<u>2,010,386</u>	<u>1,936,421</u>

The average monthly number of employees was: 45 (2019: 45) and the average monthly number of employees during the year expressed as follows.

Full-time equivalents was as follows (including part-time and fixed period temporary staff):

	2020	2019
	No.	No.
Donor recruitment	9	11
Fundraising	5	5
Communications	7	9
Medical	13	9
Administration	11	11
Total	<u>45</u>	<u>45</u>

The number of higher paid employees was:

	2020	2019
	No.	No.
In the band £60,001 - £70,000	2	2
In the band £70,001 - £80,000	0	2
In the band £80,001 - £90,000	0	1
In the band £90,001 - £100,000	0	0
In the band £100,001- £110,000	0	0
In the band £110,001- £120,000	0	0
In the band £120,001- £130,000	1	0
Total	<u>3</u>	<u>5</u>

The Trustees were not paid or received any other benefits from employment with the charitable company in the year (2019: £Nil) neither were they reimbursed expenses during the year (2019: £Nil). No Trustee received payment for professional or other services supplied to the charitable company (2019: £Nil).

The key management personnel of the charitable company are the Trustees, the Chief Executive Officer and the heads of departments. There are seven heads of department (2019: 7), two of whom received remuneration in excess of £60,000 during the year (2019: 5). Total employee benefits of key management personnel of the charitable company were £516,792 (2019: £492,426).

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020

12. Tangible assets

	Office equipment	Computer equipment	Leasehold improvements	Total funds
	£	£	£	£
Cost				
At 1 January 2020	68,713	119,674	228,855	417,242
Additions	787	16,638	-	17,425
At 31 December 2020	<u>69,500</u>	<u>136,312</u>	<u>228,855</u>	<u>434,667</u>
Accumulated Depreciation at				
1 January 2020	45,306	70,504	107,134	222,944
Charge for the year	4,976	33,053	33,197	71,226
At 31 December 2020	<u>50,282</u>	<u>103,557</u>	<u>140,331</u>	<u>294,170</u>
Net book value				
At 31 December 2020	<u>19,218</u>	<u>32,755</u>	<u>88,524</u>	<u>140,497</u>
At 31 December 2019	<u>23,407</u>	<u>49,170</u>	<u>121,721</u>	<u>194,298</u>

13. Fixed asset investments

	Shares in Group undertakings £
Costs	
At 1 January and 31 December 2020	<u>1</u>

The company's wholly owned subsidiary, Delete Blood Cancer UK Marketing Limited, registered at Ashburnham House, Castle Row, Horticultural Place, London W4 4JQ is a dormant company. Its net liability position at 31 December 2020 of £10,245 (2019: £10,245) is represented by amounts due to the parent company and is fully provided for in the accounts of the parent company.

14. Inventory

Inventory costs were as follows:	2020	2019
	£	£
Materials stock	129,903	188,437
Work in progress costs	14,368	41,621
	<u>144,271</u>	<u>230,058</u>

Inventories are valued at lower of cost and net realisable value. Work in progress costs are reimbursable costs incurred for active stem cell collections awaiting to be billed.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020

15. Debtors

	2020	2019
	£	£
Due within one year		
Trade debtors	701,885	967,908
Amounts owed by group undertakings	10,245	10,245
Amounts owed by related charity	984,975	381,706
Other debtors	4,445	144,569
Prepayments and accrued income	176,459	96,969
	<u>1,878,009</u>	<u>1,601,397</u>

16. Creditors: amounts falling due within one year

	2020	2019
	£	£
Trade creditors	325,906	349,906
Amounts owed to related charity	213,039	326,830
Other creditors	415,615	-
Other taxation and social security	57,773	48,377
Accruals	964,664	770,281
	<u>1,976,997</u>	<u>1,495,394</u>

17. Financial Instruments

	2020	2019
	£	£
Financial assets		
Financial assets that are debt instruments measured at amortised cost	1,701,550	1,504,428
Financial liabilities		
Financial liabilities measured at amortised cost	(538,946)	(676,736)
	<u>1,162,604</u>	<u>827,692</u>

Financial assets measured at amortised cost include trade debtors, amounts owed by group companies, other debtors and amounts owed by related charity.

Financial liabilities include trade creditors and amounts owed to a related charity.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020

18. Summary of funds

	2020	2019
	£	£
At 1 January	1,303,751	1,087,005
Income for year	8,921,145	10,440,788
Resource expended	(9,267,212)	(10,224,042)
At 31 December	<u>957,684</u>	<u>1,303,751</u>

19. Analysis of net assets between funds

Analysis of net assets between funds - current year

	Unrestricted funds 2020 £	Total funds 2020 £
Tangible fixed assets	140,497	140,497
Fixed asset investments	1	1
Current assets	2,794,183	2,794,183
Creditors due within one year	(1,976,997)	(1,976,997)
	<u>957,684</u>	<u>957,684</u>

Analysis of net assets between funds - prior year

	Unrestricted funds 2019 £	Total funds 2019 £
Tangible fixed assets	194,298	194,298
Fixed asset investments	1	1
Current assets	2,604,846	2,604,846
Creditors due within one year	(1,495,394)	(1,495,394)
	<u>1,303,751</u>	<u>1,303,751</u>

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020

20. Reconciliation of net movement in funds to net cash flow from operating activities

	2020	2019
	£	£
Net (expenditure)/income for the year (as per Statement of Financial activities)	(346,067)	216,746
Adjustment for:		
Depreciation charges	71,226	43,307
Increase in debtors	(276,613)	(288,689)
Increase in creditors	481,603	479,274
Decrease/(increase) in inventory	85,788	(104,572)
	<u>15,937</u>	<u>346,066</u>

21. Analysis of cash and cash equivalents

	2020	2019
	£	£
Cash at bank and in hand	771,903	773,391
Total	<u>771,903</u>	<u>773,391</u>

22. Operating lease commitments

At 31 December 2020 the total of the charity's future minimum lease payments under non-cancellable operating leases was:

	2020	2019
	£	£
Within 1 year	281,925	234,938
Between 2 and 5 years	493,369	646,078
Over 5 years	-	-
	<u>775,294</u>	<u>881,016</u>

Lease payments recognised as an expense amounted to £218,171 (2019: £153,825).

The company entered into a new 4 year lease ending 30 September 2023 for its current office premises at annual rent of £234,938 + VAT including a 6 month rent-free period at the start of the lease.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020

23. Related party transactions

The company has taken advantage of the exemption contained in FRS 102 section 33 “Related Party Disclosures” from disclosing transactions with entities which are a wholly owned part of the group.

Transactions with other related parties are as follows:

Name (relationship)	Transaction	Amount		Amount due from/(to) related party	
		2020	2019	2020	2019
		£	£	£	£
DKMS Gemeinnutzige GmbH (Common Trustees)	Donated services	3,139,795	2,915,555	921,171	368,099
DKMS Gemeinnutzige GmbH (Common Trustees)	Intercompany recharges	195,217	324,347	62,503	12,306
DKMS Gemeinnutzige GmbH (Common Trustees)	International money donation	-	9,322	-	-
DKMS Life Science Lab (Common Trustees)	Intercompany recharges	2,686,250	3,364,750	(211,958)	(265,243)
DKMS USA (Common Trustees)	Intercompany recharges	-	61,806	1,301	(60,505)
DKMS USA (Common Trustees)	International money donation	245,700	228,866	-	-

Amounts owed to related parties are unsecured, interest-free and due for repayment within one year.

DKMS Gemeinnutzige GmbH is the Controlling company and exercises full control over the charitable company through its common Trustees who are also directors of the company. The controlling company recharges the charitable company actual or appropriately apportioned costs it incurs in providing support to the latter.

DKMS Life Science Lab is one of the leading HLA laboratories. Its testing services are competitively priced and provides and charges the charitable company for this service at contractual price established for all DKMS entities annually.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020

24. Post balance sheet events

The Controlling company DKMS Gemeinnutzige GmbH is currently in the process of finalising a contract with DKMS Life Science Lab whereby DKMS Foundation will receive typing services for no consideration.

DKMS Gemeinnutzige GmbH and related entities implemented a simplified pricing structure for stem cell treatment from 21 April 2021. This pricing model provides donor search free of costs to patient clinics, thereby simplifying the process for clinicians and clinics as well as making treatment more affordable.

25. Controlling party

The trustees are the immediate controlling party and DKMS Gemeinnutzige GmbH is the ultimate parent. The principal address of the ultimate parent is Kressbach 1, 72072 Tübingen, Germany.

Copies of the group financial statements are available at www.dkms.de.

REFERENCE AND ADMINISTRATIVE DETAILS OF THE COMPANY, ITS TRUSTEES AND
ADVISERS FOR THE YEAR ENDED 31 DECEMBER 2020

Trustees

Dr E Neujahr
B J Abel
S Geist
Dr A H Schmidt
S Schumacher

Principal staff

Jonathan Pearce, CEO

Registered company number

08151279 (England & Wales)

Charity registered number

1150056 (England & Wales)
SC046917 (Scotland)

Registered office

Ashburnham House, Castle Row, Horticultural Place
London, W4 4JQ

Company secretary

B J Abel

Independent auditors

PricewaterhouseCoopers LLP
141 Bothwell Street
Glasgow, G2 7EQ

Bankers

Barclays Bank plc
74 Shepherds Bush Green
Shepherds Bush
London W12 8QB

Commerzbank AG
30 Gresham Street
London EC2V 7PG

90,406
Transplants for
people in need*

10.5+
million
Potential donors
registered*

21
Lifesaving blood
stem cell donations
worldwide
each day*

*Global DKMS statistics as
of January 2021